7972002	163207	SYSTEM	2026-04-30 22:32:24.557508	exported from DB
7972004	163055	SYSTEM	2026-04-30 22:32:24.57584	exported from DB
7972006	163049	SYSTEM	2026-04-30 22:32:24.594562	exported from DB
7972008	162789	SYSTEM	2026-04-30 22:32:24.612311	exported from DB
7972010	162819	SYSTEM	2026-04-30 22:32:24.630364	exported from DB
7972012	163053	SYSTEM	2026-04-30 22:32:24.648765	exported from DB
7972014	163085	SYSTEM	2026-04-30 22:32:24.66684	exported from DB
7972016	162991	SYSTEM	2026-04-30 22:32:24.685598	exported from DB
7972018	162737	SYSTEM	2026-04-30 22:32:24.70384	exported from DB
7972020	162971	SYSTEM	2026-04-30 22:32:24.722155	exported from DB
7972022	162873	SYSTEM	2026-04-30 22:32:24.740302	exported from DB
7972024	162833	SYSTEM	2026-04-30 22:32:24.758928	exported from DB
7972026	163121	SYSTEM	2026-04-30 22:32:24.777513	exported from DB
7972028	163093	SYSTEM	2026-04-30 22:32:24.796458	exported from DB
7972030	163195	SYSTEM	2026-04-30 22:32:24.81549	exported from DB
7972032	162813	SYSTEM	2026-04-30 22:32:24.83431	exported from DB
7972034	468344	SYSTEM	2026-04-30 22:32:24.853162	exported from DB
7972036	163267	SYSTEM	2026-04-30 22:32:24.87133	exported from DB
7972038	163215	SYSTEM	2026-04-30 22:32:24.890141	exported from DB
7972040	163167	SYSTEM	2026-04-30 22:32:24.909336	exported from DB
7972042	163211	SYSTEM	2026-04-30 22:32:24.92785	exported from DB
7972044	163157	SYSTEM	2026-04-30 22:32:24.946861	exported from DB
7972046	163051	SYSTEM	2026-04-30 22:32:24.96661	exported from DB
7972048	163159	SYSTEM	2026-04-30 22:32:24.985517	exported from DB
7972050	162775	SYSTEM	2026-04-30 22:32:25.004032	exported from DB
7972052	163163	SYSTEM	2026-04-30 22:32:25.02267	exported from DB
7972054	163189	SYSTEM	2026-04-30 22:32:25.0419	exported from DB
7972056	163175	SYSTEM	2026-04-30 22:32:25.060017	exported from DB
7972058	163293	SYSTEM	2026-04-30 22:32:25.078358	exported from DB
7972060	162913	SYSTEM	2026-04-30 22:32:25.096842	exported from DB
7972062	162839	SYSTEM	2026-04-30 22:32:25.114414	exported from DB
7972064	2457825	SYSTEM	2026-04-30 22:32:25.132161	exported from DB
7972066	163171	SYSTEM	2026-04-30 22:32:25.149937	exported from DB
7972068	163239	SYSTEM	2026-04-30 22:32:25.167507	exported from DB
7972070	162801	SYSTEM	2026-04-30 22:32:25.185223	exported from DB
7972072	2457739	SYSTEM	2026-04-30 22:32:25.20269	exported from DB
7972074	162825	SYSTEM	2026-04-30 22:32:25.220321	exported from DB
7972076	163143	SYSTEM	2026-04-30 22:32:25.239294	exported from DB
7972078	162927	SYSTEM	2026-04-30 22:32:25.257894	exported from DB
7972080	2457873	SYSTEM	2026-04-30 22:32:25.27579	exported from DB
7972082	162871	SYSTEM	2026-04-30 22:32:25.293966	exported from DB
7972084	162903	SYSTEM	2026-04-30 22:32:25.312206	exported from DB
7972086	163253	SYSTEM	2026-04-30 22:32:25.330905	exported from DB
7972088	468390	SYSTEM	2026-04-30 22:32:25.349427	exported from DB
7972090	162899	SYSTEM	2026-04-30 22:32:25.369188	exported from DB
7972092	163113	SYSTEM	2026-04-30 22:32:25.387944	exported from DB
7972094	163261	SYSTEM	2026-04-30 22:32:25.408892	exported from DB
7972096	163217	SYSTEM	2026-04-30 22:32:25.426759	exported from DB
7972098	163161	SYSTEM	2026-04-30 22:32:25.444577	exported from DB
7972100	163197	SYSTEM	2026-04-30 22:32:25.461901	exported from DB
7972102	162817	SYSTEM	2026-04-30 22:32:25.479247	exported from DB
7972104	2458073	SYSTEM	2026-04-30 22:32:25.497751	exported from DB
7972106	162753	SYSTEM	2026-04-30 22:32:25.515116	exported from DB
7972108	162977	SYSTEM	2026-04-30 22:32:25.532951	exported from DB
7972110	163245	SYSTEM	2026-04-30 22:32:25.550177	exported from DB
7972112	163025	SYSTEM	2026-04-30 22:32:25.567477	exported from DB
7972114	163155	SYSTEM	2026-04-30 22:32:25.584892	exported from DB
7972116	468396	SYSTEM	2026-04-30 22:32:25.602351	exported from DB
7972118	162959	SYSTEM	2026-04-30 22:32:25.61983	exported from DB
7972120	162947	SYSTEM	2026-04-30 22:32:25.638168	exported from DB
7972122	163297	SYSTEM	2026-04-30 22:32:25.655705	exported from DB
7972124	162821	SYSTEM	2026-04-30 22:32:25.674158	exported from DB
7972126	162791	SYSTEM	2026-04-30 22:32:25.692747	exported from DB
7972128	162761	SYSTEM	2026-04-30 22:32:25.710359	exported from DB
7972130	163301	SYSTEM	2026-04-30 22:32:25.72794	exported from DB
7972132	2458097	SYSTEM	2026-04-30 22:32:25.745362	exported from DB
7972134	162919	SYSTEM	2026-04-30 22:32:25.763168	exported from DB
7972136	163005	SYSTEM	2026-04-30 22:32:25.780188	exported from DB
7972138	1607721	SYSTEM	2026-04-30 22:32:25.797647	exported from DB
7972140	163265	SYSTEM	2026-04-30 22:32:25.815298	exported from DB
7972142	163149	SYSTEM	2026-04-30 22:32:25.832641	exported from DB
7972144	163181	SYSTEM	2026-04-30 22:32:25.849728	exported from DB
7972146	163241	SYSTEM	2026-04-30 22:32:25.866959	exported from DB
7972148	163007	SYSTEM	2026-04-30 22:32:25.884952	exported from DB
7972150	162939	SYSTEM	2026-04-30 22:32:25.902422	exported from DB
7972152	162863	SYSTEM	2026-04-30 22:32:25.919831	exported from DB
7972154	2457757	SYSTEM	2026-04-30 22:32:25.937452	exported from DB
7972156	2457981	SYSTEM	2026-04-30 22:32:25.954686	exported from DB
7972158	162803	SYSTEM	2026-04-30 22:32:25.97171	exported from DB
7972160	162793	SYSTEM	2026-04-30 22:32:25.988764	exported from DB
7972162	2458231	SYSTEM	2026-04-30 22:32:26.00587	exported from DB
7972164	163001	SYSTEM	2026-04-30 22:32:26.023489	exported from DB
7972166	162891	SYSTEM	2026-04-30 22:32:26.041203	exported from DB
7972168	163191	SYSTEM	2026-04-30 22:32:26.058909	exported from DB
7972170	1607813	SYSTEM	2026-04-30 22:32:26.077073	exported from DB
7972172	162953	SYSTEM	2026-04-30 22:32:26.094871	exported from DB
7972174	162837	SYSTEM	2026-04-30 22:32:26.11294	exported from DB
7972176	162921	SYSTEM	2026-04-30 22:32:26.130825	exported from DB
7972178	162915	SYSTEM	2026-04-30 22:32:26.148699	exported from DB
7972180	162983	SYSTEM	2026-04-30 22:32:26.166264	exported from DB
7972182	162979	SYSTEM	2026-04-30 22:32:26.183653	exported from DB
7972184	162955	SYSTEM	2026-04-30 22:32:26.20139	exported from DB
7972186	163219	SYSTEM	2026-04-30 22:32:26.218409	exported from DB
7972188	162841	SYSTEM	2026-04-30 22:32:26.236744	exported from DB
7972190	163263	SYSTEM	2026-04-30 22:32:26.254579	exported from DB
7972192	468364	SYSTEM	2026-04-30 22:32:26.271692	exported from DB
7972194	162861	SYSTEM	2026-04-30 22:32:26.288799	exported from DB
7972196	163201	SYSTEM	2026-04-30 22:32:26.305996	exported from DB
7972198	163039	SYSTEM	2026-04-30 22:32:26.323091	exported from DB
7972200	162975	SYSTEM	2026-04-30 22:32:26.339998	exported from DB
7972202	163015	SYSTEM	2026-04-30 22:32:26.357097	exported from DB
7972204	163041	SYSTEM	2026-04-30 22:32:26.374901	exported from DB
7972206	163083	SYSTEM	2026-04-30 22:32:26.39214	exported from DB
7972208	2620284	SYSTEM	2026-04-30 22:32:26.409901	exported from DB
7972210	163145	SYSTEM	2026-04-30 22:32:26.428692	exported from DB
7972212	163057	SYSTEM	2026-04-30 22:32:26.446364	exported from DB
7972214	2458077	SYSTEM	2026-04-30 22:32:26.463818	exported from DB
7972216	163165	SYSTEM	2026-04-30 22:32:26.481964	exported from DB
7972218	2458237	SYSTEM	2026-04-30 22:32:26.499914	exported from DB
7972220	163043	SYSTEM	2026-04-30 22:32:26.518153	exported from DB
7972222	163079	SYSTEM	2026-04-30 22:32:26.535533	exported from DB
7972224	163281	SYSTEM	2026-04-30 22:32:26.552702	exported from DB
7972226	163225	SYSTEM	2026-04-30 22:32:26.570862	exported from DB
7972228	2457707	SYSTEM	2026-04-30 22:32:26.588744	exported from DB
7972230	163221	SYSTEM	2026-04-30 22:32:26.60678	exported from DB
7972232	163091	SYSTEM	2026-04-30 22:32:26.623737	exported from DB
7972234	163131	SYSTEM	2026-04-30 22:32:26.641021	exported from DB
7972236	163095	SYSTEM	2026-04-30 22:32:26.657838	exported from DB
7972238	162765	SYSTEM	2026-04-30 22:32:26.674869	exported from DB
7972240	163275	SYSTEM	2026-04-30 22:32:26.69157	exported from DB
7972242	2458099	SYSTEM	2026-04-30 22:32:26.70856	exported from DB
7972244	2457967	SYSTEM	2026-04-30 22:32:26.725266	exported from DB
7972246	163059	SYSTEM	2026-04-30 22:32:26.742449	exported from DB
7972248	163077	SYSTEM	2026-04-30 22:32:26.759423	exported from DB
7972250	162897	SYSTEM	2026-04-30 22:32:26.776379	exported from DB
7972252	2458193	SYSTEM	2026-04-30 22:32:26.793183	exported from DB
7972254	163129	SYSTEM	2026-04-30 22:32:26.810382	exported from DB
7972256	163173	SYSTEM	2026-04-30 22:32:26.827391	exported from DB
7972258	162925	SYSTEM	2026-04-30 22:32:26.846264	exported from DB
7972260	162867	SYSTEM	2026-04-30 22:32:26.86414	exported from DB
7972262	163123	SYSTEM	2026-04-30 22:32:26.88181	exported from DB
7972264	162845	SYSTEM	2026-04-30 22:32:26.899263	exported from DB
7972266	162881	SYSTEM	2026-04-30 22:32:26.917088	exported from DB
7972268	162847	SYSTEM	2026-04-30 22:32:26.934587	exported from DB
7972270	3011472	SYSTEM	2026-04-30 22:32:26.951875	exported from DB
7972272	162805	SYSTEM	2026-04-30 22:32:26.968917	exported from DB
7972274	162747	SYSTEM	2026-04-30 22:32:26.98545	exported from DB
7972276	163017	SYSTEM	2026-04-30 22:32:27.002379	exported from DB
7972278	163111	SYSTEM	2026-04-30 22:32:27.019385	exported from DB
7972280	163223	SYSTEM	2026-04-30 22:32:27.036254	exported from DB
7972282	162889	SYSTEM	2026-04-30 22:32:27.053082	exported from DB
7972284	163247	SYSTEM	2026-04-30 22:32:27.069751	exported from DB
7972286	2620790	SYSTEM	2026-04-30 22:32:27.090901	exported from DB
7972288	162885	SYSTEM	2026-04-30 22:32:27.111359	exported from DB
7972290	162887	SYSTEM	2026-04-30 22:32:27.131882	exported from DB
7972292	162917	SYSTEM	2026-04-30 22:32:27.151335	exported from DB
7972294	162859	SYSTEM	2026-04-30 22:32:27.170702	exported from DB
7972296	2620236	SYSTEM	2026-04-30 22:32:27.189962	exported from DB
7972298	162909	SYSTEM	2026-04-30 22:32:27.208838	exported from DB
7972300	162875	SYSTEM	2026-04-30 22:32:27.227843	exported from DB
7972302	162835	SYSTEM	2026-04-30 22:32:27.247023	exported from DB
7972304	162945	SYSTEM	2026-04-30 22:32:27.266096	exported from DB
7972306	163035	SYSTEM	2026-04-30 22:32:27.284806	exported from DB
7972308	162981	SYSTEM	2026-04-30 22:32:27.304035	exported from DB
7972310	163291	SYSTEM	2026-04-30 22:32:27.323076	exported from DB
7972312	162961	SYSTEM	2026-04-30 22:32:27.342869	exported from DB
7972314	163011	SYSTEM	2026-04-30 22:32:27.362421	exported from DB
7972316	162949	SYSTEM	2026-04-30 22:32:27.381683	exported from DB
7972318	163033	SYSTEM	2026-04-30 22:32:27.400994	exported from DB
7972320	162807	SYSTEM	2026-04-30 22:32:27.420794	exported from DB
7972322	163283	SYSTEM	2026-04-30 22:32:27.440478	exported from DB
7972324	163277	SYSTEM	2026-04-30 22:32:27.459929	exported from DB
7972326	162993	SYSTEM	2026-04-30 22:32:27.478838	exported from DB
7972328	162769	SYSTEM	2026-04-30 22:32:27.498063	exported from DB
7972330	162777	SYSTEM	2026-04-30 22:32:27.51716	exported from DB
7972332	5406409	SYSTEM	2026-04-30 22:32:27.536693	exported from DB
7972334	162749	SYSTEM	2026-04-30 22:32:27.556337	exported from DB
7972336	163231	SYSTEM	2026-04-30 22:32:27.575848	exported from DB
7972338	5406649	SYSTEM	2026-04-30 22:32:27.595136	exported from DB
7972340	162799	SYSTEM	2026-04-30 22:32:27.614092	exported from DB
7972342	163235	SYSTEM	2026-04-30 22:32:27.633199	exported from DB
7972344	162757	SYSTEM	2026-04-30 22:32:27.652392	exported from DB
7972346	163255	SYSTEM	2026-04-30 22:32:27.671199	exported from DB
7972348	163287	SYSTEM	2026-04-30 22:32:27.691106	exported from DB
7972350	5406479	SYSTEM	2026-04-30 22:32:27.711736	exported from DB
7972352	162743	SYSTEM	2026-04-30 22:32:27.731666	exported from DB
7972354	5406717	SYSTEM	2026-04-30 22:32:27.751454	exported from DB
7972356	5406583	SYSTEM	2026-04-30 22:32:27.77131	exported from DB
7972358	162787	SYSTEM	2026-04-30 22:32:27.791078	exported from DB
7972360	162755	SYSTEM	2026-04-30 22:32:27.811043	exported from DB
7972362	163295	SYSTEM	2026-04-30 22:32:27.831012	exported from DB
7972364	162823	SYSTEM	2026-04-30 22:32:27.851311	exported from DB
7972366	162943	SYSTEM	2026-04-30 22:32:27.871421	exported from DB
7972368	5406625	SYSTEM	2026-04-30 22:32:27.891539	exported from DB
7972370	5406789	SYSTEM	2026-04-30 22:32:27.912655	exported from DB
7972372	163279	SYSTEM	2026-04-30 22:32:27.935689	exported from DB
7972374	162785	SYSTEM	2026-04-30 22:32:27.956857	exported from DB
7972376	162829	SYSTEM	2026-04-30 22:32:27.978028	exported from DB
7972378	162779	SYSTEM	2026-04-30 22:32:27.999173	exported from DB
7972380	162759	SYSTEM	2026-04-30 22:32:28.028941	exported from DB
7972382	162809	SYSTEM	2026-04-30 22:32:28.049412	exported from DB
7972384	162795	SYSTEM	2026-04-30 22:32:28.069468	exported from DB
7972386	162815	SYSTEM	2026-04-30 22:32:28.089608	exported from DB
7972388	3011372	SYSTEM	2026-04-30 22:32:28.109802	exported from DB
7972390	162751	SYSTEM	2026-04-30 22:32:28.130052	exported from DB
7972392	162811	SYSTEM	2026-04-30 22:32:28.150146	exported from DB
7972394	162741	SYSTEM	2026-04-30 22:32:28.170848	exported from DB
7972396	2620676	SYSTEM	2026-04-30 22:32:28.192376	exported from DB
7972398	163227	SYSTEM	2026-04-30 22:32:28.212989	exported from DB
7972400	163243	SYSTEM	2026-04-30 22:32:28.233594	exported from DB
7972402	162745	SYSTEM	2026-04-30 22:32:28.253697	exported from DB
7972404	162911	SYSTEM	2026-04-30 22:32:28.273678	exported from DB
7972406	162773	SYSTEM	2026-04-30 22:32:28.293868	exported from DB
7972408	162771	SYSTEM	2026-04-30 22:32:28.313694	exported from DB
7972410	162827	SYSTEM	2026-04-30 22:32:28.333468	exported from DB
7972412	162767	SYSTEM	2026-04-30 22:32:28.353973	exported from DB
7972414	162783	SYSTEM	2026-04-30 22:32:28.374074	exported from DB
7972416	162851	SYSTEM	2026-04-30 22:32:28.39375	exported from DB
7972418	163237	SYSTEM	2026-04-30 22:32:28.413618	exported from DB
7972420	162797	SYSTEM	2026-04-30 22:32:28.433305	exported from DB
7972422	162895	SYSTEM	2026-04-30 22:32:28.452826	exported from DB
7972424	162923	SYSTEM	2026-04-30 22:32:28.472426	exported from DB
7972426	162849	SYSTEM	2026-04-30 22:32:28.491914	exported from DB
7972428	162883	SYSTEM	2026-04-30 22:32:28.510832	exported from DB
7972430	162905	SYSTEM	2026-04-30 22:32:28.52976	exported from DB
7972432	162929	SYSTEM	2026-04-30 22:32:28.548734	exported from DB
7972434	162877	SYSTEM	2026-04-30 22:32:28.56812	exported from DB
7972436	162853	SYSTEM	2026-04-30 22:32:28.587933	exported from DB
7972438	162893	SYSTEM	2026-04-30 22:32:28.60759	exported from DB
7972440	163251	SYSTEM	2026-04-30 22:32:28.627672	exported from DB
7972442	162901	SYSTEM	2026-04-30 22:32:28.64871	exported from DB
7972444	162857	SYSTEM	2026-04-30 22:32:28.66918	exported from DB
7972446	162879	SYSTEM	2026-04-30 22:32:28.689667	exported from DB
7972448	162869	SYSTEM	2026-04-30 22:32:28.709482	exported from DB
7972450	162855	SYSTEM	2026-04-30 22:32:28.729311	exported from DB
7972452	163233	SYSTEM	2026-04-30 22:32:28.748712	exported from DB
7972454	162941	SYSTEM	2026-04-30 22:32:28.767791	exported from DB
7972456	163169	SYSTEM	2026-04-30 22:32:28.78686	exported from DB
7972458	3011518	SYSTEM	2026-04-30 22:32:28.80601	exported from DB
7972460	162937	SYSTEM	2026-04-30 22:32:28.825372	exported from DB
7972462	162973	SYSTEM	2026-04-30 22:32:28.845529	exported from DB
7972464	163303	SYSTEM	2026-04-30 22:32:28.866272	exported from DB
7972466	163187	SYSTEM	2026-04-30 22:32:28.886266	exported from DB
7972468	163147	SYSTEM	2026-04-30 22:32:28.905081	exported from DB
7972470	163019	SYSTEM	2026-04-30 22:32:28.924015	exported from DB
7972472	163153	SYSTEM	2026-04-30 22:32:28.943202	exported from DB
7972474	163037	SYSTEM	2026-04-30 22:32:28.962224	exported from DB
7972476	163047	SYSTEM	2026-04-30 22:32:28.981642	exported from DB
7972478	621499	SYSTEM	2026-04-30 22:32:29.000704	exported from DB
7972480	162965	SYSTEM	2026-04-30 22:32:29.02	exported from DB
7972482	163045	SYSTEM	2026-04-30 22:32:29.040432	exported from DB
7972484	162957	SYSTEM	2026-04-30 22:32:29.060172	exported from DB
7972486	163213	SYSTEM	2026-04-30 22:32:29.079476	exported from DB
7972488	162967	SYSTEM	2026-04-30 22:32:29.098354	exported from DB
7972490	163199	SYSTEM	2026-04-30 22:32:29.11829	exported from DB
7972492	2457827	SYSTEM	2026-04-30 22:32:29.138345	exported from DB
7972494	162989	SYSTEM	2026-04-30 22:32:29.15772	exported from DB
7972496	163021	SYSTEM	2026-04-30 22:32:29.177016	exported from DB
7972498	163127	SYSTEM	2026-04-30 22:32:29.19626	exported from DB
7972500	163029	SYSTEM	2026-04-30 22:32:29.216104	exported from DB
7972502	163259	SYSTEM	2026-04-30 22:32:29.235293	exported from DB
7972504	163013	SYSTEM	2026-04-30 22:32:29.254393	exported from DB
7972506	163031	SYSTEM	2026-04-30 22:32:29.273202	exported from DB
7972508	3010962	SYSTEM	2026-04-30 22:32:29.291766	exported from DB
7972510	162935	SYSTEM	2026-04-30 22:32:29.311406	exported from DB
7972512	468374	SYSTEM	2026-04-30 22:32:29.330522	exported from DB
7972514	163229	SYSTEM	2026-04-30 22:32:29.350994	exported from DB
7972516	162951	SYSTEM	2026-04-30 22:32:29.370902	exported from DB
7972518	163003	SYSTEM	2026-04-30 22:32:29.390741	exported from DB
7972520	163257	SYSTEM	2026-04-30 22:32:29.409981	exported from DB
7972522	163273	SYSTEM	2026-04-30 22:32:29.42953	exported from DB
7972524	163289	SYSTEM	2026-04-30 22:32:29.449229	exported from DB
7972526	162999	SYSTEM	2026-04-30 22:32:29.46876	exported from DB
7972528	162985	SYSTEM	2026-04-30 22:32:29.488294	exported from DB
7972530	162987	SYSTEM	2026-04-30 22:32:29.50775	exported from DB
7972532	163023	SYSTEM	2026-04-30 22:32:29.527394	exported from DB
7972534	162963	SYSTEM	2026-04-30 22:32:29.548287	exported from DB
7972536	162997	SYSTEM	2026-04-30 22:32:29.568524	exported from DB
7972538	163081	SYSTEM	2026-04-30 22:32:29.588635	exported from DB
7972540	163067	SYSTEM	2026-04-30 22:32:29.608613	exported from DB
7972542	163101	SYSTEM	2026-04-30 22:32:29.628405	exported from DB
7972544	163103	SYSTEM	2026-04-30 22:32:29.648496	exported from DB
7972546	163087	SYSTEM	2026-04-30 22:32:29.668429	exported from DB
7972548	163099	SYSTEM	2026-04-30 22:32:29.688201	exported from DB
7972550	163107	SYSTEM	2026-04-30 22:32:29.707612	exported from DB
7972552	163089	SYSTEM	2026-04-30 22:32:29.72694	exported from DB
7972554	163135	SYSTEM	2026-04-30 22:32:29.746267	exported from DB
7972556	163269	SYSTEM	2026-04-30 22:32:29.765816	exported from DB
7972558	163069	SYSTEM	2026-04-30 22:32:29.785847	exported from DB
7972560	163063	SYSTEM	2026-04-30 22:32:29.806049	exported from DB
7972562	163115	SYSTEM	2026-04-30 22:32:29.825992	exported from DB
7972564	163183	SYSTEM	2026-04-30 22:32:29.846042	exported from DB
7972566	163249	SYSTEM	2026-04-30 22:32:29.866196	exported from DB
7972568	163125	SYSTEM	2026-04-30 22:32:29.886622	exported from DB
7972570	163179	SYSTEM	2026-04-30 22:32:29.907631	exported from DB
7972572	162931	SYSTEM	2026-04-30 22:32:29.928395	exported from DB
7972574	162933	SYSTEM	2026-04-30 22:32:29.948566	exported from DB
7972576	163141	SYSTEM	2026-04-30 22:32:29.968328	exported from DB
7972578	162831	SYSTEM	2026-04-30 22:32:29.988326	exported from DB
7972580	163209	SYSTEM	2026-04-30 22:32:30.008267	exported from DB
7972582	162739	SYSTEM	2026-04-30 22:32:30.02836	exported from DB
7972584	162843	SYSTEM	2026-04-30 22:32:30.048427	exported from DB
7972586	163305	SYSTEM	2026-04-30 22:32:30.068452	exported from DB
7972588	163027	SYSTEM	2026-04-30 22:32:30.088315	exported from DB
7972590	163105	SYSTEM	2026-04-30 22:32:30.108067	exported from DB
7972592	163071	SYSTEM	2026-04-30 22:32:30.12853	exported from DB
7972594	163073	SYSTEM	2026-04-30 22:32:30.148121	exported from DB
7972596	163133	SYSTEM	2026-04-30 22:32:30.167642	exported from DB
7972598	163109	SYSTEM	2026-04-30 22:32:30.187243	exported from DB
7972600	163097	SYSTEM	2026-04-30 22:32:30.206633	exported from DB
7972602	162969	SYSTEM	2026-04-30 22:32:30.225993	exported from DB
7972604	163065	SYSTEM	2026-04-30 22:32:30.245111	exported from DB
7972606	163075	SYSTEM	2026-04-30 22:32:30.264325	exported from DB
7972608	163193	SYSTEM	2026-04-30 22:32:30.283532	exported from DB
7972610	163205	SYSTEM	2026-04-30 22:32:30.302827	exported from DB
7972612	163151	SYSTEM	2026-04-30 22:32:30.322368	exported from DB
7972614	621581	SYSTEM	2026-04-30 22:32:30.34253	exported from DB
7972616	163307	SYSTEM	2026-04-30 22:33:16.885114	exported from DB
7972618	163309	SYSTEM	2026-04-30 22:33:16.930137	exported from DB
7972620	468420	SYSTEM	2026-04-30 22:33:16.977991	exported from DB
7972622	876619	SYSTEM	2026-04-30 22:33:17.013546	exported from DB
7972624	163311	SYSTEM	2026-04-30 22:33:17.061079	exported from DB
7972626	163313	SYSTEM	2026-04-30 22:33:17.118092	exported from DB
7972628	163315	SYSTEM	2026-04-30 22:33:17.143924	exported from DB
7972630	163325	SYSTEM	2026-04-30 22:33:17.303282	exported from DB
7972632	163329	SYSTEM	2026-04-30 22:33:17.336339	exported from DB
7972634	163331	SYSTEM	2026-04-30 22:33:17.377286	exported from DB
7972636	163333	SYSTEM	2026-04-30 22:33:17.401641	exported from DB
7972638	163335	SYSTEM	2026-04-30 22:33:17.426767	exported from DB
7972640	163339	SYSTEM	2026-04-30 22:33:17.467775	exported from DB
7972642	2458301	SYSTEM	2026-04-30 22:33:17.490865	exported from DB
7972644	2458303	SYSTEM	2026-04-30 22:33:17.513913	exported from DB
7972646	163347	SYSTEM	2026-04-30 22:33:17.541588	exported from DB
7972648	163349	SYSTEM	2026-04-30 22:33:17.566476	exported from DB
7972650	163351	SYSTEM	2026-04-30 22:33:17.593992	exported from DB
7972652	2458311	SYSTEM	2026-04-30 22:33:17.617689	exported from DB
7972654	2458313	SYSTEM	2026-04-30 22:33:17.64236	exported from DB
7972656	163359	SYSTEM	2026-04-30 22:33:17.67013	exported from DB
7972658	3127886	SYSTEM	2026-04-30 22:33:17.700239	exported from DB
7972660	2458317	SYSTEM	2026-04-30 22:33:17.723742	exported from DB
7972662	3011624	SYSTEM	2026-04-30 22:33:17.746705	exported from DB
7972664	163367	SYSTEM	2026-04-30 22:33:17.772024	exported from DB
7972666	1608353	SYSTEM	2026-04-30 22:33:17.795533	exported from DB
7972668	2458323	SYSTEM	2026-04-30 22:33:17.818596	exported from DB
7972670	5407063	SYSTEM	2026-04-30 22:33:17.847398	exported from DB
7972672	163375	SYSTEM	2026-04-30 22:33:17.869384	exported from DB
7972674	163377	SYSTEM	2026-04-30 22:33:17.911475	exported from DB
7972676	1608361	SYSTEM	2026-04-30 22:33:17.956832	exported from DB
7972678	2458331	SYSTEM	2026-04-30 22:33:17.981327	exported from DB
7972680	2458333	SYSTEM	2026-04-30 22:33:18.004529	exported from DB
7972682	6603888	SYSTEM	2026-04-30 22:33:18.027791	exported from DB
7972684	2458335	SYSTEM	2026-04-30 22:33:18.050394	exported from DB
7972686	2458337	SYSTEM	2026-04-30 22:33:18.073651	exported from DB
7972688	163385	SYSTEM	2026-04-30 22:33:18.100951	exported from DB
7972690	2458341	SYSTEM	2026-04-30 22:33:18.125642	exported from DB
7972692	163393	SYSTEM	2026-04-30 22:33:18.266724	exported from DB
7972694	2458345	SYSTEM	2026-04-30 22:33:18.29173	exported from DB
7972696	876715	SYSTEM	2026-04-30 22:33:18.315695	exported from DB
7972698	163399	SYSTEM	2026-04-30 22:33:18.356494	exported from DB
7972700	163403	SYSTEM	2026-04-30 22:33:18.381474	exported from DB
7972702	2458353	SYSTEM	2026-04-30 22:33:18.405404	exported from DB
7972704	2458355	SYSTEM	2026-04-30 22:33:18.430325	exported from DB
7972706	163405	SYSTEM	2026-04-30 22:33:18.459524	exported from DB
7972708	2458359	SYSTEM	2026-04-30 22:33:18.483367	exported from DB
7972710	163409	SYSTEM	2026-04-30 22:33:18.509028	exported from DB
7972712	876729	SYSTEM	2026-04-30 22:33:18.532651	exported from DB
7972714	163411	SYSTEM	2026-04-30 22:33:18.577155	exported from DB
7972716	2458367	SYSTEM	2026-04-30 22:33:18.602013	exported from DB
7972718	2458369	SYSTEM	2026-04-30 22:33:18.626016	exported from DB
7972720	468524	SYSTEM	2026-04-30 22:33:18.653466	exported from DB
7972722	468414	SYSTEM	2026-04-30 22:33:18.680892	exported from DB
7972724	3127948	SYSTEM	2026-04-30 22:33:18.710789	exported from DB
7972726	163317	SYSTEM	2026-04-30 22:33:18.734801	exported from DB
7972728	163319	SYSTEM	2026-04-30 22:33:18.759273	exported from DB
7972730	2458379	SYSTEM	2026-04-30 22:33:18.784077	exported from DB
7972732	163321	SYSTEM	2026-04-30 22:33:18.809177	exported from DB
7972734	3011690	SYSTEM	2026-04-30 22:33:18.832475	exported from DB
7972736	163323	SYSTEM	2026-04-30 22:33:18.854943	exported from DB
7972738	163327	SYSTEM	2026-04-30 22:33:18.879416	exported from DB
7972740	1608305	SYSTEM	2026-04-30 22:33:18.903309	exported from DB
7972742	3011698	SYSTEM	2026-04-30 22:33:18.926163	exported from DB
7972744	163337	SYSTEM	2026-04-30 22:33:18.95575	exported from DB
7972746	2458391	SYSTEM	2026-04-30 22:33:18.978692	exported from DB
7972748	2458393	SYSTEM	2026-04-30 22:33:19.001554	exported from DB
7972750	163341	SYSTEM	2026-04-30 22:33:19.028188	exported from DB
7972752	876653	SYSTEM	2026-04-30 22:33:19.05028	exported from DB
7972754	163343	SYSTEM	2026-04-30 22:33:19.075725	exported from DB
7972756	163345	SYSTEM	2026-04-30 22:33:19.099457	exported from DB
7972758	2458403	SYSTEM	2026-04-30 22:33:19.122894	exported from DB
7972760	3011716	SYSTEM	2026-04-30 22:33:19.146882	exported from DB
7972762	2458405	SYSTEM	2026-04-30 22:33:19.170496	exported from DB
7972764	163353	SYSTEM	2026-04-30 22:33:19.194516	exported from DB
7972766	876667	SYSTEM	2026-04-30 22:33:19.218268	exported from DB
7972768	163355	SYSTEM	2026-04-30 22:33:19.248997	exported from DB
7972770	163357	SYSTEM	2026-04-30 22:33:19.285311	exported from DB
7972772	163361	SYSTEM	2026-04-30 22:33:19.317416	exported from DB
7972774	163363	SYSTEM	2026-04-30 22:33:19.341652	exported from DB
7972776	163365	SYSTEM	2026-04-30 22:33:19.480709	exported from DB
7972778	163369	SYSTEM	2026-04-30 22:33:19.61928	exported from DB
7972780	163371	SYSTEM	2026-04-30 22:33:19.64542	exported from DB
7972782	2458425	SYSTEM	2026-04-30 22:33:19.668161	exported from DB
7972784	163373	SYSTEM	2026-04-30 22:33:19.692007	exported from DB
7972786	163379	SYSTEM	2026-04-30 22:33:19.719098	exported from DB
7972788	163381	SYSTEM	2026-04-30 22:33:19.756376	exported from DB
7972790	163383	SYSTEM	2026-04-30 22:33:19.786923	exported from DB
7972792	1608369	SYSTEM	2026-04-30 22:33:19.811882	exported from DB
7972794	163387	SYSTEM	2026-04-30 22:33:19.835762	exported from DB
7972796	2458439	SYSTEM	2026-04-30 22:33:19.859678	exported from DB
7972798	2458441	SYSTEM	2026-04-30 22:33:19.882852	exported from DB
7972800	163389	SYSTEM	2026-04-30 22:33:19.937561	exported from DB
7972802	163391	SYSTEM	2026-04-30 22:33:19.965397	exported from DB
7972804	1608381	SYSTEM	2026-04-30 22:33:19.989023	exported from DB
7972806	163395	SYSTEM	2026-04-30 22:33:20.016724	exported from DB
7972808	876711	SYSTEM	2026-04-30 22:33:20.039144	exported from DB
7972810	1608387	SYSTEM	2026-04-30 22:33:20.073202	exported from DB
7972812	163397	SYSTEM	2026-04-30 22:33:20.211581	exported from DB
7972814	2458457	SYSTEM	2026-04-30 22:33:20.235167	exported from DB
7972816	2458459	SYSTEM	2026-04-30 22:33:20.257934	exported from DB
7972818	163401	SYSTEM	2026-04-30 22:33:20.279593	exported from DB
7972820	2458463	SYSTEM	2026-04-30 22:33:20.302089	exported from DB
7972822	2458465	SYSTEM	2026-04-30 22:33:20.324927	exported from DB
7972824	163407	SYSTEM	2026-04-30 22:33:20.34915	exported from DB
7972826	2458469	SYSTEM	2026-04-30 22:33:20.371724	exported from DB
7972828	2458471	SYSTEM	2026-04-30 22:33:20.394273	exported from DB
7972830	2458473	SYSTEM	2026-04-30 22:33:20.416752	exported from DB
7972832	876733	SYSTEM	2026-04-30 22:33:20.439339	exported from DB
7972834	1508593	SYSTEM	2026-04-30 22:33:38.639468	exported from DB
7972836	1508595	SYSTEM	2026-04-30 22:33:38.674431	exported from DB
7972838	3186721	SYSTEM	2026-04-30 22:33:38.706283	exported from DB
7972840	2458481	SYSTEM	2026-04-30 22:33:38.732588	exported from DB
7972842	1508597	SYSTEM	2026-04-30 22:33:38.761034	exported from DB
7972844	1508601	SYSTEM	2026-04-30 22:33:38.875203	exported from DB
7972846	1608423	SYSTEM	2026-04-30 22:33:38.913121	exported from DB
7972848	1508605	SYSTEM	2026-04-30 22:33:38.938991	exported from DB
7972850	2458491	SYSTEM	2026-04-30 22:33:38.959431	exported from DB
7972852	1508607	SYSTEM	2026-04-30 22:33:38.980047	exported from DB
7972854	5407245	SYSTEM	2026-04-30 22:33:39.002029	exported from DB
7972856	1608435	SYSTEM	2026-04-30 22:33:39.023159	exported from DB
7972858	1508611	SYSTEM	2026-04-30 22:33:39.044898	exported from DB
7972860	1508613	SYSTEM	2026-04-30 22:33:39.064737	exported from DB
7972862	1508619	SYSTEM	2026-04-30 22:33:39.09065	exported from DB
7972864	1508621	SYSTEM	2026-04-30 22:33:39.130342	exported from DB
7972866	2458505	SYSTEM	2026-04-30 22:33:39.150832	exported from DB
7972868	1508625	SYSTEM	2026-04-30 22:33:39.173676	exported from DB
7972870	2458509	SYSTEM	2026-04-30 22:33:39.193204	exported from DB
7972872	2458511	SYSTEM	2026-04-30 22:33:39.212534	exported from DB
7972874	1608451	SYSTEM	2026-04-30 22:33:39.232689	exported from DB
7972876	1508627	SYSTEM	2026-04-30 22:33:39.275051	exported from DB
7972878	2458517	SYSTEM	2026-04-30 22:33:39.295309	exported from DB
7972880	1508629	SYSTEM	2026-04-30 22:33:39.335295	exported from DB
7972882	2458521	SYSTEM	2026-04-30 22:33:39.355926	exported from DB
7972884	1508633	SYSTEM	2026-04-30 22:33:39.375827	exported from DB
7972886	2458525	SYSTEM	2026-04-30 22:33:39.395159	exported from DB
7972888	2458527	SYSTEM	2026-04-30 22:33:39.416655	exported from DB
7972890	1508637	SYSTEM	2026-04-30 22:33:39.437029	exported from DB
7972892	1508639	SYSTEM	2026-04-30 22:33:39.456363	exported from DB
7972894	1508641	SYSTEM	2026-04-30 22:33:39.480935	exported from DB
7972896	3011848	SYSTEM	2026-04-30 22:33:39.500108	exported from DB
7972898	1508647	SYSTEM	2026-04-30 22:33:39.523273	exported from DB
7972900	1508649	SYSTEM	2026-04-30 22:33:39.54479	exported from DB
7972902	2458539	SYSTEM	2026-04-30 22:33:39.565539	exported from DB
7972904	1508653	SYSTEM	2026-04-30 22:33:39.589761	exported from DB
7972906	1508655	SYSTEM	2026-04-30 22:33:39.610275	exported from DB
7972908	2458545	SYSTEM	2026-04-30 22:33:39.63053	exported from DB
7972910	1508659	SYSTEM	2026-04-30 22:33:39.651503	exported from DB
7972912	6604118	SYSTEM	2026-04-30 22:33:39.672602	exported from DB
7972914	2458549	SYSTEM	2026-04-30 22:33:39.702662	exported from DB
7972916	1508665	SYSTEM	2026-04-30 22:33:39.726517	exported from DB
7972918	1508667	SYSTEM	2026-04-30 22:33:39.752631	exported from DB
7972920	1508669	SYSTEM	2026-04-30 22:33:39.852825	exported from DB
7972922	1508671	SYSTEM	2026-04-30 22:33:39.874835	exported from DB
7972924	2458559	SYSTEM	2026-04-30 22:33:39.894872	exported from DB
7972926	2458561	SYSTEM	2026-04-30 22:33:39.91509	exported from DB
7972928	1508677	SYSTEM	2026-04-30 22:33:39.952736	exported from DB
7972930	1508679	SYSTEM	2026-04-30 22:33:39.971998	exported from DB
7972932	2458567	SYSTEM	2026-04-30 22:33:39.991907	exported from DB
7972934	1508689	SYSTEM	2026-04-30 22:33:40.015642	exported from DB
7972936	2458571	SYSTEM	2026-04-30 22:33:40.034687	exported from DB
7972938	1508695	SYSTEM	2026-04-30 22:33:40.056031	exported from DB
7972940	1508697	SYSTEM	2026-04-30 22:33:40.080443	exported from DB
7972942	2458577	SYSTEM	2026-04-30 22:33:40.099325	exported from DB
7972944	2458579	SYSTEM	2026-04-30 22:33:40.120699	exported from DB
7972946	2458581	SYSTEM	2026-04-30 22:33:40.140376	exported from DB
7972948	1608533	SYSTEM	2026-04-30 22:33:40.160802	exported from DB
7972950	2458585	SYSTEM	2026-04-30 22:33:40.179937	exported from DB
7972952	3128170	SYSTEM	2026-04-30 22:33:40.204403	exported from DB
7972954	1508709	SYSTEM	2026-04-30 22:33:40.224453	exported from DB
7972956	2458589	SYSTEM	2026-04-30 22:33:40.244875	exported from DB
7972958	2458591	SYSTEM	2026-04-30 22:33:40.264646	exported from DB
7972960	3011908	SYSTEM	2026-04-30 22:33:40.283862	exported from DB
7972962	1508599	SYSTEM	2026-04-30 22:33:40.303755	exported from DB
7972964	1508603	SYSTEM	2026-04-30 22:33:40.331228	exported from DB
7972966	2458597	SYSTEM	2026-04-30 22:33:40.352298	exported from DB
7972968	1508609	SYSTEM	2026-04-30 22:33:40.375609	exported from DB
7972970	1508615	SYSTEM	2026-04-30 22:33:40.39759	exported from DB
7972972	1508617	SYSTEM	2026-04-30 22:33:40.495655	exported from DB
7972974	2458605	SYSTEM	2026-04-30 22:33:40.515645	exported from DB
7972976	1508623	SYSTEM	2026-04-30 22:33:40.536969	exported from DB
7972978	1827505	SYSTEM	2026-04-30 22:33:40.564854	exported from DB
7972980	1508631	SYSTEM	2026-04-30 22:33:40.583836	exported from DB
7972982	2458613	SYSTEM	2026-04-30 22:33:40.603479	exported from DB
7972984	1508635	SYSTEM	2026-04-30 22:33:40.623603	exported from DB
7972986	2458617	SYSTEM	2026-04-30 22:33:40.642415	exported from DB
7972988	1508643	SYSTEM	2026-04-30 22:33:40.661104	exported from DB
7972990	2458621	SYSTEM	2026-04-30 22:33:40.680206	exported from DB
7972992	1508645	SYSTEM	2026-04-30 22:33:40.70403	exported from DB
7972994	2458625	SYSTEM	2026-04-30 22:33:40.723564	exported from DB
7972996	1508651	SYSTEM	2026-04-30 22:33:40.74325	exported from DB
7972998	2458629	SYSTEM	2026-04-30 22:33:40.761963	exported from DB
7973000	1508657	SYSTEM	2026-04-30 22:33:40.785447	exported from DB
7973002	3011950	SYSTEM	2026-04-30 22:33:40.804092	exported from DB
7973004	1508661	SYSTEM	2026-04-30 22:33:40.823473	exported from DB
7973006	1508663	SYSTEM	2026-04-30 22:33:40.842701	exported from DB
7973008	1508673	SYSTEM	2026-04-30 22:33:40.862544	exported from DB
7973010	1608501	SYSTEM	2026-04-30 22:33:40.881981	exported from DB
7973012	1508675	SYSTEM	2026-04-30 22:33:40.901615	exported from DB
7973014	1508681	SYSTEM	2026-04-30 22:33:40.998446	exported from DB
7973016	1508683	SYSTEM	2026-04-30 22:33:41.021742	exported from DB
7973018	1508685	SYSTEM	2026-04-30 22:33:41.046175	exported from DB
7973020	2458649	SYSTEM	2026-04-30 22:33:41.064819	exported from DB
7973022	1508687	SYSTEM	2026-04-30 22:33:41.086877	exported from DB
7973024	1508691	SYSTEM	2026-04-30 22:33:41.106645	exported from DB
7973026	2458655	SYSTEM	2026-04-30 22:33:41.125865	exported from DB
7973028	1508693	SYSTEM	2026-04-30 22:33:41.144861	exported from DB
7973030	1508699	SYSTEM	2026-04-30 22:33:41.166073	exported from DB
7973032	1508701	SYSTEM	2026-04-30 22:33:41.268275	exported from DB
7973034	2458663	SYSTEM	2026-04-30 22:33:41.289067	exported from DB
7973036	3011984	SYSTEM	2026-04-30 22:33:41.308245	exported from DB
7973038	1508703	SYSTEM	2026-04-30 22:33:41.32733	exported from DB
7973040	1508705	SYSTEM	2026-04-30 22:33:41.346465	exported from DB
7973042	1508707	SYSTEM	2026-04-30 22:33:41.36879	exported from DB
7973044	1508711	SYSTEM	2026-04-30 22:33:41.389297	exported from DB
7973046	2458673	SYSTEM	2026-04-30 22:33:41.40806	exported from DB
7973048	1508713	SYSTEM	2026-04-30 22:33:41.426552	exported from DB
7973050	163513	SYSTEM	2026-04-30 22:33:58.813584	exported from DB
7973052	876865	SYSTEM	2026-04-30 22:33:59.297913	exported from DB
7973054	622215	SYSTEM	2026-04-30 22:34:00.370407	exported from DB
\.


--
-- Data for Name: file_note; Type: TABLE DATA; Schema: cpic; Owner: -
--

COPY cpic.file_note (type, entityid, note, ordinal, version) FROM stdin;
GENE_CDS	ABCG2	The phenotype is used to store an interpretation of the test result. This is a design decision that may differ among sites.	0	1
GENE_CDS	ABCG2	For this example, a priority result is defined as a genetic test result that results in a change in drug, drug dose, or drug monitoring.	1	1
GENE_CDS	ABCG2	The specific wording of the interpretive text may differ among sites.	2	1
FREQUENCY	MT-RNR1	For full references see "References" tab.	0	1
FREQUENCY	MT-RNR1	aAverage frequencies based on the reported frequencies in one or multiple studies.	1	1
FREQUENCY	MT-RNR1	bBased on the PharmGKB biogeographical groups https://www.pharmgkb.org/page/biogeographicalGroups	2	1
TEST_ALERT	RxNorm:17128	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:17128	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:17128	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:17128	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
TEST_ALERT	RxNorm:1191	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:1191	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:1191	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:1191	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
TEST_ALERT	RxNorm:6878	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:6878	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:10638	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:10638	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
ALLELE_DEFINITION	VKORC1	rsID=RefSNP accession ID number (http://www.ncbi.nlm.nih.gov/snp/)	0	1
ALLELE_DEFINITION	VKORC1	All variants are annotated to the positive DNA strand.	1	1
GENE_CDS	CACNA1S	The phenotype is used to store an interpretation of the test result. This is a design decision that may differ among sites.	0	1
GENE_CDS	CACNA1S	For this example, a priority result is defined as a genetic test result that results in a change in drug, drug dose, or drug monitoring.	1	1
GENE_CDS	CACNA1S	The specific wording of the interpretive text may differ among sites.	2	1
FREQUENCY	NUDT15	For full references see "References" tab.	0	1
FREQUENCY	NUDT15	Average frequencies based on the reported frequencies in one or multiple studies.	1	1
FREQUENCY	NUDT15	Based on the PharmGKB biogeographical groups https://www.pharmgkb.org/page/biogeographicalGroups	2	1
FREQUENCY	NUDT15	See allele definition table (https://www.pharmgkb.org/page/nudt15RefMaterials) for allele definitions	3	1
FREQUENCY	NUDT15	Because NUDT15*1 is not genotyped directly, all alleles that are negative for a sequence variation are defaulted to a NUDT15*1 assignment. The inferred frequency for NUDT15*1 is calculated as: 1 - (sum of averaged variant allele frequencies).	4	1
TEST_ALERT	RxNorm:6472	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:6472	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:38400	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:38400	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:38400	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:38400	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
TEST_ALERT	RxNorm:6918	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:6918	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:10689	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:10689	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
ALLELE_FUNCTION_REFERENCE	CYP2B6	CYP2B6 functional metabolic effects may be substrate specific (and extrapolations to other substrates may not be reliable).	0	1
GENE_CDS	CYP2B6	The phenotype is used to store an interpretation of the test result. This is a design decision that may differ among sites.	0	1
GENE_CDS	CYP2B6	For this example, a priority result is defined as a genetic test result that results in a change in drug, drug dose, or drug monitoring.	1	1
GENE_CDS	CYP2B6	The specific wording of the interpretive text may differ among sites.	2	1
GENE_CDS	CYP2B6	Although two CYP2B6 alleles, *4 and *22, are categorized as increased function alleles, the effect of *4 and *22 on CYP2B6 function with respect to efavirenz plasma exposure appears to be modest based on current evidence. However, the phenotype categories of CYP2B6 rapid metabolizer (RM; one normal function allele and one increased function allele) and CYP2B6 ultra-rapid metabolizer (UM; two increased function alleles) were created to allow for the possibility that these may be clinically relevant for CYP2B6 substrates other than efavirenz. As there is no recommendation for altering dosing for CYP2B6 RMs or UMs for efavirenz, the EHR priority is sent to "normal" for these metabolizers.	3	1
FREQUENCY	RYR1	For full references see "References" tab.	0	1
TEST_ALERT	RxNorm:6857	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:6857	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:1256	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:1256	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:7240	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:7240	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:7240	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:7240	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
TEST_ALERT	RxNorm:27392	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:27392	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
ALLELE_FUNCTION_REFERENCE	CYP2D6	CNV alleles are based on Table 2 'CYP2D6 Identical Gene Duplications/Multiplications' from the PharmVar CYP2D6 structural variation document (https://a.storyblok.com/f/70677/x/d80b535e9c/cyp2d6_structural-variation_v3-2.pdf).	0	1
GENE_CDS	CYP2C19	The phenotype is used to store an interpretation of the test result. This is a design decision that may differ among sites.	0	1
GENE_CDS	CYP2C19	For this example, a priority result is defined as a genetic test result that results in a change in drug, drug dose, or drug monitoring.	1	1
GENE_CDS	CYP2C19	The specific wording of the interpretive text may differ among sites.	2	1
FREQUENCY	SLCO1B1	For full references see "References" tab.	0	1
FREQUENCY	SLCO1B1	Average frequencies based on the reported frequencies in one or multiple studies.	1	1
FREQUENCY	SLCO1B1	Based on the PharmGKB biogeographical groups https://www.pharmgkb.org/page/biogeographicalGroups	2	1
FREQUENCY	SLCO1B1	See allele definition table (https://www.pharmgkb.org/page/slco1b1RefMaterials) for allele definitions	3	1
FREQUENCY	SLCO1B1	Because SLCO1B1*1 is not genotyped directly, all alleles that are negative for a sequence variation are defaulted to a SLCO1B!*1 assignment. The inferred frequency for SLCO1B1*1 is calculated as: 1 - (sum of averaged variant allele frequencies).	4	1
TEST_ALERT	RxNorm:7531	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:7531	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:194000	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:194000	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:7299	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:7299	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:39786	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:39786	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
ALLELE_FUNCTION_REFERENCE	NAT2	The NAT gene nomenclature committee has curated, annotated, and assigned function to NAT2 star alleles since 1997. In March 2024, NAT2 nomenclature was transferred to PharmVar with some major changes. Most notably, the creation of NAT2*1 as the reference allele in accordance with the reference genome GRCh38. NAT2*4, the former reference allele, is defined by the presence of the SNV c.803G>A. Historically, acetylation function was assigned to NAT2 * alleles as either "rapid" or "slow". Under the CPIC allele function terminology, rapid acetylation alleles are categorized as "Increased Function" and slow acetylation alleles are categorized as "Decreased Function". More information can be found at the NAT gene nomenclature committee website, including legacy allele nomenclature and functional assignments (see links below). Additionally, see the PharmVar NAT2 Read Me document (link below)	0	1
ALLELE_FUNCTION_REFERENCE	NAT2	NAT Gene Nomenclature Committee Homepage, https://nat.mbg.duth.gr/Homepage.htm	1	1
ALLELE_FUNCTION_REFERENCE	NAT2	Legacy NAT2 allele nomenclature and functional assignments, https://nat.mbg.duth.gr/Human_NAT2_alleles.htm	2	1
ALLELE_FUNCTION_REFERENCE	NAT2	PharmVar NAT2 Read Me, https://a.storyblok.com/f/70677/x/047a3728ff/gene-info_nat2_v1-2.pdf.	3	1
GENE_CDS	CYP2C9	The phenotype is used to store an interpretation of the test result. This is a design decision that may differ among sites. Assignment of all Genotype/Phenotype Summaries based on diplotype is available on the 'Possible CYP2C19' Diplotype tab.	0	1
GENE_CDS	CYP2C9	A priority result is defined as a genetic test result that results in a change in drug, drug dose, or drug monitoring.	1	1
GENE_CDS	CYP2C9	The specific wording of the interpretive text may differ among sites.	2	1
FREQUENCY	TPMT	For full references see "References" tab.	0	1
FREQUENCY	TPMT	Average frequencies based on the reported frequencies in one or multiple studies.	1	1
FREQUENCY	TPMT	Based on the PharmGKB biogeographical groups https://www.pharmgkb.org/page/biogeographicalGroups	2	1
FREQUENCY	TPMT	See the Allele Definition Tables at https://www.pharmgkb.org/page/tpmtRefMaterials for allele definitions	3	1
FREQUENCY	TPMT	Because TPMT*1 is not genotyped directly, all alleles that are negative for a sequence variation are defaulted to a TPMT*1 assignment. The inferred frequency for TPMT*1 is calculated as: 1 - (sum of averaged variant allele frequencies).	4	1
TEST_ALERT	RxNorm:7646	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:7646	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:7646	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:7646	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
TEST_ALERT	RxNorm:140587	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:140587	Pharmacist, pharmacologist, or a clinician with pharmacogenetic expertise/training.	1	1
TEST_ALERT	RxNorm:7337	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:7337	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:1151	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:1151	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:1151	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:1151	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
ALLELE_FUNCTION_REFERENCE	RYR1	Variant selection based on an update of the CPIC guideline for potent volatile anesthetic agents and succinylcholine. The guideline update includes the published list of RYR1 variants (supplemental Table S2), which are evaluated by the ClinGen malignant hyperthermia susceptibility (MHS) variant curation expert panel (VCEP) and classified for RYR1-related malignant hyperthermia susceptibility based on specified ACMG/AMP criteria (PMID 35849058). The entries in the column 'Allele Functional Status (Optional)' are from the 'Pathogenicity' column and the entries in the column 'Findings (Optional)' are from the ACMG/AMP Criteria column in Table S2 (PMID 35849058).	0	1
ALLELE_FUNCTION_REFERENCE	RYR1	Variants 1209C>G, 7522C>G, 14387A>G, 14693T>C are not included in the PMID 35849058 and are classified as VUS by the RYR1 VCEP in May 2023.	1	1
ALLELE_FUNCTION_REFERENCE	RYR1	Variant classification was re-evaluated and updated by the RYR1 VCEP in May 2023 for the following variants: c.488G>T, c.1589G>A, c.7522C>T, c.14210G>A, c.14582G>A, c.6612C>G, c.14918C>T, c.5183C>T, c.5132A>G, c.6838G>A	2	1
ALLELE_FUNCTION_REFERENCE	RYR1	Variant classification was re-evaluated and updated by the RYR1 VCEP in Nov 2023 for the following variants: c.6488G>T, c.14627A>G, c.14813T>C	3	1
ALLELE_FUNCTION_REFERENCE	RYR1	Allele Clinical Functional Status is mapped to the classification by the ClinGen malignant hyperthermia susceptibility (MHS) variant curation expert panel PMID: 35849058 as follows:	4	1
ALLELE_FUNCTION_REFERENCE	RYR1	Pathogenic = Malignant Hyperthermia associated	5	1
ALLELE_FUNCTION_REFERENCE	RYR1	Likely Pathogenic = Malignant Hyperthermia associated	6	1
ALLELE_FUNCTION_REFERENCE	RYR1	Variant of uncertain significance = Uncertain function	7	1
ALLELE_FUNCTION_REFERENCE	RYR1	Likely Benign = Normal function	8	1
ALLELE_FUNCTION_REFERENCE	RYR1	Benign = Normal function	9	1
ALLELE_FUNCTION_REFERENCE	RYR1	"Reference" is included in the CPIC RYR1 allele definition table. Allele Clinical Functional Status is assigned Normal function.	10	1
GENE_CDS	CYP3A5	The coded diplotype/phenotype summary is used to store an interpretation of the test result. This is a design decision that may differ among sites. Assignment of all Genotype/Phenotype Summaries based on diplotype is available on the 'Possible CYP2C19' Diplotype tab.	0	1
GENE_CDS	CYP3A5	For this example, a priority result is defined as a genetic test result that results in a change in drug, drug dose, or drug monitoring.	1	1
GENE_CDS	CYP3A5	The specific wording of the interpretive text may differ among sites.	2	1
FREQUENCY	UGT1A1	For full references see "References" tab.	0	1
FREQUENCY	UGT1A1	Average frequencies are based on the actual number of subjects with each allele as reported in one or multiple studies.	1	1
FREQUENCY	UGT1A1	Based on the PharmGKB biogeographical groups https://www.pharmgkb.org/page/biogeographicalGroups	2	1
FREQUENCY	UGT1A1	See allele definition table (https://www.pharmgkb.org/page/ugt1a1RefMaterials) for allele definitions	3	1
FREQUENCY	UGT1A1	Because UGT1A1*1 is not genotyped directly, all alleles that are negative for a sequence variation are defaulted to a UGT1A1*1 assignment. The inferred frequency for UGT1A1*1 is calculated as: 1 - (sum of averaged variant allele frequencies).	4	1
TEST_ALERT	RxNorm:26225	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:26225	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:2348	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:2348	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:2348	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:2348	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
TEST_ALERT	RxNorm:7454	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:7454	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:11258	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:11258	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:11258	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:11258	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
GENE_CDS	DPYD	The phenotype is used to store an interpretation of the test result. This is a design decision that may differ among sites.	0	1
GENE_CDS	DPYD	For this example, a priority result is defined as a genetic test result that results in a change in drug, drug dose, or drug monitoring.	1	1
GENE_CDS	DPYD	The specific wording of the interpretive text may differ among sites.	2	1
FREQUENCY	VKORC1	For full references see "References" tab.	0	1
FREQUENCY	VKORC1	Average frequencies based on the reported frequencies in one or multiple studies.	1	1
FREQUENCY	VKORC1	Based on the PharmGKB biogeographical groups https://www.pharmgkb.org/page/biogeographicalGroups	2	1
TEST_ALERT	RxNorm:32624	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:32624	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:2393	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:2393	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:2393	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:2393	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
TEST_ALERT	RxNorm:7517	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:7517	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:7517	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:7517	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
TEST_ALERT	RxNorm:1455099	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:1455099	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
DIPLOTYPE_PHENOTYPE	RYR1	The CPIC guideline includes RYR1 variants assigned a Allele Clinical Functional Status of Normal function, Uncertain function, and Malignant Hyperthermia associated (see the "RYR1_allele_functionality_reference" file). A translation of Allele Function combinations to Phenotype is available in the "RYR1_phenotypes" file. It might be possible that a subject could have more than 2 RYR1 variants and this RYR1_Diplotype_Phenotype_Table is a representation of possible RYR1 genotypes considering the two functionally most impacted RYR1 variants.	0	1
GENE_CDS	G6PD	For this example, a priority result is defined as a genetic test result that results in a change in drug, drug dose, or drug monitoring.	0	1
GENE_CDS	G6PD	The specific wording of the interpretive text may differ among sites.	1	1
TEST_ALERT	RxNorm:704	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:704	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:40790	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:40790	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:40790	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:40790	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
TEST_ALERT	RxNorm:2551	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:2551	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:2551	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:2551	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
TEST_ALERT	RxNorm:7623	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:7623	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:7623	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:7623	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
GENE_CDS	HLA-A	The phenotype is used to store an interpretation of the test result. This is a design decision that may differ among sites.	0	1
GENE_CDS	HLA-A	For this example, a priority result is defined as a genetic test result that results in a change in drug, drug dose, or drug monitoring.	1	1
GENE_CDS	HLA-A	The specific wording of the interpretive text may differ among sites.	2	1
TEST_ALERT	RxNorm:343047	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:343047	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:32937	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:32937	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:2670	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:2670	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:7934	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:7934	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
ALLELE_DEFINITION	CACNA1S	Variant selection based on the CPIC guideline for potent volatile anesthetic agents and succinylcholine and RYR1 and CACNA1S.	0	1
GENE_CDS	HLA-B	The phenotype is used to store an interpretation of the test result. This is a design decision that may differ among sites.	0	1
GENE_CDS	HLA-B	For this example, a priority result is defined as a genetic test result that results in a change in drug, drug dose, or drug monitoring.	1	1
GENE_CDS	HLA-B	The specific wording of the interpretive text may differ among sites.	2	1
TEST_ALERT	RxNorm:83367	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:83367	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:8183	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:8183	Pharmacist, pharmacologist, or a clinician with pharmacogenetic expertise/training.	1	1
TEST_ALERT	RxNorm:3108	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:3108	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:1011650	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:1011650	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
ALLELE_DEFINITION	CFTR	rsID=RefSNP accession ID number (http://www.ncbi.nlm.nih.gov/snp/)	0	1
ALLELE_DEFINITION	CFTR	All variants are annotated to the positive chromosomal strand.	1	1
ALLELE_DEFINITION	CFTR	Class is defined in PMID: 20932301.	2	1
ALLELE_DEFINITION	CFTR	Table includes variants listed as ivacaftor responsive on FDA-approved ivacaftor (Kalydeco) label (see change log for updates).	3	1
ALLELE_DEFINITION	CFTR	The ivacaftor (Kalydeco) label includes the CFTR variants as amino acid changes. Based on information in dbSNP, for four variants, the amino acid change can be coded by >1 nucleotide change at the same genomic position. In these cases the variant was named with the protein change and the nucleotide change in parentheses.	4	1
ALLELE_DEFINITION	CFTR	The ivacaftor label includes F311del. The variant is caused by a 3 bp deletion within a repetitive sequence C TTC TTC TTC T at nucleotide position 1059-1069. This results in a deletion of one of the phenylalanine residues at either position 311, 312 or 313.	5	1
ALLELE_DEFINITION	CFTR	F508C;S1251N includes the following footnote for Table 3 of the FDA-approved ivacaftor label (annotated by ClinPGx 10/05/2023): "Complex/compound mutations where a single allele of the CFTR gene has multiple mutations; these exist independent of the presence of mutations on the other allele."	6	1
GENE_CDS	MT-RNR1	The phenotype is used to store an interpretation of the test result. This is a design decision that may differ among sites.	0	1
GENE_CDS	MT-RNR1	For this example, a priority result is defined as a genetic test result that results in a change in drug, drug dose, or drug monitoring.	1	1
GENE_CDS	MT-RNR1	The specific wording of the interpretive text may differ among sites.	2	1
TEST_ALERT	RxNorm:2002	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:2002	"Clinical Pharmacist" could be a pharmacist, pharmacologist, or a clinician with pharmacogenetic expertise/training.	1	1
TEST_ALERT	RxNorm:8356	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:8356	Pharmacist, pharmacologist, or a clinician with pharmacogenetic expertise/training.	1	1
TEST_ALERT	RxNorm:3328	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:3328	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:8120	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:8120	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:8120	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:8120	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
ALLELE_DEFINITION	CYP2B6	rsID=RefSNP accession ID number (http://www.ncbi.nlm.nih.gov/snp/)	0	1
ALLELE_DEFINITION	CYP2B6	All variants are annotated to the positive chromosomal strand.	1	1
ALLELE_DEFINITION	CYP2B6	See PharmVar website (http://www.pharmvar.org) for comprehensive haplotype definitions of CYP2B6 variant alleles and updated allele information.	2	1
ALLELE_DEFINITION	CYP2B6	An important caveat for all genotyping tests is that the decision to assign an allele a "wild-type" status is based upon a genotyping test that interrogates only the most common and already-proven sites of functional variation. In human DNA, it is always possible that a new, previously undiscovered (and therefore un-interrogated) site of variation may confer loss-of-function in an individual, and thus lead to the rare possibility of a non-functional allele being erroneously called as "wild-type."	3	1
GENE_CDS	NAT2	The phenotype is used to store an interpretation of the test result. This is a design decision that may differ among sites.	0	1
GENE_CDS	NAT2	For this example, a priority result is defined as a genetic test result that results in a change in drug, drug dose, or drug monitoring.	1	1
GENE_CDS	NAT2	The specific wording of the interpretive text may differ among sites.	2	1
TEST_ALERT	RxNorm:2556	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:2556	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:861634	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:861634	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:3445	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:3445	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:3445	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:3445	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
TEST_ALERT	RxNorm:2049549	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:2049549	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
ALLELE_DEFINITION	CYP2C19	The variants included in the alleles are based on the PharmVar core alleles (for core allele definitions only, see https://www.pharmvar.org/gene/CYP2C19). In addition, variants that present in the core allele for one star allele but also present in some but not allsuballeles of another star allele are included in the other star allele as ambiguous changes using the IUPAC nucleotide code (https://www.bioinformatics.org/sms/iupac.html), e.g. the *4 consensus allele includes a "Y" being either C or T at the -806C>T position since this variant is part of the *17 core allele but is not part of the *4 core allele at PharmVar since it is not present in all *4 suballeles. These postions are represented in grey in the Comparative Allele ViewEr (CAVE) tool at PharmVar.	0	1
ALLELE_DEFINITION	CYP2C19	PharmVAR releases new alleles based on received submissions, see https://www.pharmvar.org for comprehensive haplotype definitions of CYP2C19 variant alleles, including sub-alleles, and updated allele information.	1	1
ALLELE_DEFINITION	CYP2C19	rsID=RefSNP accession ID number (http://www.ncbi.nlm.nih.gov/snp/)	2	1
ALLELE_DEFINITION	CYP2C19	All variants are annotated to the positive DNA strand.	3	1
ALLELE_DEFINITION	CYP2C19	An important caveat for all genotyping tests is that the decision to assign an allele a wild-type status is based upon a genotyping test that interrogates only the most common and already- proven sites of functional variation. It is always possible that a novel, previously undiscovered (and therefore un-interrogated) site of variation may confer loss-of-function in an individual, and thus lead to the rare possibility of a non-functional allele being erroneously called as wild-type.	4	1
ALLELE_DEFINITION	CYP2C19	The deterimental CYP2C19*4-defining SNP (rs28399504) has been identified to be linked (i.e. on the same chromosome) with *17 (-806C>T; rs12248560) in certain ethnic subpopulations. To distinguish the *4 (no function) and *17 (increased function) alleles, both rs28399504 and rs12248560 needs to be genotyped [PMID: 21358751, PMID: 24012947]). This haplotype is designated CYP2C19*4B [PMID: 21716271, PMID: 21358751].	5	1
ALLELE_DEFINITION	CYP2C19	The SNP c.463G>T (rs374036992) has been identified to occur in linkage with the *17-defining SNP (- 806C>T; rs12248560). To distinguish *17 from this haplotype, c.463G>T needs to be genotyped [PMID: 25141895]. This allele has not been submitted to PharmVar for a star allele designation.	6	1
ALLELE_DEFINITION	CYP2C19	CYP2C19*27 was reassigned to CYP2C19*1.006 with PharmVar Version 4.0 Last Updated May 7 2019	7	1
DIPLOTYPE_PHENOTYPE	DPYD	It is possible that a subject has > 2 DPYD variants and this DPYD_Diplotype_Phenotype_Table is a representation of possible DPYD genotypes considering the two functionally most impacted (lowest activity value) variants. Based on the CPIC guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (PMID: 29152729), the DPD phenotype is assigned using a gene activity score (DPYD-AS; based on the DPYD Allele Functionality Table), calculated as the sum of the two DPYD variants with the lowest variant activity value. A translation of Allele Function combinations to Phenotype is available in the "DPYD_phenotypes" file. If two decreased/no function variants are present, each decreased/no function variant is considered to be on a different gene copy when the phase is not known.	0	1
ALLELE_DEFINITION	CYP2C19	CYP2C19*36 is a full gene deletion and *37 is a partial gene deletion that includes at least exon 1; for details see the PharmVar CYP2C19 GeneFocus (PMID 32602114) and the CYP2C19 Structural Variation document at https://www.pharmvar.org/gene/CYP2C19).	8	1
ALLELE_DEFINITION	CYP2C19	CYP2C19*38 was set as reference allele as this allele matches the human genome CYP2C19 Reference sequence LRG_584 / NG_008384.3. The RefSeq (LRG_584 / NG_008384.3) has 80161A while many of star alleles, including all *1 suballeles have 80161G. Thus, the CYP2C19*1 core allele is defined by one amino acid (I331V), while the *38 core allele definition does not have any amino acid changes.	9	1
GENE_CDS	NUDT15	The phenotype is used to store an interpretation of the test result. This is a design decision that may differ among sites.	0	1
GENE_CDS	NUDT15	For this example, a priority result is defined as a genetic test result that results in a change in drug, drug dose, or drug monitoring.	1	1
GENE_CDS	NUDT15	The specific wording of the interpretive text may differ among sites.	2	1
TEST_ALERT	RxNorm:2597	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:2597	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:42463	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:42463	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:3639	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:3639	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:3639	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:3639	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
TEST_ALERT	RxNorm:8687	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:8687	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:8687	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:8687	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
ALLELE_DEFINITION	CYP2C9	PharmVAR releases new alleles based on received submissions, see https://www.pharmvar.org for comprehensive haplotype definitions of CYP2C9 variant alleles, including sub-alleles, and updated allele information.	0	1
ALLELE_DEFINITION	CYP2C9	rsID=RefSNP accession ID number (http://www.ncbi.nlm.nih.gov/snp/)	1	1
ALLELE_DEFINITION	CYP2C9	All variants are annotated to the positive DNA strand.	2	1
ALLELE_DEFINITION	CYP2C9	An important caveat for all genotyping tests is that the decision to assign an allele a "wild-type" status is based upon a genotyping test that interrogates only the most common and already-proven sites of functional variation. In human DNA, it is always possible that a new, previously undiscovered (and therefore un-interrogated) site of variation may confer loss-of-function in an individual, and thus lead to the rare possibility of a non-functional allele being erroneously called as "wild-type."	3	1
ALLELE_DEFINITION	CYP2C9	Citations for assignment of function can be found at https://www.pharmgkb.org/page/cyp2c9RefMaterials	4	1
ALLELE_DEFINITION	CYP2C9	Content is accessed through the PharmVar API. HGVS and 'PharmVar-style' (accessible on the PharmVar website) positions may differ for indels in some instances which is most likely explained by differences in sequence alignments. Also, PharmVar displays single nucleotide insertions as 'ins' while the HGVS display is as duplications or 'dub' if the insertion is the same base as the prior base.	5	1
GENE_CDS	RYR1	The phenotype is used to store an interpretation of the test result. This is a design decision that may differ among sites.	0	1
GENE_CDS	RYR1	For this example, a priority result is defined as a genetic test result that results in a change in drug, drug dose, or drug monitoring.	1	1
GENE_CDS	RYR1	The specific wording of the interpretive text may differ among sites.	2	1
TEST_ALERT	RxNorm:32968	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:32968	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:301542	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:301542	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:4492	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:4492	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:9071	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:9071	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:9071	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:9071	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
ALLELE_DEFINITION	CYP2D6	The variants included in the alleles are based on the PharmVar core alleles (for core allele definitions only, see https://www.pharmvar.org/gene/CYP2D6). In addition, variants that present in the core allele for one star allele but also present in some but not all suballeles of another star allele are included in the other star allele as ambiguous changes using the IUPAC nucleotide code (https://www.bioinformatics.org/sms/iupac.html), e.g. the *4 consensus allele includes a "R" being either G or A (positive strand) at the 100C>T (P34S) position since this variant is part of other core star alleles, e.g. *10, but is not part of the *4 core allele at PharmVar since it is not present in all *4 suballeles. These postions are represented in grey (G) in the Comparative Allele ViewEr (CAVE) tool at PharmVar. The g.42129130C>G position is an exception. The SNP by itself causes a synonymous change, therefore by itself the SNP would not be part of a core allele based on the core allele definition. However, in *29 and *70 the SNP is needed for the amino acid change and therefore part of the *29 and *70 core allele definition in PharmVar. To follow the above, "S" is added at the position for star alleles in which not all suballeles carry the SNP. In case all suballeles have the SNP "G" is added.	0	1
ALLELE_DEFINITION	CYP2D6	At PharmVar, information about duplications and gene hybrids are available through https://www.pharmvar.org/gene-support/Variation_CYP2D6.pdf.	1	1
ALLELE_DEFINITION	CYP2D6	PharmVAR releases new alleles based on received submissions, see https://www.pharmvar.org for comprehensive haplotype definitions of CYP2D6 variant alleles, including sub-alleles, and updated allele information.	2	1
ALLELE_DEFINITION	CYP2D6	Amino acid changes are displayed per single variantion. However, in some alleles the 2 consecutive variants together cause a different amino acid change as each by itself. *29, *70: 1660G>A and 1662G>C result in V136I; *82: 1021A>T and 1022C>A result in T107Y; in exon 9 conversion: 4156C>T and 4157A>T result in H478S, 4168G>A and 4169C>G result in A482S	3	1
ALLELE_DEFINITION	CYP2D6	All variants are annotated to the positive DNA strand	4	1
ALLELE_DEFINITION	CYP2D6	rsID are RefSNP accession ID number (http://www.ncbi.nlm.nih.gov/snp/).	5	1
ALLELE_DEFINITION	CYP2D6	The CYP2D6*1 allele is characterized by the absence of any sequence variations. Consequently, this allele cannot be identified by a SNP; rather CYP2D6*1 is assigned by default when no SNPs are detected during testing.	6	1
ALLELE_DEFINITION	CYP2D6	The CYP2D6*2 allele is typically characterized by two amino acid changes; both, however also occur in many other CYP2D6 alleles. Therefore, if an allele carries these two SNPs exclusively, it is designated CYP2D6*2. Interrogating for additional SNPs is the only way to distinguish CYP2D6*2 from other alleles (e.g., CYP2D6*17 and *41).	7	1
GENE_CDS	SLCO1B1	The phenotype is used to store an interpretation of the test result. This is a design decision that may differ among sites.	0	1
GENE_CDS	SLCO1B1	For this example, a priority result is defined as a genetic test result that results in a change in drug, drug dose, or drug monitoring.	1	1
GENE_CDS	SLCO1B1	The specific wording of the interpretive text may differ among sites.	2	1
TEST_ALERT	RxNorm:27340	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:27340	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:36437	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:36437	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:4502	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:4502	Pharmacist, pharmacologist, or a clinician with pharmacogenetic expertise/training.	1	1
TEST_ALERT	RxNorm:283821	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:283821	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
ALLELE_DEFINITION	CYP2D6	4180G>C is present on many allelic variants including functional and non-functional variants. Specifically, it has been found on some CYP2D6*4 subvariants. While some tests include this SNP, it cannot be utilized to identify an allelic variant with certainty.	8	1
ALLELE_DEFINITION	CYP2D6	An important caveat for all genotyping tests is that the decision to assign an allele a wild-type status is based upon a genotyping test that interrogates only the most common and already- proven sites of functional variation. It is always possible that a novel, previously undiscovered (and therefore un-interrogated) site of variation may confer loss-of-function in an individual, and thus lead to the rare possibility of a non-functional allele being erroneously called as wild-type.	9	1
ALLELE_DEFINITION	CYP2D6	Content is accessed through the PharmVar API. HGVS and 'PharmVar-style' (accessible on the PharmVar website) positions may differ for indels in some instances which is most likely explained by differences in sequence alignments. Also, PharmVar displays single nucleotide insertions as 'ins' while the HGVS display is as duplications or 'dup' if the insertion is the same base as the prior base. The entries in the 'Free Text' field in row 2 reflect the default variant names on the CYP2D6 PharmVar page (https://www.pharmvar.org/gene/CYP2D6). Additional variant coordinates are consistent with the content displayed on the upper section of the 'Variant Positions' window which can be accessed by clicking on the variant of interest on the CYP2D6 PharmVar page.	10	1
GENE_CDS	TPMT	The phenotype is used to store an interpretation of the test result. This is a design decision that may differ among sites.	0	1
GENE_CDS	TPMT	For this example, a priority result is defined as a genetic test result that results in a change in drug, drug dose, or drug monitoring.	1	1
GENE_CDS	TPMT	The specific wording of the interpretive text may differ among sites.	2	1
TEST_ALERT	RxNorm:3247	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:3247	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:36453	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:36453	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:4601	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:4601	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:4601	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:4601	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
TEST_ALERT	RxNorm:NA	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:NA	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
ALLELE_DEFINITION	CYP3A5	The variants included are based on the PharmVar core alleles (for core alleles only see https://www.pharmvar.org/gene/CYP3a5).	0	1
ALLELE_DEFINITION	CYP3A5	See PharmVar website (http://www.pharmvar.org) for comprehensive haplotype definitions of CYP3A5 variant alleles, including sub-alleles, and updated allele information.	1	1
ALLELE_DEFINITION	CYP3A5	rsID=RefSNP accession ID number (http://www.ncbi.nlm.nih.gov/snp/)	2	1
ALLELE_DEFINITION	CYP3A5	All variants are annotated to the positive DNA strand.	3	1
ALLELE_DEFINITION	CYP3A5	An important caveat for all genotyping tests is that the decision to assign an allele a "wild- type" status is based upon a genotyping test that interrogates only the most common and already-proven sites of functional variation. In human DNA, it is always possible that a new, previously undiscovered (and therefore un-interrogated) site of variation may confer loss-of- function in an individual, and thus lead to the rare possibility of a non-functional allele being erroneously called as "wild-type"	4	1
ALLELE_DEFINITION	CYP3A5	Citations for assignment of function can be found at https://www.pharmgkb.org/page/cyp3a5RefMaterials	5	1
ALLELE_DEFINITION	CYP3A5	Content is accessed through the PharmVar API. HGVS and 'PharmVar-style' (accessible on the PharmVar website) positions may differ for indels in some instances which is most likely explained by differences in sequence alignments. Also, PharmVar displays single nucleotide insertions as 'ins' while the HGVS display is as duplications or 'dub' if the insertion is the same base as the prior base.	6	1
GENE_CDS	UGT1A1	The phenotype is used to store an interpretation of the test result. This is a design decision that may differ among sites.	0	1
GENE_CDS	UGT1A1	For this example, a priority result is defined as a genetic test result that results in a change in drug, drug dose, or drug monitoring.	1	1
GENE_CDS	UGT1A1	The specific wording of the interpretive text may differ among sites.	2	1
TEST_ALERT	RxNorm:816346	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:816346	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:816346	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:816346	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
TEST_ALERT	RxNorm:36567	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:36567	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	ATC:D06AX07	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	ATC:D06AX07	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:10109	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:10109	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
ALLELE_DEFINITION	CYP4F2	rsID=RefSNP accession ID number (http://www.ncbi.nlm.nih.gov/snp/)	0	1
ALLELE_DEFINITION	CYP4F2	All variants are annotated to the positive DNA strand.	1	1
ALLELE_DEFINITION	CYP4F2	See PharmVar website (http://pharmvar.org) for comprehensive haplotype definitions of CYP4F2 variant alleles and updated allele information.	2	1
ALLELE_DEFINITION	CYP4F2	An important caveat for all genotyping tests is that the decision to assign an allele a "wild-type" status is based upon a genotyping test that interrogates only the most common and already-proven sites of functional variation. In human DNA, it is always possible that a new, previously undiscovered (and therefore un-interrogated) site of variation may confer loss-of-function in an individual, and thus lead to the rare possibility of a non-functional allele being erroneously called as "wild-type."	3	1
FREQUENCY	CACNA1S	For full references see "References" tab.	0	1
TEST_ALERT	RxNorm:3638	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:3638	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:10154	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:10154	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:4815	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:4815	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:4815	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:4815	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
TEST_ALERT	RxNorm:10171	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:10171	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:10171	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:10171	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
ALLELE_DEFINITION	DPYD	Variant selection is based on the CPIC guideline for Fluoropyrimidines and DPYD (https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/) and sourced from PharmVar (https://www.pharmvar.org/gene/DPYD).	0	1
ALLELE_DEFINITION	DPYD	All variants are annotated to the positive DNA strand.	1	1
ALLELE_DEFINITION	DPYD	As an individual only carries a maximum of two fully functional DPYD copies, common normal function variants may be located on the same gene copy as other normal	2	1
ALLELE_DEFINITION	DPYD	c.1129-5923C>G is likely the HapB3 haplotype causal variant. c.1236G>A (E412E) is a proxy SNP for HapB3.	3	1
ALLELE_DEFINITION	DPYD	Individual patients have been reported (PMID 38129972) to carry only one of the two SNPs in the HapB3 haplotype (i.e., c.1236G>A without c.1129-5923C>G), suggesting that the two variants are not in complete linkage disequilibrium. CPIC updated the allele definition to include the c.1129-5923C>G SNP separately as this is likely the causal variant leading to decreased function. CPIC also retained the HapB3 haplotype definition for cases where only the c.1236G>A variant is tested (e.g. whole exome sequencing). While CPIC recommends to directly test the causal SNP if possible, in cases where only c.1236G>A is tested or results are available for, it should be clearly stated in the test report that "decreased function" was inferred by detecting the exonic tag SNP, and disclose that in rare cases, the causal decreased function variant c.1129-5923C>G may not be present despite having this tag SNP.	4	1
ALLELE_DEFINITION	DPYD	c.680+139G>A is not exclusive to HapB3 and therefore not a suitable proxy.	5	1
ALLELE_DEFINITION	DPYD	rsID rs3918290, when combined with rs1801159, makes up DPYD*2B	6	1
ALLELE_DEFINITION	DPYD	rs56293913, rs3790387, rs2811202 are all part of a common haplotype that also encompasses c.496A>G (M166V).	7	1
ALLELE_DEFINITION	DPYD	The rs115632870 variant was found to be in linkage disequilibrium (D'=1) with the decreased function variant rs115232898 (Y186C); the decreased function associated with this variant is likely due to this linkage.	8	1
ALLELE_DEFINITION	DPYD	Content is accessed through the PharmVar API. HGVS and 'PharmVar-style' (accessible on the PharmVar website) positions may differ for indels in some instances which is most likely explained by differences in sequence alignments. Also, PharmVar displays single nucleotide insertions as 'ins' while the HGVS display is as duplications or 'dub' if the insertion is the same base as the prior base.	9	1
FREQUENCY	CYP2B6	For full references see "references" tab.	0	1
FREQUENCY	CYP2B6	Average frequencies based on the reported frequencies in one or multiple studies.	1	1
FREQUENCY	CYP2B6	Based on the PharmGKB biogeographical groups https://www.pharmgkb.org/page/biogeographicalGroups	2	1
FREQUENCY	CYP2B6	See allele definition table (https://www.pharmgkb.org/page/cyp2b6RefMaterials) for allele definitions	3	1
FREQUENCY	CYP2B6	Because CYP2B6*1 is not genotyped directly, all alleles that are negative for a sequence variation are defaulted to a CYP2B6*1 assignment. The inferred frequency for CYP2B6*1 is calculated as: 1 - (sum of averaged variant allele frequencies).	4	1
TEST_ALERT	RxNorm:195085	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:195085	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:42316	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:42316	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:5470	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:5470	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:10178	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:10178	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:10178	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:10178	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
ALLELE_DEFINITION	G6PD	This modified table of G6PD variants is from PMID:22293322, https://grenada.lumc.nl/LOVD2/MR/home.php?select_db=G6PD, with several additional variants.	0	1
ALLELE_DEFINITION	G6PD	rsID=RefSNP accession ID number (http://www.ncbi.nlm.nih.gov/snp/)	1	1
ALLELE_DEFINITION	G6PD	All variants are annotated to the positive DNA strand.	2	1
ALLELE_DEFINITION	G6PD	Please note; WHO class as reported in PMID:22293322 and Luzzatto, L. & Poggi, V. Glucose-6-Phosphate Dehydrogenase Deficiency In: Nathan and Oski's Hematology of Infancy and Childhood, 7th Edition (ed. Meloni, D., Anderson, A. Authors of the book: Orkin, S.H., Fisher, D.E., Look, A.T., Lux IV, S.E., Ginsburg, D., Nathan, D.G. ) (Saunders, Elsevier., 2009) or individual references. This class may have been assigned based on just clinical\nmanifestations and not enzyme activity level or characterization of the enzyme variant.	3	1
ALLELE_DEFINITION	G6PD	Likely phenotype as referenced in this guideline, based on converting assigned WHO class to 3 phenotypes. "Normal" defined as very mild or no enzyme deficiency (>60% normal enzyme levels); "Deficient" defined as mild to severely deficient (<10-60% normal) enzyme levels; "Deficient with CNSHA" defined as severe G6PD enzyme deficiency (<10% activity) with chronic non-spherocytic hemolytic anemia based on Luzzatto, L. & Poggi, V. Glucose-6-Phosphate Dehydrogenase Deficiency In: Nathan and Oski's Hematology of Infancy and Childhood, 7th Edition (ed. Meloni, D., Anderson, A. Authors of the book: Orkin, S.H., Fisher, D.E., Look, A.T., Lux IV, S.E., Ginsburg, D., Nathan, D.G. ) (Saunders, Elsevier., 2009).	4	1
FREQUENCY	CYP2C9	For full references see "References" tab.	0	1
FREQUENCY	CYP2C9	Average frequencies based on the reported frequencies in one or multiple studies.	1	1
FREQUENCY	CYP2C9	Based on the PharmGKB biogeographical groups https://www.pharmgkb.org/page/biogeographicalGroups	2	1
FREQUENCY	CYP2C9	See allele definition table (https://www.pharmgkb.org/page/cyp2c9RefMaterials) for allele definitions	3	1
FREQUENCY	CYP2C9	Because CYP2C9*1 is not genotyped directly, all alleles that are negative for a sequence variation are defaulted to a CYP2C9*1 assignment. The inferred frequency for CYP2C9*1 is calculated as: 1 - (sum of averaged variant allele frequencies).	4	1
TEST_ALERT	RxNorm:3920	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:3920	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:10324	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:10324	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:5489	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:5489	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:10831	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:10831	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:10831	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:10831	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
ALLELE_DEFINITION	IFNL3	rsID=RefSNP accession ID number (http://www.ncbi.nlm.nih.gov/snp/)	0	1
ALLELE_DEFINITION	IFNL3	All variants are annotated to the positive DNA strand.	1	1
FREQUENCY	CYP2D6	In the Sub-Saharan African group, presented data for Twesigomwe et al., 2022 PMID 36111505 is a combination of frequencies from PMID 36111505 and Wang et al. 2022 PMID 36294714. See the Methods and Caveats tab for how *1 frequencies are determined for this file.	0	1
TEST_ALERT	RxNorm:321988	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:321988	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:37790	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:37790	Pharmacist, pharmacologist, or a clinician with pharmacogenetic expertise/training.	1	1
TEST_ALERT	RxNorm:5521	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:5521	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:5521	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:5521	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
TEST_ALERT	RxNorm:10184	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:10184	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:10184	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:10184	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
ALLELE_DEFINITION	MT-RNR1	Variant selection based on the CPIC guideline for aminoglycoside antibiotics and MT-RNR1.	0	1
FREQUENCY	CYP3A5	For full references see "References" tab.	0	1
FREQUENCY	CYP3A5	Average frequencies based on the reported frequencies in one or multiple studies.	1	1
FREQUENCY	CYP3A5	Based on the PharmGKB biogeographical groups https://www.pharmgkb.org/page/biogeographicalGroups	2	1
FREQUENCY	CYP3A5	See the Allele Definition Table at http://www.pharmgkb.org/cyp3a5RefMaterials for allele definitions	3	1
FREQUENCY	CYP3A5	Because CYP3A5*1 is not genotyped directly, all alleles that are negative for a sequence variation are defaulted to a CYP3A5*1 assignment. The inferred frequency for CYP3A5*1 is calculated as: 1 - (sum of averaged variant allele frequencies).	4	1
TEST_ALERT	RxNorm:41127	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:41127	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:10834	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:10834	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:5640	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:5640	Pharmacist, pharmacologist, or a clinician with pharmacogenetic expertise/training.	1	1
TEST_ALERT	RxNorm:9524	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:9524	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:9524	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:9524	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
ALLELE_DEFINITION	NAT2	rsID = RefSNP accession ID number (http://www.ncbi.nlm.nih.gov/snp/)	0	1
ALLELE_DEFINITION	NAT2	All variants are annotated to the positive DNA strand.	1	1
ALLELE_DEFINITION	NAT2	Structural variants are represented using the PharmVar ID.	2	1
ALLELE_DEFINITION	NAT2	See PharmVar website (http://www.pharmvar.org) for comprehensive haplotype definitions of NAT2 variant alleles and updated allele information.	3	1
ALLELE_DEFINITION	NAT2	An important caveat for all genotyping tests is that the decision to assign an allele a "wild-type" status is based upon a genotyping test that interrogates only the most common and already-proven sites of functional variation. In human DNA, it is always possible that a new, previously undiscovered (and therefore un-interrogated) site of variation may confer loss-of-function in an individual, and thus lead to the rare possibility of a non-functional allele being erroneously called as "wild-type."	4	1
ALLELE_DEFINITION	NAT2	Some drastic changes have been made to NAT2 nomenclature during transition from the original (Database of Arylamine N-Acetyltransferases (NATs)) to the new (https://www.pharmvar.org/gene/NAT2) "star" allele definitions:	5	1
ALLELE_DEFINITION	NAT2	The NAT2 reference allele has now changed: The NG_012246.1 RefSeq differs from X14672.1 (which was used in the past to define star alleles) at the position that corresponds to c.803 (rs1208), where X14672.1 has "A" while NG_012246.1 has "G". Thus, depending on which reference sequence is utilized, this position is reported as either reference or variant. The transition of allele definitions to the NG_012246.1 RefSeq caused "variant switching", meaning that all star alleles which were previously described as having c.803A>G lost this variant, as "G" is now considered reference, while all other star alleles gained c.803G>A, as "A" is now considered variant.	6	1
ALLELE_DEFINITION	NAT2	The new reference allele is now catalogued as NAT2*1: The sequence of NG_012246.1 RefSeq corresponds to the allele that was formerly described as NAT2*12A. Its renaming as NAT2*1.001 facilitates the application of PharmVar rules to NAT2 allelic nomenclature, while it also enables the use of NAT2*1 name to describe the reference allele, in line with the star allele nomenclature of other pharmacogenes. To avoid confusion during the transition from the legacy to the new nomenclature, *12 is now retired. Having a NAT2*1 allele grouping in place also facilitates NGS analyses using GRCh38 as a reference.	7	1
ALLELE_DEFINITION	NAT2	NAT2*4 is no longer considered as the reference allele: Alleles carrying c.803G>A as their only amino acid changing SNV will be called as *4 according to the new nomenclature. This includes the former NAT2*4 reference allele of sequence X14672.1, now considered a variant and listed as NAT2*4.001. Although this will no longer be used as a reference, it is considered to be functionally equivalent to NAT2*1.001 (formerly NAT2*12A) and may still be used to compare the enzymatic or structural properties of polymorphic NAT2 proteins.	8	1
ALLELE_DEFINITION	NAT2	Not all previously defined star alleles have been transferred: In the past, it has not always been clear how a NAT2 haplotype was determined. Many have been inferred via computational phase analysis and were not verified experimentally. In the case of haplotypes where the available evidence from the literature was deemed insufficient to support confident allele definition, those haplotypes were not transferred to PharmVar, but they will remain posted on the original Database of Arylamine N-Acetyltransferases (NATs).	9	1
ALLELE_DEFINITION	NAT2	This file contains the PharmVar NAT2 core allele definitions.	10	1
ALLELE_DEFINITION	NAT2	Alleles with content annotated in PharmGKB but not included in PharmVar (*5G, *5J, *5M, *5U, *6J, *7G, *17) are added using the the original Database of Arylamine N-Acetyltransferases (NATs, http://nat.mbg.duth.gr/Human%20NAT2%20alleles_2013.htm) definitions. This results in the inclusion of 2 synonymous SNPs (added in grey). PharmVar NAT2 core alleles do not include these SNPs although those are part of many NAT2 suballeles and the cells in the core alleles are therefore left blank in this file (see PharmVar for all transitioned NAT2 suballeles and about what is included in a core allele definition). Additionally, with transitioning to PharmVar, the change at p.268 is now according to the reference sequence R268K (see above information). Therefore, original definitions that include K268R will have a blank cell, while alleles that did not include the SNP will now have an "A" at this position.\nPositions added: \n226T>G part of *7G\n434A>C part of *17\n282C>T and 481C>T synonymous SNPs\n*5G has K268R - 803G =ref at this position, therefore blank\n*5J has 803A \n*5M has K268R - 803G =ref at this position, therefore blank\n*5U has K268R - 803G =ref at this position, therefore blank\n*6J has 803A \n*7G has 803A \n*17 has 803A	11	1
FREQUENCY	CYP4F2	For full references see "references" tab.	0	1
FREQUENCY	CYP4F2	Average frequencies based on the reported frequencies in one or multiple studies.	1	1
FREQUENCY	CYP4F2	Based on the PharmGKB biogeographical groups https://www.pharmgkb.org/page/biogeographicalGroups	2	1
FREQUENCY	CYP4F2	See allele definition table (https://www.pharmgkb.org/page/cyp4f2RefMaterials) for allele definitions	3	1
FREQUENCY	CYP4F2	Because CYP4F2*1 is not genotyped directly, all alleles that are negative for a sequence variation are defaulted to a CYP4F2*1 assignment. The inferred frequency for CYP4F2*1 is calculated as: 1 - (sum of averaged variant allele frequencies).	4	1
TEST_ALERT	RxNorm:42355	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:42355	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:121243	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:121243	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:121243	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:121243	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
TEST_ALERT	RxNorm:6099	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:6099	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:10207	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:10207	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:10207	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:10207	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
ALLELE_DEFINITION	NUDT15	PharmVAR releases new alleles based on received submissions, see https://www.pharmvar.org/gene/NUDT15 for comprehensive haplotype definitions of NUDT15 variant alleles, including sub-alleles, and updated allele information.	0	1
ALLELE_DEFINITION	NUDT15	The variants included in the alleles are based on the PharmVar core alleles (for core allele definitions only, see https://www.pharmvar.org/gene/NUDT15). In addition, variants that present in the core allele for one star allele but also present in some but not all suballeles of another star allele are included in the other star allele as ambiguous changes, e.g. the *3 consensus allele includes a "GAGTCG(3) or GAGTCG(4)" at the position 55_56insGAGTCG since this variant defines the *6 core allele but is not part of the *3 core allele definition in PharmVar since it is not present in all *3 suballeles. These postions are represented in grey (G) in the Comparative Allele ViewEr (CAVE) tool at PharmVar.	1	1
ALLELE_DEFINITION	NUDT15	rsID=RefSNP accession ID number (http://www.ncbi.nlm.nih.gov/snp/)	2	1
ALLELE_DEFINITION	NUDT15	All variants are annotated to the positive DNA strand.	3	1
ALLELE_DEFINITION	NUDT15	rs554405994 was merged into rs869320766 which was merged into rs746071566	4	1
ALLELE_DEFINITION	NUDT15	Content is accessed through the PharmVar API. HGVS and 'PharmVar-style' (accessible on the PharmVar website) positions may differ for indels in some instances which is most likely explained by differences in sequence alignments. Also, PharmVar displays single nucleotide insertions as 'ins' while the HGVS display is as duplications or 'dub' if the insertion is the same base as the prior base.	5	1
FREQUENCY	DPYD	Both variants in c.1129-5923C>G, c.1236G>A (HapB3) are listed with identical frequencies in 1000 Genomes	0	1
FREQUENCY	DPYD	For full references see "References" tab.	1	1
FREQUENCY	DPYD	Average frequencies based on the reported frequencies in one or multiple studies.	2	1
FREQUENCY	DPYD	Based on the PharmGKB biogeographical groups https://www.pharmgkb.org/page/biogeographicalGroups	3	1
FREQUENCY	DPYD	See allele definition table (https://www.pharmgkb.org/page/dpydRefMaterials) for allele definitions	4	1
TEST_ALERT	RxNorm:72236	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:72236	Pharmacist, pharmacologist, or a clinician with pharmacogenetic expertise/training.	1	1
TEST_ALERT	RxNorm:190521	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:190521	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:20890	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:20890	Pharmacist, pharmacologist, or a clinician with pharmacogenetic expertise/training.	1	1
TEST_ALERT	RxNorm:2054023	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:2054023	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
ALLELE_DEFINITION	RYR1	Variant selection based on an update of the CPIC guideline for potent volatile anesthetic agents and succinylcholine. The guideline update includes the published list of RYR1 variants (supplemental table S2), which are evaluated by the ClinGen malignant hyperthermia susceptibility (MHS) variant curation expert panel and classified for RYR1-related malignant hyperthermia susceptibility based on specified the ACMG/AMP criteria (PMID 35849058).	0	1
ALLELE_DEFINITION	RYR1	The deletion of an E can be represented as E2347del orE2348del (c.7039_7041delGAG or c.7042_7044delGAG, respectivly). c.7042_7044delGAG is used to name the variant in the file to reflect the ClinGen naming, however the mapping of the variant is done according to the corresponding rsID rs121918596.	1	1
FREQUENCY	G6PD	The allele frequency table was made by searching the gnomAD database v2.1.1 except for Cairo from v3.1.2	0	1
FREQUENCY	G6PD	Based on the PharmGKB biogeographical groups https://www.pharmgkb.org/page/biogeographicalGroups	1	1
FREQUENCY	G6PD	See allele definition table (https://www.pharmgkb.org/page/g6pdRefMaterials) for allele definitions	2	1
FREQUENCY	G6PD	Because B(reference) is not genotyped directly, all alleles that are negative for a sequence variation are defaulted to a B (reference) assignment. The inferred frequency for B(reference) is calculated as: 1 - (sum of averaged variant allele frequencies) but this may not be accurate since there are many variants with no known frequency.	3	1
FREQUENCY	G6PD	Note that gnomAD does not calculate haploytpe frequencies. Some haplotypes have frequencies in this spreadsheet if a unique allele in the haplotype has frequency information in gnomAD AND if the other variant in the haplotype is known to have normal function	4	1
FREQUENCY	G6PD	Note that some variants in this spreadsheet can either be found alone or in a haplotype (in combination with other variants). Therefore the frequency reported MAY NOT BE FOR THE VARIANT ALONE, BUT ALSO FOR THE VARIANT IF FOUND IN A HAPLOTYPE.	5	1
TEST_ALERT	RxNorm:5095	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:5095	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:519	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:519	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:6572	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:6572	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:6572	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:6572	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
TEST_ALERT	RxNorm:10485	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:10485	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
ALLELE_DEFINITION	SLCO1B1	rsID=RefSNP accession ID number (http://www.ncbi.nlm.nih.gov/snp/)	0	1
ALLELE_DEFINITION	SLCO1B1	All variants are annotated to the positive DNA strand.	1	1
ALLELE_DEFINITION	SLCO1B1	An important caveat for all genotyping tests is that the decision to assign an allele a "wild-type" status is based upon a genotyping test that interrogates only the most common and already-proven sites of functional variation. In human DNA, it is always possible that a new, previously undiscovered (and therefore un-interrogated) site of variation may confer loss-of-function in an individual, and thus lead to the rare possibility of a non-functional allele being erroneously called as "wild-type."	2	1
ALLELE_DEFINITION	SLCO1B1	Citations for assignment of function can be found at https://www.pharmgkb.org/page/slco1b1RefMaterials	3	1
FREQUENCY	HLA-A	For full references see "References" tab.	0	1
FREQUENCY	HLA-A	Average frequencies based on the reported frequencies in one or multiple studies.	1	1
FREQUENCY	HLA-A	Based on the PharmGKB biogeographical groups https://www.pharmgkb.org/page/biogeographicalGroups	2	1
TEST_ALERT	RxNorm:5691	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:5691	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:641	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:641	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:41493	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:41493	Pharmacist, pharmacologist, or a clinician with pharmacogenetic expertise/training.	1	1
TEST_ALERT	RxNorm:10627	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:10627	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
ALLELE_DEFINITION	TPMT	rsID=RefSNP accession ID number (http://www.ncbi.nlm.nih.gov/snp/)	0	1
ALLELE_DEFINITION	TPMT	All variants are annotated to the positive DNA strand.	1	1
ALLELE_DEFINITION	TPMT	Variants are sourced from the TPMT nomenclature committee (TPMT Alleles), see https://liu.se/en/research/tpmt-nomenclature-committee	2	1
FREQUENCY	HLA-B	For full references see "References" tab.	0	1
FREQUENCY	HLA-B	aAverage frequencies based on the reported frequencies in one or multiple studies.	1	1
FREQUENCY	HLA-B	bBased on the PharmGKB biogeographical groups https://www.pharmgkb.org/page/biogeographicalGroups	2	1
TEST_ALERT	RxNorm:6026	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:6026	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:7833	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:7833	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:7833	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:7833	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
TEST_ALERT	RxNorm:103	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:103	"Clinical pharmacist" could also be pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	1	1
TEST_ALERT	RxNorm:10635	The specific wording of the alert text may differ among sites.	0	1
TEST_ALERT	RxNorm:10635	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenomics expertise/training.	1	1
TEST_ALERT	RxNorm:10635	The specific wording of the alert text may differ among sites.	2	1
TEST_ALERT	RxNorm:10635	"Clinical pharmacist" may be a pharmacist, pharmacologist, or a clinician with pharmacogenetics expertise/training.	3	1
ALLELE_DEFINITION	UGT1A1	rsID=RefSNP accession ID number (http://www.ncbi.nlm.nih.gov/snp/)	0	1
ALLELE_DEFINITION	UGT1A1	All variants are annotated to the positive DNA strand.	1	1
ALLELE_DEFINITION	UGT1A1	To see a full list of known UGT1A1 alleles see https://www.pharmacogenomics.pha.ulaval.ca/wp-content/uploads/2015/04/UGT1A1-allele-nomenclature.html	2	1
ALLELE_DEFINITION	UGT1A1	An important caveat for all genotyping tests is that the decision to assign an allele a "wild-type" status is based upon a genotyping test that interrogates only the most common and already- proven sites of functional variation. In human DNA, it is always possible that a new, previously undiscovered (and therefore un-interrogated) site of variation may confer loss-of-function in an individual, and thus lead to the rare possibility of a non-functional allele being erroneously called as "wild-type".	3	1
ALLELE_DEFINITION	UGT1A1	Citations for assignment of function can be found at https://www.pharmgkb.org/page/ugt1a1RefMaterials	4	1
ALLELE_DEFINITION	UGT1A1	UGT1A1*80 is in very high linkage disequilibrium with *28 and *37. However, the function of the *80 allele alone, in the absence of *28 or *37, is uncertain. If a patient is only tested for *80, decreased function may be inferred, though linkage is not 100%.	5	1
ALLELE_DEFINITION	UGT1A1	TA repeat: Historically in the literature and at the UGT nomenclature website, the TA repeat is referred to as TA(6) for *1, TA(7) for *28, TA(5) for *36, etc. The UGT allele nomenclature website (https://www.pharmacogenomics.pha.ulaval.ca/wp-content/uploads/2015/04/UGT1A1-allele-nomenclature.html) defines them in more detail as for example: A(TA)6TAA to A(TA)7TAA for *28 and A(TA)6TAA to A(TA)5TAA for *36. Note that after the repeat and number, there is an additional TA listed in the flanking sequence as "TAA". Similar nomenclature/representation is in cell C2 of the table on the "Alleles" tab as historical referencing ("CA" in front as an anchor for the point in the sequence that the TA repeats are starting from). Rows 4 and 5 align with the indicated reference sequences. In cells C4 and C5, when counting from the first TA at the given position in the sequence and including the last TA, the 5, 6, 7, 8 repeats become 6, 7, 8, 9 because there are actually 6 to 9 "TA" repeats in the genomic and gene reference sequences.	6	1
\.


--
-- Data for Name: flyway_schema_history; Type: TABLE DATA; Schema: cpic; Owner: -
--

COPY cpic.flyway_schema_history (installed_rank, version, description, type, script, checksum, installed_by, installed_on, execution_time, success) FROM stdin;
1	1	Initial bootstrap	SQL	V1__Initial_bootstrap.sql	1343833882	cpic	2020-09-30 21:02:41.398674	17646	t
2	2	initial data	SQL	V2__initial_data.sql	1569953039	cpic	2020-09-30 21:03:00.181244	1464	t
3	3	views	SQL	V3__views.sql	1637573145	cpic	2020-09-30 21:03:02.68466	2906	t
4	4	flow charts	SQL	V4__flow_charts.sql	-461764197	cpic	2020-09-30 21:03:06.637242	3674	t
5	6	nsaid release	SQL	V6__nsaid_release.sql	1899796322	cpic	2020-09-30 21:03:11.349979	2479	t
6	7	nsaid pair data	SQL	V7__nsaid_pair_data.sql	-1759040576	cpic	2020-09-30 21:03:14.862537	1507	t
7	8	data progress view	SQL	V8__data_progress_view.sql	-583739949	cpic	2020-09-30 21:03:17.405314	325	t
8	9	file view	SQL	V9__file_view.sql	-435728782	cpic	2020-09-30 21:03:18.784115	320	t
9	10	pair data update	SQL	V10__pair_data_update.sql	1561416759	cpic	2020-09-30 21:03:20.133162	720	t
10	11	guideline in drug model	SQL	V11__guideline_in_drug_model.sql	1721141764	cpic	2020-09-30 21:03:21.898691	476	t
11	12	pair data update	SQL	V12__pair_data_update.sql	-1970090295	cpic	2020-09-30 21:03:23.402028	233	t
12	13	add publications	SQL	V13__add_publications.sql	1291951866	cpic	2020-09-30 21:03:24.679997	320	t
13	14	add highlighted publications	SQL	V14__add_highlighted_publications.sql	759335679	cpic	2020-09-30 21:03:26.044179	399	t
14	15	pair data update	SQL	V15__pair_data_update.sql	81113836	cpic	2020-09-30 21:03:27.481903	243	t
15	16	update ibuprofen ATC	SQL	V16__update_ibuprofen_ATC.sql	1407599949	cpic	2020-09-30 21:03:28.777477	243	t
16	18	allele status lookup	SQL	V18__allele_status_lookup.sql	-859499970	cpic	2020-09-30 21:03:30.070317	482	t
17	19	new publication	SQL	V19__new_publication.sql	-1342471317	cpic	2020-09-30 21:03:31.581321	315	t
18	20	update sequence IDs	SQL	V20__update_sequence_IDs.sql	-75396910	cpic	2020-09-30 21:03:32.939966	480	t
19	21	recommendation lookup fn	SQL	V21__recommendation_lookup_fn.sql	-1422255981	cpic	2020-09-30 21:03:34.466215	478	t
20	22	ppi release	SQL	V22__ppi_release.sql	-1608844545	cpic	2020-09-30 21:03:35.973984	885	t
21	23	helpful views	SQL	V23__helpful_views.sql	1737227498	cpic	2020-09-30 21:03:37.894656	1362	t
22	24	new drug flowcharts	SQL	V24__new_drug_flowcharts.sql	426101726	cpic	2020-09-30 21:03:40.286768	888	t
23	25	phenytoin guideline update	SQL	V25__phenytoin_guideline_update.sql	-746232628	cpic	2020-09-30 21:03:42.235826	481	t
24	26	validate pair pmids	SQL	V26__validate_pair_pmids.sql	-1806818774	cpic	2020-09-30 21:03:43.755407	240	t
25	27	reference allele	SQL	V27__reference_allele.sql	849245471	cpic	2020-09-30 21:03:45.03582	1701	t
26	\N	apply permissions	SQL	R__apply_permissions.sql	-1445996752	cpic	2020-09-30 21:03:47.781042	1352	t
27	28	more allele frequency	SQL	V28__more_allele_frequency.sql	805701621	cpic	2020-10-06 04:45:31.882019	65	t
28	29	gene notes on diplotype	SQL	V29__gene_notes_on_diplotype.sql	-32272162	cpic	2020-10-06 04:45:31.979835	39	t
29	30	fix diplotype note column name	SQL	V30__fix_diplotype_note_column_name.sql	-1780194441	cpic	2020-10-06 20:33:55.825135	12	t
30	31	structural variant alleles	SQL	V31__structural_variant_alleles.sql	907385290	cpic	2020-10-21 16:33:11.171586	21	t
31	32	more notes	SQL	V32__more_notes.sql	946380705	cpic	2020-10-26 04:13:26.606463	33	t
32	33	remove allele frequency	SQL	V33__remove_allele_frequency.sql	370457724	cpic	2020-10-29 02:34:55.945477	28	t
33	34	add constraints to publication	SQL	V34__add_constraints_to_publication.sql	1822736403	cpic	2020-12-07 19:33:55.270759	86	t
34	35	opioid release	SQL	V35__opioid_release.sql	-334675632	cpic	2021-01-08 00:30:17.865038	51	t
35	36	update allele view	SQL	V36__update_allele_view.sql	-926799802	cpic	2021-01-15 23:54:12.278947	96	t
36	37	remove unused column	SQL	V37__remove_unused column.sql	-2122981860	cpic	2021-03-25 17:42:36.558878	134	t
37	38	gene urls	SQL	V38__gene_urls.sql	1563545318	cpic	2021-03-25 17:42:36.742551	62	t
38	\N	apply permissions	SQL	R__apply_permissions.sql	-575065814	cpic	2021-03-25 17:42:36.82488	28	t
39	39	guideline summary view	SQL	V39__guideline_summary_view.sql	480060255	cpic	2021-03-26 20:19:53.149371	58	t
40	\N	apply permissions	SQL	R__apply_permissions.sql	-1861354715	cpic	2021-03-26 20:19:53.225004	31	t
41	40	fix flowchart urls	SQL	V40__fix_flowchart_urls.sql	-1456884835	cpic	2021-05-11 18:22:43.25079	46	t
43	42	aminoglycosides guideline	SQL	V42__aminoglycosides_guideline.sql	540949488	cpic	2021-06-14 04:40:37.690857	93	t
44	43	seq loc unique key	SQL	V43__seq_loc_unique_key.sql	-1638696174	cpic	2021-06-14 04:40:37.808891	52	t
45	44	functionmethods	SQL	V44__functionmethods.sql	2079604482	cpic	2021-06-29 15:43:53.422219	16	t
46	45	sequence location position	SQL	V45__sequence_location_position.sql	1314277241	cpic	2021-07-09 21:30:29.833003	102	t
47	46	fix dbsnpid column	SQL	V46__fix_dbsnpid_column.sql	-1850897598	cpic	2021-08-05 17:38:43.759722	21	t
48	47	guideline fns	SQL	V47__guideline_fns.sql	-1198346012	cpic	2021-08-18 22:14:26.14922	30	t
49	48	update guideline allele fn	SQL	V48__update_guideline_allele_fn.sql	-1854568090	cpic	2021-09-09 21:03:26.214156	30	t
50	49	fix allele findings	SQL	V49__fix_allele_findings.sql	976892510	cpic	2021-09-09 21:03:26.268771	65	t
51	50	fix IFNL3 lookup	SQL	V50__fix_IFNL3_lookup.sql	119727388	cpic	2021-10-13 17:22:27.82421	9	t
52	51	fix guideline allele fn	SQL	V51__fix_guideline_allele_fn.sql	798068262	cpic	2021-11-10 05:57:09.346894	62	t
53	52	recommendation alleles view	SQL	V52__recommendation_alleles_view.sql	-1879594301	cpic	2021-12-07 15:59:50.932388	98	t
54	\N	apply permissions	SQL	R__apply_permissions.sql	-1576403970	cpic	2021-12-07 15:59:51.080556	20	t
55	53	statins guideline	SQL	V53__statins_guideline.sql	-374639719	cpic	2022-02-16 23:10:42.374259	18	t
56	54	publication index	SQL	V54__publication_index.sql	-1084867310	cpic	2022-02-18 22:16:35.644864	11	t
57	55	allele frequency cache	SQL	V55__allele_frequency_cache.sql	778761699	cpic	2022-03-09 23:20:36.042025	13	t
58	56	gene legacy names	SQL	V56__gene_legacy_names.sql	-442391864	cpic	2022-03-17 23:13:23.411535	13	t
59	57	pgkb recs fn update	SQL	V57__pgkb_recs_fn_update.sql	415609266	cpic	2022-06-10 14:24:09.906199	22	t
42	41	publication files	SQL	V41__publication_files.sql	389573953	cpic	2021-05-11 18:22:43.398622	319	t
60	\N	apply permissions	DELETE	R__apply_permissions.sql	-1576403970	cpic	2022-08-16 07:29:30.595272	0	t
61	58	stats table	SQL	V58__stats_table.sql	1603923816	cpic	2022-08-16 07:35:43.159887	60	t
62	59	remove allele guideline	SQL	V59__remove_allele_guideline.sql	-1144551837	cpic	2022-09-14 17:55:53.477071	21	t
63	60	reference allele	SQL	V60__reference_allele.sql	1296637883	cpic	2022-09-14 17:55:53.52649	26	t
64	61	G6PD guideline prep	SQL	V61__G6PD_guideline_prep.sql	1983975991	cpic	2022-09-14 17:55:53.577532	28	t
65	62	G6PD flow charts	SQL	V62__G6PD_flow_charts.sql	626814934	cpic	2022-09-22 16:42:28.143006	29	t
66	63	fosphenytoin flow chart	SQL	V63__fosphenytoin_flow_chart.sql	1952328724	cpic	2022-09-30 13:34:29.608278	28	t
67	64	recommendation flags	SQL	V64__recommendation_flags.sql	-797174188	cpic	2023-02-27 19:42:13.143746	42	t
68	65	frequency flags	SQL	V65__frequency_flags.sql	-477833361	cpic	2023-03-23 11:54:36.147354	42	t
69	66	ssri snri guideline	SQL	V66__ssri_snri_guideline.sql	-1949888557	cpic	2023-04-12 19:43:47.434594	34	t
70	67	frequency view fix	SQL	V67__frequency_view_fix.sql	-1816979743	cpic	2023-09-01 14:42:15.154823	41	t
71	68	fix function definitions	SQL	V68__fix_function_definitions.sql	1243132888	cpic	2024-01-12 20:33:40.207106	11	t
72	69	change log releases	SQL	V69__change_log_releases.sql	1272931372	cpic	2024-05-09 15:03:57.003783	276	t
73	70	fix allele freq view	SQL	V70__fix_allele_freq_view.sql	-957778206	cpic	2024-10-03 15:13:15.938037	9	t
74	71	fix guideline summary view	SQL	V71__fix_guideline_summary_view.sql	-1334280856	cpic	2025-03-07 16:21:39.906989	8	t
75	72	gene cds changelog	SQL	V72__gene_cds_changelog.sql	1161542228	cpic	2025-08-13 13:08:11.731509	7	t
76	73	clinpgx guideline update	SQL	V73__clinpgx_guideline_update.sql	-1024347267	cpic	2025-08-13 13:08:11.764363	15	t
77	74	supplemental file cleanup	SQL	V74__supplemental_file_cleanup.sql	822347170	cpic	2025-08-21 13:23:06.297301	15	t
78	75	hydrazaline guideline	SQL	V75__hydrazaline_guideline.sql	1311712376	cpic	2025-09-08 15:29:54.084279	6	t
79	76	rename summary level	SQL	V76__rename_summary_level.sql	-1125398572	cpic	2026-03-13 12:58:42.488466	8	t
80	77	pharmgkb rename	SQL	V77__pharmgkb_rename.sql	1687555689	cpic	2026-03-13 12:58:42.52321	13	t
81	78	thiopurines correction	SQL	V78__thiopurines_correction.sql	291071853	cpic	2026-05-11 20:30:04.945932	6	t
\.


--
-- Data for Name: gene; Type: TABLE DATA; Schema: cpic; Owner: -
--

COPY cpic.gene (symbol, chr, genesequenceid, proteinsequenceid, chromosequenceid, mrnasequenceid, hgncid, ncbiid, ensemblid, clinpgxid, frequencymethods, lookupmethod, version, notesondiplotype, url, functionmethods, notesonallelenaming, includephenotypefrequencies, includediplotypefrequencies) FROM stdin;
F5	chr1	NG_011806	NP_000121	\N	\N	HGNC:3542	2153	ENSG00000198734	PA159	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
CYB5R3	chr22	NG_012194	NP_000389	\N	\N	HGNC:2873	1727	ENSG00000100243	PA27331	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
CHRNA3	chr15	NG_016143	NP_000734	\N	\N	HGNC:1957	1136	ENSG00000080644	PA113	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
HMGCR	chr5	NG_011449	NP_000850	\N	\N	HGNC:5006	3156	ENSG00000113161	PA189	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
MTRR	chr5	NG_008856	NP_002445	\N	\N	HGNC:7473	4552	ENSG00000124275	PA31277	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
LPA	chr6	NG_016147	NP_005568	\N	\N	HGNC:6667	4018	ENSG00000198670	PA30432	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
ADRA2C	\N	\N	\N	\N	\N	HGNC:283	152	ENSG00000184160	PA37	\N	PHENOTYPE	27	\N	https://cpicpgx.org/gene/adra2c/	\N	\N	t	t
NAT1	chr8	NG_012245	NP_000653	\N	\N	HGNC:7645	9	ENSG00000171428	PA17	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
CPS1	chr2	NG_008285	NP_001866	\N	\N	HGNC:2323	1373	ENSG00000021826	PA26840	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
EGF	chr4	NG_011441	NP_001954	\N	\N	HGNC:3229	1950	ENSG00000138798	PA27664	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
CRHR1	chr17	NG_009902	NP_004373	\N	\N	HGNC:2357	1394	ENSG00000120088	PA26874	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
ACE	chr17	NG_011648	NP_000780	\N	\N	HGNC:2707	1636	ENSG00000159640	PA139	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
CALU	chr7	\N	NP_001210	\N	\N	HGNC:1458	813	ENSG00000128595	PA26047	\N	PHENOTYPE	115	\N	\N	\N	\N	t	t
ITPA	chr20	NG_012093	NP_258412	\N	\N	HGNC:6176	3704	ENSG00000125877	PA29973	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
MC4R	chr18	NG_016441	NP_005903	\N	\N	HGNC:6932	4160	ENSG00000166603	PA30676	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
COQ2	chr4	NG_015825	NP_056512	\N	\N	HGNC:25223	27235	ENSG00000173085	PA142672084	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
DYNC2H1	chr11	NG_016423	NP_001368	\N	\N	HGNC:2962	79659	ENSG00000187240	PA27433	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
GNB3	chr12	NG_009100	NP_002066	\N	\N	HGNC:4400	2784	ENSG00000111664	PA176	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
SEMA3C	chr7	\N	NP_006370	\N	\N	HGNC:10725	10512	ENSG00000075223	PA35647	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
KIF6	chr6	\N	NP_659464	\N	\N	HGNC:21202	221458	ENSG00000164627	PA134920075	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
CCHCR1	chr6	\N	NP_061925	\N	\N	HGNC:13930	54535	ENSG00000204536	PA134942738	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
FCGR3A	chr1	NG_009066	NP_000560	\N	\N	HGNC:3619	2214	ENSG00000203747	PA28065	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
NAGS	chr17	NG_008106	NP_694551	\N	\N	HGNC:17996	162417	ENSG00000161653	PA134968729	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
LDLR	chr19	NG_009060	NP_000518	\N	\N	HGNC:6547	3949	ENSG00000130164	PA227	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
ASL	chr7	NG_009288	NP_000039	\N	\N	HGNC:746	435	ENSG00000126522	PA25046	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
HPRT1	chrX	NG_012329	NP_000185	\N	\N	HGNC:5157	3251	ENSG00000165704	PA29427	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
ANKK1	chr11	NG_012976	NP_848605	\N	\N	HGNC:21027	255239	ENSG00000170209	PA134872551	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
XPC	chr3	NG_011763	NP_004619	\N	\N	HGNC:12816	7508	ENSG00000154767	PA37413	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
ADRB2	chr5	NG_016421	NP_000015	\N	\N	HGNC:286	154	ENSG00000169252	PA39	\N	PHENOTYPE	4	\N	https://cpicpgx.org/gene/adrb2/	\N	\N	t	t
FKBP5	chr6	NG_012645	NP_004108	\N	\N	HGNC:3721	2289	ENSG00000096060	PA28162	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
TXNRD2	chr22	NG_011835	NP_006431	\N	\N	HGNC:18155	10587	ENSG00000184470	PA38302	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
GBA	chr1	NG_009783	NP_000148	\N	\N	HGNC:4177	2629	ENSG00000177628	PA28591	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
HLA-DRB1	chr6	NG_002392	NP_002115	\N	\N	HGNC:4948	3123	ENSG00000196126	PA35072	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
CETP	chr16	NG_008952	NP_000069	\N	\N	HGNC:1869	1071	ENSG00000087237	PA108	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
UGT1A4	chr2	NG_002601	NP_009051	\N	\N	HGNC:12536	54657	ENSG00000244474	PA37179	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
TP53	chr17	NG_017013	NP_000537	\N	\N	HGNC:11998	7157	ENSG00000141510	PA36679	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
PRKCA	chr17	NG_012206	NP_002728	\N	\N	HGNC:9393	5578	ENSG00000154229	PA33759	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
HTR2C	chrX	NG_012082	NP_000859	\N	\N	HGNC:5295	3358	ENSG00000147246	PA194	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
OTC	chrX	NG_008471	NP_000522	\N	\N	HGNC:8512	5009	ENSG00000036473	PA32840	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
CES1	chr16	NG_012057	NP_001257	\N	\N	HGNC:1863	1066	ENSG00000198848	PA107	\N	PHENOTYPE	114	\N	\N	\N	\N	t	t
ERCC1	chr19	NG_015839	NP_001974	\N	\N	HGNC:3433	2067	ENSG00000012061	PA155	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
POLG	chr15	NG_008218	NP_002684	\N	\N	HGNC:9179	5428	ENSG00000140521	PA33500	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
ASS1	chr9	NG_011542	NP_000041	\N	\N	HGNC:758	445	ENSG00000130707	PA162376926	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
DRD2	chr11	NG_008841	NP_000786	\N	\N	HGNC:3023	1813	ENSG00000149295	PA27478	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
ATIC	chr2	NG_013002	NP_004035	\N	\N	HGNC:794	471	ENSG00000138363	PA25094	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
APOE	chr19	NG_007084	NP_000032	\N	\N	HGNC:613	348	ENSG00000130203	PA55	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
GSTM1	chr1	NG_009246	NP_000552	\N	\N	HGNC:4632	2944	ENSG00000134184	PA182	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
CYB5R1	chr1	\N	NP_057327	\N	\N	HGNC:13397	51706	ENSG00000159348	PA134979668	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
SLC28A3	chr9	\N	NP_071410	\N	\N	HGNC:16484	64078	ENSG00000197506	PA426	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
FDPS	chr1	\N	NP_001995	\N	\N	HGNC:3631	2224	ENSG00000160752	PA28075	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
PTGFR	chr1	\N	NP_000950	\N	\N	HGNC:9600	5737	ENSG00000122420	PA290	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
KCNIP4	chr4	\N	NP_671711	\N	\N	HGNC:30083	80333	ENSG00000185774	PA134893552	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
TCF7L2	chr10	NG_012631	NP_110383	\N	\N	HGNC:11641	6934	ENSG00000148737	PA36394	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
HLA-DQA1	chr6	\N	NP_002113	\N	\N	HGNC:4942	3117	ENSG00000196735	PA35066	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
ADD1	chr4	NG_012037	NP_001110	\N	\N	HGNC:243	118	ENSG00000087274	PA31	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
ABCC4	chr13	\N	NP_005836	\N	\N	HGNC:55	10257	ENSG00000125257	PA397	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
ABL2	chr1	\N	NP_005149	\N	\N	HGNC:77	27	ENSG00000143322	PA24414	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
UGT2B15	chr4	\N	NP_001067	\N	\N	HGNC:12546	7366	ENSG00000196620	PA37188	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
YEATS4	chr12	\N	NP_006521	\N	\N	HGNC:24859	8089	ENSG00000127337	PA134992686	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
TANC1	chr2	\N	NP_203752	\N	\N	HGNC:29364	85461	ENSG00000115183	PA142670838	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
TMEM43	chr3	NG_008975	NP_077310	\N	\N	HGNC:28472	79188	ENSG00000170876	PA134871907	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
CRHR2	chr7	\N	NP_001874	\N	\N	HGNC:2358	1395	ENSG00000106113	PA26875	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
SOD2	chr6	NG_008729	NP_000627	\N	\N	HGNC:11180	6648	ENSG00000112096	PA36017	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
SERPINC1	chr1	NG_012462	NP_000479	\N	\N	HGNC:775	462	ENSG00000117601	PA35026	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
TNF	chr6	NG_007462	NP_000585	\N	\N	HGNC:11892	7124	ENSG00000232810	PA435	\N	PHENOTYPE	3	\N	\N	\N	\N	t	t
C11orf65	chr11	\N	NP_689800	\N	\N	HGNC:28519	160140	ENSG00000166323	PA144596484	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
HAS3	chr16	\N	NP_005320	\N	\N	HGNC:4820	3038	ENSG00000103044	PA29196	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
CYB5R2	chr11	\N	NP_057313	\N	\N	HGNC:24376	51700	ENSG00000166394	PA142672060	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
SLC47A2	chr17	\N	NP_001093116	\N	\N	HGNC:26439	146802	ENSG00000180638	PA162403847	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
CBR3	chr21	\N	NP_001227	\N	\N	HGNC:1549	874	ENSG00000159231	PA26122	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
NT5C2	chr10	\N	NP_036361	\N	\N	HGNC:8022	22978	ENSG00000076685	PA31801	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
CYB5R4	chr6	\N	NP_057314	\N	\N	HGNC:20147	51167	ENSG00000065615	PA134904907	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
C8orf34	chr8	\N	NP_443190	\N	\N	HGNC:30905	116328	ENSG00000165084	PA142672353	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
ADRB1	\N	\N	\N	\N	\N	HGNC:285	153	ENSG00000043591	PA38	\N	PHENOTYPE	113	\N	https://cpicpgx.org/gene/adrb1/	\N	\N	t	t
ADORA2A	chr22	\N	NP_000666	\N	\N	HGNC:263	135	ENSG00000128271	PA24584	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
PTGS1	chr9	\N	NP_000953	\N	\N	HGNC:9604	5742	ENSG00000095303	PA24346	\N	PHENOTYPE	115	\N	\N	\N	\N	t	t
NAT2	chr8	NG_012246.1	NP_000006.2	NC_000008.11	NM_001042351.2	HGNC:7646	10	ENSG00000156006	PA18	\N	PHENOTYPE	140	\N	\N	\N	Common name	t	t
CYP2A7P1	chr19	NG_000008	\N	\N	\N	HGNC:2612	1550	ENSG00000213908	PA27103	\N	PHENOTYPE	115	\N	\N	\N	\N	t	t
FLOT1	chr6	\N	NP_005794	\N	\N	HGNC:3757	10211	ENSG00000137312	PA28175	\N	PHENOTYPE	115	\N	\N	\N	\N	t	t
GRIK4	chr11	\N	NP_055434	\N	\N	HGNC:4582	2900	ENSG00000149403	PA28976	\N	PHENOTYPE	115	\N	\N	\N	\N	t	t
NEDD4L	chr18	\N	NP_056092	\N	\N	HGNC:7728	23327	ENSG00000049759	PA31534	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
GRK4	\N	\N	\N	\N	\N	HGNC:4543	2868	ENSG00000125388	PA28941	\N	PHENOTYPE	27	\N	https://cpicpgx.org/gene/grk4/	\N	\N	t	t
GRK5	\N	\N	\N	\N	\N	HGNC:4544	2869	ENSG00000198873	PA180	\N	PHENOTYPE	113	\N	https://cpicpgx.org/gene/grk5/	\N	\N	t	t
HLA-C	chr6	NG_002397	NP_002108	\N	\N	HGNC:4933	3107	ENSG00000204525	PA35057	\N	PHENOTYPE	114	\N	\N	\N	\N	t	t
HLA-DPB1	chr6	\N	NP_002112	\N	\N	HGNC:4940	3115	ENSG00000223865	PA35064	\N	PHENOTYPE	115	\N	\N	\N	\N	t	t
HTR1A	chr5	\N	NP_000515	\N	\N	HGNC:5286	3350	ENSG00000178394	PA192	\N	PHENOTYPE	115	\N	\N	\N	\N	t	t
IFNL4	chr19	\N	\N	\N	\N	HGNC:44480	101180976	ENSG00000272395	PA166049147	\N	PHENOTYPE	117	\N	https://cpicpgx.org/gene/ifnl/	\N	\N	t	t
LTC4S	chr5	\N	NP_665874	\N	\N	HGNC:6719	4056	ENSG00000213316	PA235	\N	PHENOTYPE	115	\N	\N	\N	\N	t	t
OPRM1	chr6	NG_021208	NP_000905	\N	\N	HGNC:8156	4988	ENSG00000112038	PA31945	\N	PHENOTYPE	108	\N	https://cpicpgx.org/gene/oprm1/	\N	\N	t	t
XRCC1	chr19	\N	NP_006288	\N	\N	HGNC:12828	7515	ENSG00000073050	PA369	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
COL22A1	chr8	\N	NP_690848	\N	\N	HGNC:22989	169044	ENSG00000169436	PA134914705	\N	PHENOTYPE	4	\N	\N	\N	\N	t	t
DPYD	chr1	NG_008807.2	NP_000101.2	NC_000001.11	NM_000110.4	HGNC:3012	282617	ENSG00000188641	PA145	Methods:\nThe DPYD frequency table was created using data from ExAC (http://exac.broadinstitute.org/) and the 1000 Genomes project (http://www.ensembl.org/Homo_sapiens/Info/Index).\nThe average allele frequencies by race were calculated by taking the number with the variant in all studies divided by the total number of individuals tested for the variant in all studies.\nAll nucleotide changes are according to reference sequence NM_000110.3 and all protein changes are according to reference sequence NP_000101.2\nCaveats\nIf 1000 Genomes and/or ExAC did not return any frequency data for a given variant, cells were left blank\n\nBiogeographical groups. Biogeographical groups are derived from PMID 30506572. Further details can be found at https://www.pharmgkb.org/page/biogeographicalGroups. These tables group individuals from particular geographic locations into larger biogeographical groups. It is difficult to group populations with certainty, because some populations are often admixed, or at the least, a combination of different ethnicities. Therefore, the margin of error is increased when different subpopulations are grouped together.\n\n\n\n\n\n\n\n	ACTIVITY_SCORE	447	The DPYD phenotype is assigned using a gene activity score (DPYD-AS; based on the DPYD Allele Functionality Table), calculated as the sum of the two DPYD variants with the lowest variant activity value. Briefly, carriers of two no function variants (DPYD-AS: 0) OR one decreased function variant (DPD-AS: 0.5) are classified as DPYD poor metabolizers; carriers of two decreased function variants OR carriers of only one no function variant (DPYD-AS: 1) OR carriers of only one decreased function variant (DPYD-AS: 1.5) are considered DPYD intermediate metabolizers , and those with only normal function variants are classified as DPYD normal metabolizers (DPYD-AS: 2). If two decreased/no function variants are present, each decreased/no function variant is considered to be on a different gene copy. Irrespective of the presence of decreased/no function variants, patients may carry multiple normal function variants. As an individual only carries a maximum of two fully functional DPYD copies, common normal function variants may be located on the same gene copy as other normal function variants or decreased/no function variants.	https://cpicpgx.org/gene/dpyd/	\N	Legacy Name/Class	f	f
HLA-A	chr6	NG_002398	NP_002107	\N	\N	HGNC:4931	3105	ENSG00000206503	PA35055	Methods\n\nThe allele frequency table was made by searching the PubMed® database (1995 to September 2019). The following criteria were used for HLA-A: (HLA-A) AND (allele OR frequency). In addition, reports were also identified from citations by others or review articles. Studies were considered for inclusion in the HLA-A frequency table if: (1) the ethnicity of the population was clearly indicated, (2) either allele frequencies or genotype frequencies were reported, (3) the method by which the genes were genotyped was indicated, (4) the sample population consisted of at least 50 individuals with a few exceptions (e.g., smaller cohorts that were part of larger studies) and (5) the study represented an original publication (no reviews or meta-analyses). Allele frequencies reported in phase 3 1000 Genomes (http://browser.1000genomes.org/index.html) and from allelefrequencies.net (https://www.allelefrequencies.net) were also included .\nCaveats to estimated allele frequencies:\n\nSampling. Allele frequencies collected by CPIC for the supplemental tables are based on published literature reports which typically study small groups of people based on a geographic location (e.g. Malaysia, Berlin, Cairo). Almost no studies use genetic markers to estimate ancestry. Manuscripts are often focused on a specific phenotype (e.g. disease) or study only individuals taking a particular drug. Such samples would not be considered a random sample of the general population. Another consideration is that sample size is important, and PGx studies are typically not large. The frequencies collected from these studies are then used to estimate general estimates of entire ethnic population allele frequencies. Therefore, frequencies from larger groups of subjects and frequencies averaged from many sample populations probably result in better estimates.\n\nBiogeographical groups. Biogeographical groups are derived from PMID 30506572. Further details, including the definitions of each group, can be found at https://www.pharmgkb.org/page/biogeographicalGroups. We strongly recommend that users use either the publication or the PharmGKB link provided to familiarize themselves with the grouping system before using these allele frequencies. These tables group individuals from particular geographic locations into larger biogeographical groups. It is difficult to group populations with certainty, because some populations are often admixed, or at the least, a combination of different ethnicities. Therefore, the margin of error is increased when different subpopulations are grouped together.	ALLELE_STATUS	224	\N	https://cpicpgx.org/gene/hla/	\N	\N	f	f
NUDT15	chr13	NG_047021.1	NP_060753.1	NC_000013.11	NM_001042351.2	HGNC:23063	55270	ENSG00000136159	PA134963132	The allele frequency table was made by searching the PubMed® database (no start date to 1/2018). Allele frequencies reported in the gnomAD browser (http://gnomad.broadinstitute.org/ - exomes and genomes) and ensembl (grch37.ensembl.org - exomes or genomes) were also included. URLs are included in the "PMID" column.\n\nDiplotype and phenotype frequencies were estimated using the equation describing Hardy Weinberg equilibrium based on reported allele frequencies.\n\nCaveats to estimated allele, diplotype and phenotype frequencies:\n\nSampling. Allele frequencies collected by CPIC for the supplemental tables are based on published literature reports which typically study small groups of people based on a geographic location (e.g. Malaysia, Berlin, Cairo). Almost no studies use genetic markers to estimate ancestry. Manuscripts are often focused on a specific phenotype (e.g. disease) or study only individuals taking a particular drug. Such samples would not be considered a random sample of the general population. Another consideration is that sample size is important, and PGx studies are typically not large. The frequencies collected from these studies are then used to estimate general estimates of entire ethnic population allele frequencies. Therefore, frequencies from larger groups of subjects and frequencies averaged from many sample populations probably result in better estimates.\n\nEstimation of *1 frequency. In general, there are no population studies that test for all known variant alleles. Because *1 is not genotyped directly in many studies, all alleles that are negative for a sequence variation are defaulted to a *1 assignment. The inferred frequency for *1 is estimated as: 100 - (sum of averaged variant allele frequencies). For genes where many alleles are not tested for in any population, and frequency of 'common' alleles is not well documented in many understudied populations (Oceania, South Asian, Latino), the *1 frequency will deviate even more from true values.\n\nDiplotype/Phenotype frequency estimates. Diplotype and phenotype frequencies were estimated using the equation describing Hardy Weinberg equilibrium based on reported allele frequencies. When calculating diplotype frequencies from these allele frequencies, the margin of error is compounded based on the margin of error on each allele in the diplotype. So, the margin of error will necessarily increase for diplotype frequency estimates compared to allele frequency estimates. For allele frequencies with already large margins of error due to small and non-random sampling, the diplotype margin of error could potentially be quite large. On the other hand, for well-studied alleles, the margin of error is likely low.\n\nBiogeographical groups. Biogeographical groups are derived from PMID 30506572. Further details can be found at https://www.pharmgkb.org/page/biogeographicalGroups. These tables group individuals from particular geographic locations into larger biogeographical groups. It is difficult to group populations with certainty, because some populations are often admixed, or at the least, a combination of different ethnicities. Therefore, the margin of error is increased when different subpopulations are grouped together.	PHENOTYPE	438	\N	https://cpicpgx.org/gene/nudt15/	\N	Common name	t	t
RYR1	chr19	NG_008866.1	NP_000531.2	NC_000019.10	NM_000540.2	HGNC:10483	6261	ENSG00000196218	PA34896	Methods\n\nTable includes variants based on an update of the CPIC guideline for potent volatile anesthetic agents and succinylcholine. The guideline update includes the published list of RYR1 variants (supplemental table S2), which are evaluated by the ClinGen malignant hyperthermia susceptibility (MHS) variant curation expert panel and classified for RYR1-related malignant hyperthermia susceptibility based on specified ACMG/AMP criteria (PMID 35849058).\n\ngnomAD v2.1.1 was queried with the variant positions or rsIDs.\ngnomAD population description - PharmGKB biogeographical group mapping:\nAfrican/African American - Sub-Saharan African\nSouth Asian - Central/South Asian\nLatino/Admixed American - Latino\nEast Asian - East Asian\nNon-Finnish European - European\nAshkenazi Jewish - Near Eastern\n\nCaveats to estimated allele, frequencies:\n\nBiogeographical groups. Biogeographical groups are derived from PMID 30506572. Further details, including the definitions of each group, can be found at https://www.pharmgkb.org/page/biogeographicalGroups. We strongly recommend that users use either the publication or the PharmGKB link provided to familiarize themselves with the grouping system before using these allele frequencies. These tables group individuals from particular geographic locations into larger biogeographical groups. It is difficult to group populations with certainty, because some populations are often admixed, or at the least, a combination of different ethnicities. Therefore, the margin of error is increased when different subpopulations are grouped together.	PHENOTYPE	438	\N	https://cpicpgx.org/gene/ryr1/	\N	Common name	f	f
ABCB1	chr7	NG_011513	NP_000918	\N	\N	HGNC:40	5243	ENSG00000085563	PA267	\N	PHENOTYPE	114	\N	\N	\N	\N	t	t
MT-RNR1	chrM	NG_042193.1	NP_000101.2	NC_012920.1	NM_001042351.2	HGNC:7470	4549	ENSG00000211459	PA31274	Methods\n\nThe allele frequency table was made by searching the PubMed® database (1995 to September 2019). The following criteria were used for MT-RNR1: (Mitochondrial AND (A1555G OR C1494T OR T1095C) AND frequency). In addition, reports were also identified from citations by others or review articles. Studies were considered for inclusion in the MT-RNR1 frequency table if: (1) the ethnicity of the population was clearly indicated, (2) the method by which the genes were genotyped was indicated, (3) the sample population consisted of at least 50 individuals with a few exceptions (e.g., smaller cohorts that were part of larger studies) and (4) the study represented an original publication (no reviews or meta-analyses). Homoplasmic allele frequencies reported in gnomAD (https://gnomad.broadinstitute.org/) were also included .\nCaveats to estimated allele, diplotype and phenotype frequencies:\n\nSampling. Allele frequencies collected by CPIC for the supplemental tables are based on published literature reports which typically study small groups of people based on a geographic location (e.g. Malaysia, Berlin, Cairo). Almost no studies use genetic markers to estimate ancestry. Manuscripts are often focused on a specific phenotype (e.g. disease) or study only individuals taking a particular drug. Such samples would not be considered a random sample of the general population. Another consideration is that sample size is important, and PGx studies are typically not large. The frequencies collected from these studies are then used to estimate general estimates of entire ethnic population allele frequencies. Therefore, frequencies from larger groups of subjects and frequencies averaged from many sample populations probably result in better estimates.\n\nBiogeographical groups. Biogeographical groups are derived from PMID 30506572. Further details, including the definitions of each group, can be found at https://www.pharmgkb.org/page/biogeographicalGroups. We strongly recommend that users use either the publication or the PharmGKB link provided to familiarize themselves with the grouping system before using these allele frequencies. These tables group individuals from particular geographic locations into larger biogeographical groups. It is difficult to group populations with certainty, because some populations are often admixed, or at the least, a combination of different ethnicities. Therefore, the margin of error is increased when different subpopulations are grouped together.	PHENOTYPE	402	\N	https://cpicpgx.org/gene/mt-rnr1/	\N	Common name	f	f
CYP4F2	chr19	NG_007971.2	NP_001073.3	NC_000019.10	NM_000069.2	HGNC:2645	8529	ENSG00000186115	PA27121	Methods\n\nThe allele frequency table was made by searching the PubMed® database (1995 to 2016). Allele frequencies reported in and gnomD browser and phase 3 1000 Genomes were also included (https://gnomad.broadinstitute.org/, http://browser.1000genomes.org/index.html) for alleles that contain single unique variant.\n\nCaveats to estimated allele, diplotype and phenotype frequencies:\n\nSampling. Allele frequencies collected by CPIC for the supplemental tables are based on published literature reports which typically study small groups of people based on a geographic location (e.g. Malaysia, Berlin, Cairo). Almost no studies use genetic markers to estimate ancestry. Manuscripts are often focused on a specific phenotype (e.g. disease) or study only individuals taking a particular drug. Such samples would not be considered a random sample of the general population. Another consideration is that sample size is important, and PGx studies are typically not large. The frequencies collected from these studies are then used to estimate general estimates of entire ethnic population allele frequencies. Therefore, frequencies from larger groups of subjects and frequencies averaged from many sample populations probably result in better estimates.\n\nEstimation of *1 frequency. In general, there are no population studies that test for all known variant alleles. Because *1 is not genotyped directly in many studies, all alleles that are negative for a sequence variation are defaulted to a *1 assignment. Because CYP4F2*1 is not genotyped directly, all alleles that are negative for a sequence variation are defaulted to a CYP4F2*1 assignment. Likewise, sequence variations of alleles that are not tested may default to a CYP4F2*1 assignment and hence contribute to the frequencies reported for this allele. Therefore, the inferred frequency for CYP4F2*1 was calculated as an average from studies describing allele frequencies for the most common alleles found in a particular biogeographical group.\n\nBiogeographical groups. Biogeographical groups are derived from PMID 30506572. Further details can be found at https://www.pharmgkb.org/page/biogeographicalGroups. These tables group individuals from particular geographic locations into larger biogeographical groups. It is difficult to group populations with certainty, because some populations are often admixed, or at the least, a combination of different ethnicities. Therefore, the margin of error is increased when different subpopulations are grouped together.	PHENOTYPE	348	CYP4F2 diplotype to phenotype translation is not applicable to the warfarin guideline.	https://cpicpgx.org/gene/cyp4f2/	\N	Legacy Name/Class	f	f
BCHE	chr3	NG_009031	NP_000046	\N	\N	HGNC:983	590	ENSG00000114200	PA25294	\N	PHENOTYPE	114	\N	\N	\N	\N	t	t
TYMS	chr18	\N	NP_001062	\N	\N	HGNC:12441	7298	ENSG00000176890	PA359	\N	PHENOTYPE	115	\N	\N	\N	\N	t	t
ABCG2	chr4	NG_032067.2	NP_001335914.1	NC_000004.12	NM_004827.3	HGNC:74	9429	ENSG00000118777	PA390	Methods\n\nThe allele frequency table was made by searching the Genome Aggregation Database (gnomAD) and 1000 Genomes phase 3 data by rsID. In addition, pubmed were also searched to include frequencies for certain biogeographical groups (eg. Oceanian and American).\n\nCaveats to estimated allele, frequencies:\n\nSampling. Allele frequencies collected by CPIC for the supplemental tables are based on published literature reports which typically study small groups of people based on a geographic location (e.g. Malaysia, Berlin, Cairo). Almost no studies use genetic markers to estimate ancestry. Manuscripts are often focused on a specific phenotype (e.g. disease) or study only individuals taking a particular drug. Such samples would not be considered a random sample of the general population. Another consideration is that sample size is important, and PGx studies are typically not large. The frequencies collected from these studies are then used to estimate general estimates of entire ethnic population allele frequencies. Therefore, frequencies from larger groups of subjects and frequencies averaged from many sample populations probably result in better estimates.\n\nBiogeographical groups. Biogeographical groups are derived from PMID 30506572. Further details, including the definitions of each group, can be found at https://www.pharmgkb.org/page/biogeographicalGroups. We strongly recommend that users use either the publication or the PharmGKB link provided to familiarize themselves with the grouping system before using these allele frequencies. These tables group individuals from particular geographic locations into larger biogeographical groups. It is difficult to group populations with certainty, because some populations are often admixed, or at the least, a combination of different ethnicities. Therefore, the margin of error is increased when different subpopulations are grouped together.	PHENOTYPE	345	\N	https://cpicpgx.org/gene/abcg2/	\N	\N	t	t
ACYP2	\N	\N	\N	\N	\N	HGNC:180	98	ENSG00000170634	PA24500	\N	PHENOTYPE	88	\N	\N	\N	\N	t	t
UMPS	chr3	NG_017037	NP_000364	\N	\N	HGNC:12563	7372	ENSG00000114491	PA363	\N	PHENOTYPE	114	\N	\N	\N	\N	t	t
CFTR	chr7	NG_016465.4	NP_000483.3	NC_000007.14	NM_000069.2	HGNC:1884	1080	ENSG00000001626	PA109	\N	PHENOTYPE	334	\N	https://cpicpgx.org/gene/cftr/	\N	Legacy Name/Class	t	t
CYP2C9	chr10	NG_008385.2	NP_000762.2	NC_000010.11	NM_000069.2	HGNC:2623	1559	ENSG00000138109	PA126	Methods\n\nThe allele frequency table was made by searching the PubMed® database (1995 to July 2019). The following criteria were used for CYP2C9: (CYP2C9 or 2C9 or cytochrome P4502C9) AND (genotype OR allele OR frequency OR minor allele OR variant OR ethnic OR race OR racial OR ethnicity OR population) with filter limits set to retrieve "full-text" and "English" literature. In addition, reports were also identified from citations by others or review articles. Studies were considered for inclusion in the CYP2C9 frequency table if: (1) the ethnicity of the population was clearly indicated, (2) either allele frequencies or genotype frequencies were reported, (3) the method by which the genes were genotyped was indicated, (4) the sample population consisted of at least 50 individuals with a few exceptions (e.g., smaller cohorts that were part of larger studies) and (5) the study represented an original publication (no reviews or meta-analyses). Allele frequencies reported in and gnomD browser and phase 3 1000 Genomes were also included (https://gnomad.broadinstitute.org/, http://browser.1000genomes.org/index.html) for alleles that contain single unique variant.\n\nDiplotype and Phenotype Calculations. Diplotype and phenotype frequencies were estimated using the equation describing Hardy Weinberg equilibrium based on reported allele frequencies.\n\nCaveats to estimated allele, diplotype and phenotype frequencies:\n\nSampling. Allele frequencies collected by CPIC for the supplemental tables are based on published literature reports which typically study small groups of people based on a geographic location (e.g. Malaysia, Berlin, Cairo). Almost no studies use genetic markers to estimate ancestry. Manuscripts are often focused on a specific phenotype (e.g. disease) or study only individuals taking a particular drug. Such samples would not be considered a random sample of the general population. Another consideration is that sample size is important, and PGx studies are typically not large. The frequencies collected from these studies are then used to estimate general estimates of entire ethnic population allele frequencies. Therefore, frequencies from larger groups of subjects and frequencies averaged from many sample populations probably result in better estimates.\n\nEstimation of *1 frequency. In general, there are no population studies that test for all known variant alleles. Because *1 is not genotyped directly in many studies, all alleles that are negative for a sequence variation are defaulted to a *1 assignment. Because CYP2C9*1 is not genotyped directly, all alleles that are negative for a sequence variation are defaulted to a CYP2C9*1 assignment. Likewise, sequence variations of alleles that are not tested may default to a CYP2C9*1 assignment and hence contribute to the frequencies reported for this allele. Therefore, the inferred frequency for CYP2C9*1 was calculated as an average from studies describing allele frequencies for the most common alleles found in a particular biogeographical group.\n\nDiplotype/Phenotype frequency estimates. When calculating diplotype frequencies from these allele frequencies, the margin of error is compounded based on the margin of error on each allele in the diplotype. So, the margin of error will necessarily increase for diplotype frequency estimates compared to allele frequency estimates. For allele frequencies with already large margins of error due to small and non-random sampling, the diplotype margin of error could potentially be quite large. On the other hand, for well-studied alleles, the margin of error is likely low.\n\nBiogeographical groups. Biogeographical groups are derived from PMID 30506572. Further details can be found at https://www.pharmgkb.org/page/biogeographicalGroups. These tables group individuals from particular geographic locations into larger biogeographical groups. It is difficult to group populations with certainty, because some populations are often admixed, or at the least, a combination of different ethnicities. Therefore, the margin of error is increased when different subpopulations are grouped together.	ACTIVITY_SCORE	449	CYP2C9 diplotype to phenotype translation is not applicable to the warfarin guideline.	https://cpicpgx.org/gene/cyp2c9/	Methods:\nThe PubMed and PharmGKB databases were searched for the following keywords: (CYP2C9 OR cytochrome p450 2c9)AND [genomic identifiers (e.g. dbSNP rs number, star alleles, additional common names)] AND English [Language]. Study inclusion criteria included publications that incorporated analyses for the association between CYP2C9 genotype and drug pharmacokinetic parameters, clinical outcomes, or allele function.	Legacy Name/Class	t	t
UGT1A1	chr2	NG_002601.2	NP_000454.1	NC_000002.12	NM_000540.2	HGNC:12530	54658	ENSG00000241635	PA420	Methods\n\nThe allele frequency table was made by searching the PubMed® database (1995 to 2015). Allele frequencies reported in phase 3 1000 Genomes were also included (http://browser.1000genomes.org/index.html).\n\nCaveats to estimated allele, diplotype and phenotype frequencies:\n\nSampling. Allele frequencies collected by CPIC for the supplemental tables are based on published literature reports which typically study small groups of people based on a geographic location (e.g. Malaysia, Berlin, Cairo). Almost no studies use genetic markers to estimate ancestry. Manuscripts are often focused on a specific phenotype (e.g. disease) or study only individuals taking a particular drug. Such samples would not be considered a random sample of the general population. Another consideration is that sample size is important, and PGx studies are typically not large. The frequencies collected from these studies are then used to estimate general estimates of entire ethnic population allele frequencies. Therefore, frequencies from larger groups of subjects and frequencies averaged from many sample populations probably result in better estimates.\n\nEstimation of *1 frequency. In general, there are no population studies that test for all known variant alleles. Because *1 is not genotyped directly in many studies, all alleles that are negative for a sequence variation are defaulted to a *1 assignment. Because UGT1A1*1 is not genotyped directly, all alleles that are negative for a sequence variation are defaulted to a UGT1A1*1 assignment. Likewise, sequence variations of alleles that are not tested may default to a UGT1A1*1 assignment and hence contribute to the frequencies reported for this allele. Therefore, the inferred frequency for UGT1A1*1 was calculated as an average from studies describing allele frequencies for the most common alleles found in a particular biogeographical group.\n\nBiogeographical groups. Biogeographical groups are derived from PMID 30506572. Further details can be found at https://www.pharmgkb.org/page/biogeographicalGroups. These tables group individuals from particular geographic locations into larger biogeographical groups. It is difficult to group populations with certainty, because some populations are often admixed, or at the least, a combination of different ethnicities. Therefore, the margin of error is increased when different subpopulations are grouped together.	PHENOTYPE	438	\N	https://cpicpgx.org/gene/ugt1a1/	\N	Nucleotide changes from the UGT nomenclature page: https://www.pharmacogenomics.pha.ulaval.ca/wp-content/uploads/2015/04/UGT1A1-allele-nomenclature.html	f	f
VDR	chr12	NG_008731	NP_000367	\N	\N	HGNC:12679	7421	ENSG00000111424	PA37301	\N	PHENOTYPE	114	\N	\N	\N	\N	t	t
COMT	chr22	NG_011526	NP_000745	\N	\N	HGNC:2228	1312	ENSG00000093010	PA117	\N	PHENOTYPE	108	\N	https://cpicpgx.org/gene/comt/	\N	\N	t	t
CYP2C8	chr10	NG_007972	NP_000761	\N	\N	HGNC:2622	1558	ENSG00000138115	PA125	\N	PHENOTYPE	114	\N	\N	\N	\N	t	t
CYP3A4	chr7	NG_000004	NP_059488	\N	\N	HGNC:2637	1576	ENSG00000160868	PA130	\N	PHENOTYPE	114	\N	\N	\N	\N	t	t
CYP2D6	chr22	NG_008376.4	NP_000097.3	NC_000022.11	NM_000069.2	HGNC:2625	1565	ENSG00000100197	PA128	Methods:\n\nThe CYP2D6 allele frequency tables (CYP2D6 frequency table; link to PharmGKB) are updates of those previously published in CPIC guidelines (PMID: 25974703, 24458010). Updates to the CYP2D6 allele frequency tables were made by searching the PubMed® database (1995 to 2018). The following criteria were used for CYP2D6: (CYP2D6 or 2D6 or cytochrome P4502D6) AND (genotype OR allele OR frequency OR minor allele OR variant OR ethnic OR race OR racial OR ethnicity) with filter limits set to retrieve "full-text" and "English" literature. In addition, reports were also identified from citations by others or review articles. Studies were considered for inclusion in the CYP2D6 frequency table if: (1) the ethnicity of the population was clearly indicated, (2) either allele frequencies or genotype frequencies were reported, (3) the method by which the genes were genotyped was indicated, (4) the sample population consisted of at least 50 individuals with a few exceptions (e.g., smaller cohorts that were part of larger studies) and (5) the study represented an original publication (no reviews or meta-analyses).\nDiplotype and phenotype frequencies were estimated using the equation describing Hardy Weinberg equilibrium based on reported allele frequencies. Because the frequencies for each allele are averages from all studies for that population, allele frequencies may not add up to100%. To account for this in diplotype and phenotype frequencies calculations, *1 frequency was calculated as 1 - sum (non *1 allele frequency).\n\n\nCaveats to estimated allele, diplotype and phenotype frequencies:\n\nSampling. Allele frequencies collected by CPIC for the supplemental tables are based on published literature reports which typically study small groups of people based on a geographic location (e.g. Malaysia, Berlin, Cairo). Almost no studies use genetic markers to estimate ancestry. Manuscripts are often focused on a specific phenotype (e.g. disease) or study only individuals taking a particular drug. Such samples would not be considered a random sample of the general population. Another consideration is that sample size is important, and PGx studies are typically not large. The frequencies collected from these studies are then used to estimate general estimates of entire ethnic population allele frequencies. Therefore, frequencies from larger groups of subjects and frequencies averaged from many sample populations probably result in better estimates.\n\nEstimation of *1 frequency. In general, there are no population studies that test for all known variant alleles. Because CYP2D6*1 is not genotyped directly, all alleles that are negative for a sequence variation are defaulted to a CYP2D6*1 assignment. Likewise, sequence variations of alleles that are not tested may default to a CYP2D6*1 assignment and hence contribute to the frequencies reported for this allele. Therefore, the inferred frequency for CYP2D6*1 was calculated as an average from studies describing allele frequencies for the most common alleles found in a particular ethnic group.\n\nDiplotype/Phenotype frequency estimates. When calculating diplotype frequencies from these allele frequencies, the margin of error is compounded based on the margin of error on each allele in the diplotype. So, the margin of error will necessarily increase for diplotype frequency estimates compared to allele frequency estimates. For allele frequencies with already large margins of error due to small and non-random sampling, the diplotype margin of error could potentially be quite large. On the other hand, for well-studied alleles, the margin of error is likely low.\n\nBiogeographical groups. Biogeographical groups are derived from PMID 30506572. Further details, including the definitions of each group, can be found at https://www.pharmgkb.org/page/biogeographicalGroups. We strongly recommend that users use either the publication or the PharmGKB link provided to familiarize themselves with the grouping system before using these allele frequencies. These tables group individuals from particular geographic locations into larger biogeographical groups. It is difficult to group populations with certainty, because some populations are often admixed, or at the least, a combination of different ethnicities. Therefore, the margin of error is increased when different subpopulations are grouped together.\n\nOverestimation of allele frequencies. CYP2D6*2 is a 'default' assignment and, unless tested and discriminated for CYP2D6*8, *11, *17, *35,*41 and other variants, will default to a CYP2D6*2 assignment. The frequencies shown here may therefore be over-estimated. CYP2D6*10 is a 'default' assignment and, unless tested and discriminated for, CYP2D6*14 and *36 and other variants, will default to a CYP2D6*10 assignment. The frequencies shown here may therefore be over-estimated. CYP2D6*17 is a 'default' assignment and, unless tested and discriminated for, CYP2D6*40 and *58 will default to a CYP2D6*17 assignment. The frequencies shown here may therefore be over-estimated. CYP2D6*41 has not consistently been determined by its defining SNP (2988G>A) across studies; some platforms still use the -1584C>G SNP to discriminate between CYP2D6*2 and *41. This may lead to an overestimation of the CYP2D6*41 frequency, especially in those of African ancestry.\n\nCNV alleles. Many studies do not specify the exact copy number of duplicated alleles found in their study population and instead report the total frequency of observed CNVs as "xN". Where possible, these frequencies have been included in the CNV column for that allele (e.g. *1xN frequencies are included in the *1x2 column, *4xN frequencies are included in the *4x2 column). Users should be aware that this will lead to an overestimation of the frequency of that exact copy number in the population.	ACTIVITY_SCORE	444	\N	https://cpicpgx.org/gene/cyp2d6/	\N	Legacy Name/Class	t	t
HLA-B	chr6	NG_002397	NP_005505	\N	\N	HGNC:4932	3106	ENSG00000234745	PA35056	Methods\n\nThe allele frequency table was made by searching the PubMed® database (1995 to September 2019). The following criteria were used for HLA-B: (HLA-B) AND (allele OR frequency). In addition, reports were also identified from citations by others or review articles. Studies were considered for inclusion in the HLA-B frequency table if: (1) the ethnicity of the population was clearly indicated, (2) either allele frequencies or genotype frequencies were reported, (3) the method by which the genes were genotyped was indicated, (4) the sample population consisted of at least 50 individuals with a few exceptions (e.g., smaller cohorts that were part of larger studies) and (5) the study represented an original publication (no reviews or meta-analyses). Allele frequencies reported in phase 3 1000 Genomes (http://browser.1000genomes.org/index.html) and from allelefrequencies.net (https://www.allelefrequencies.net) were also included .\nCaveats to estimated allele, diplotype and phenotype frequencies:\n\nSampling. Allele frequencies collected by CPIC for the supplemental tables are based on published literature reports which typically study small groups of people based on a geographic location (e.g. Malaysia, Berlin, Cairo). Almost no studies use genetic markers to estimate ancestry. Manuscripts are often focused on a specific phenotype (e.g. disease) or study only individuals taking a particular drug. Such samples would not be considered a random sample of the general population. Another consideration is that sample size is important, and PGx studies are typically not large. The frequencies collected from these studies are then used to estimate general estimates of entire ethnic population allele frequencies. Therefore, frequencies from larger groups of subjects and frequencies averaged from many sample populations probably result in better estimates.\n\nBiogeographical groups. Biogeographical groups are derived from PMID 30506572. Further details, including the definitions of each group, can be found at https://www.pharmgkb.org/page/biogeographicalGroups. We strongly recommend that users use either the publication or the PharmGKB link provided to familiarize themselves with the grouping system before using these allele frequencies. These tables group individuals from particular geographic locations into larger biogeographical groups. It is difficult to group populations with certainty, because some populations are often admixed, or at the least, a combination of different ethnicities. Therefore, the margin of error is increased when different subpopulations are grouped together.	ALLELE_STATUS	224	\N	https://cpicpgx.org/gene/hla/	\N	\N	f	f
EPHX1	chr1	NG_009776	NP_000111	\N	\N	HGNC:3401	2052	ENSG00000143819	PA27829	\N	PHENOTYPE	114	\N	\N	\N	\N	t	t
GGCX	chr2	NG_011811	NP_000812	\N	\N	HGNC:4247	2677	ENSG00000115486	PA28660	\N	PHENOTYPE	114	\N	\N	\N	\N	t	t
GP1BA	chr17	NG_008767	NP_000164	\N	\N	HGNC:4439	2811	ENSG00000185245	PA178	\N	PHENOTYPE	114	\N	\N	\N	\N	t	t
GSTP1	chr11	NG_012075	NP_000843	\N	\N	HGNC:4638	2950	ENSG00000084207	PA29028	\N	PHENOTYPE	114	\N	\N	\N	\N	t	t
HTR2A	chr13	NG_013011	NP_000612	\N	\N	HGNC:5293	3356	ENSG00000102468	PA193	\N	PHENOTYPE	114	\N	\N	\N	\N	t	t
MTHFR	chr1	NG_013351	NP_005948	\N	\N	HGNC:7436	4524	ENSG00000177000	PA245	\N	PHENOTYPE	114	\N	\N	\N	\N	t	t
NQO1	chr16	NG_011504	NP_000894	\N	\N	HGNC:2874	1728	ENSG00000181019	PA31744	\N	PHENOTYPE	114	\N	\N	\N	\N	t	t
PROC	chr2	NG_016323	NP_000303	\N	\N	HGNC:9451	5624	ENSG00000115718	PA33799	\N	PHENOTYPE	114	\N	\N	\N	\N	t	t
PROS1	chr3	NG_009813	NP_000304	\N	\N	HGNC:9456	5627	ENSG00000184500	PA33809	\N	PHENOTYPE	114	\N	\N	\N	\N	t	t
SCN1A	chr2	NG_011906	NP_008851	\N	\N	HGNC:10585	6323	ENSG00000144285	PA301	\N	PHENOTYPE	114	\N	\N	\N	\N	t	t
SLC6A4	chr17	NG_011747	NP_001036	\N	\N	HGNC:11050	6532	ENSG00000108576	PA312	\N	PHENOTYPE	114	\N	\N	\N	\N	t	t
CYP3A5	chr7	NG_007938.2	NP_000768.1	NC_000007.14	NM_000069.2	HGNC:2638	1577	ENSG00000106258	PA131	Methods\n\nThe allele frequency table was made by searching the PubMed® database (1995 to 2014).\n\nDiplotype and Phenotype Calculations. Diplotype and phenotype frequencies were estimated using the equation describing Hardy Weinberg equilibrium based on reported allele frequencies.\n\nCaveats to estimated allele frequencies:\n\nSampling. Allele frequencies collected by CPIC for the supplemental tables are based on published literature reports which typically study small groups of people based on a geographic location (e.g. Malaysia, Berlin, Cairo). Almost no studies use genetic markers to estimate ancestry. Manuscripts are often focused on a specific phenotype (e.g. disease) or study only individuals taking a particular drug. Such samples would not be considered a random sample of the general population. Another consideration is that sample size is important, and PGx studies are typically not large. The frequencies collected from these studies are then used to estimate general estimates of entire ethnic population allele frequencies. Therefore, frequencies from larger groups of subjects and frequencies averaged from many sample populations probably result in better estimates.\n\nEstimation of *1 frequency. In general, there are no population studies that test for all known variant alleles. Because *1 is not genotyped directly in many studies, all alleles that are negative for a sequence variation are defaulted to a *1 assignment. Because CYP3A5*1 is not genotyped directly, all alleles that are negative for a sequence variation are defaulted to a CYP3A5*1 assignment. Likewise, sequence variations of alleles that are not tested may default to a CYP3A5*1 assignment and hence contribute to the frequencies reported for this allele. Therefore, the inferred frequency for CYP3A5*1 was calculated as an average from studies describing allele frequencies for the most common alleles found in a particular biogeographical group.\n\nDiplotype/Phenotype frequency estimates. Diplotype and phenotype frequencies were estimated using the equation describing Hardy Weinberg equilibrium based on reported allele frequencies. When calculating diplotype frequencies from these allele frequencies, the margin of error is compounded based on the margin of error on each allele in the diplotype. So, the margin of error will necessarily increase for diplotype frequency estimates compared to allele frequency estimates. For allele frequencies with already large margins of error due to small and non-random sampling, the diplotype margin of error could potentially be quite large. On the other hand, for well-studied alleles, the margin of error is likely low.\n\nBiogeographical groups. Biogeographical groups are derived from PMID 30506572. Further details, including the definitions of each group, can be found at https://www.pharmgkb.org/page/biogeographicalGroups. We strongly recommend that users use either the publication or the PharmGKB link provided to familiarize themselves with the grouping system before using these allele frequencies. These tables group individuals from particular geographic locations into larger biogeographical groups. It is difficult to group populations with certainty, because some populations are often admixed, or at the least, a combination of different ethnicities. Therefore, the margin of error is increased when different subpopulations are grouped together.\n	PHENOTYPE	443	\N	https://cpicpgx.org/gene/cyp3a5/	\N	Legacy Name/Class	t	t
SLCO1B1	chr12	NG_011745.1	NP_006437.3	NC_000012.12	NM_000540.2	HGNC:10959	10599	ENSG00000134538	PA134865839	Methods\n\nThe allele frequency table was made by searching the PubMed® database (1995 to 2021).\n\nCaveats to estimated allele frequencies:\n\nSampling. Allele frequencies collected by CPIC for the supplemental tables are based on published literature reports which typically study small groups of people based on a geographic location (e.g. Malaysia, Berlin, Cairo). Almost no studies use genetic markers to estimate ancestry. Manuscripts are often focused on a specific phenotype (e.g. disease) or study only individuals taking a particular drug. Such samples would not be considered a random sample of the general population. Another consideration is that sample size is important, and PGx studies are typically not large. The frequencies collected from these studies are then used to estimate general estimates of entire ethnic population allele frequencies. Therefore, frequencies from larger groups of subjects and frequencies averaged from many sample populations probably result in better estimates.\n\nBiogeographical groups. Biogeographical groups are derived from PMID 30506572. Further details can be found at https://www.pharmgkb.org/page/biogeographicalGroups. These tables group individuals from particular geographic locations into larger biogeographical groups. It is difficult to group populations with certainty, because some populations are often admixed, or at the least, a combination of different ethnicities. Therefore, the margin of error is increased when different subpopulations are grouped together.	PHENOTYPE	436	\N	https://cpicpgx.org/gene/slco1b1/	\N	Common name	t	t
CYP2C19	chr10	NG_008384.3	NP_000760.1	NC_000010.11	NM_000069.2	HGNC:2621	1557	ENSG00000165841	PA124	Methods:\nThe CYP2C19 frequency table includes updates of those previously published in CPIC guidelines. Updates to the CYP2C19 frequency tables were made by searching the PubMed® database (1995 to 2015). The following criteria were used for CYP2C19: (CYP2C19 or 2C19 or cytochrome P4502C19) AND (genotype OR allele OR frequency OR minor allele OR variant OR ethnic OR race OR racial OR ethnicity) with filter limits set to retrieve "full-text" and "English" literature. In addition, reports were also identified from citations by others or review articles. Studies were considered for inclusion in the CYP2C19 frequency table if: (1) the ethnicity of the population was clearly indicated, (2) either allele frequencies or genotype frequencies were reported, (3) the method by which the genes were genotyped was indicated, (4) the sample population consisted of at least 50 individuals with a few exceptions (e.g., smaller cohorts that were part of larger studies) and (5) the study represented an original publication (no reviews or meta-analyses). Diplotype and phenotype frequencies were estimated using the equation describing Hardy Weinberg equilibrium based on reported allele frequencies.\n\nDiplotype and Phenotype Calculations. Diplotype and phenotype frequencies were estimated using the equation describing Hardy Weinberg equilibrium based on reported allele frequencies.\n\nCaveats to estimated allele, diplotype and phenotype frequencies:\n\nSampling. Allele frequencies collected by CPIC for the supplemental tables are based on published literature reports which typically study small groups of people based on a geographic location (e.g. Malaysia, Berlin, Cairo). Almost no studies use genetic markers to estimate ancestry. Manuscripts are often focused on a specific phenotype (e.g. disease) or study only individuals taking a particular drug. Such samples would not be considered a random sample of the general population. Another consideration is that sample size is important, and PGx studies are typically not large. The frequencies collected from these studies are then used to estimate general estimates of entire ethnic population allele frequencies. Therefore, frequencies from larger groups of subjects and frequencies averaged from many sample populations probably result in better estimates.\n\nEstimation of *1 frequency. In general, there are no population studies that test for all known variant alleles. Because *1 is not genotyped directly in many studies, all alleles that are negative for a sequence variation are defaulted to a *1 assignment. The inferred frequency for *1 is estimated as: 100 - (sum of averaged variant allele frequencies). For genes where many alleles are not tested for in any population, and frequency of 'common' alleles is not well documented in many understudied populations (Oceanian, Central/South Asian, Latino), the *1 frequency will deviate even more from true values.\n\nDiplotype/Phenotype frequency estimates. Diplotype and phenotype frequencies were estimated using the equation describing Hardy Weinberg equilibrium based on reported allele frequencies. When calculating diplotype frequencies from these allele frequencies, the margin of error is compounded based on the margin of error on each allele in the diplotype. So, the margin of error will necessarily increase for diplotype frequency estimates compared to allele frequency estimates. For allele frequencies with already large margins of error due to small and non-random sampling, the diplotype margin of error could potentially be quite large. On the other hand, for well-studied alleles, the margin of error is likely low.\n\nBiogeographical groups. Biogeographical groups are derived from PMID 30506572. Further details, including the definitions of each group, can be found at https://www.pharmgkb.org/page/biogeographicalGroups. We strongly recommend that users use either the publication or the PharmGKB link provided to familiarize themselves with the grouping system before using these allele frequencies. These tables group individuals from particular geographic locations into larger biogeographical groups. It is difficult to group populations with certainty, because some populations are often admixed, or at the least, a combination of different ethnicities. Therefore, the margin of error is increased when different subpopulations are grouped together.	PHENOTYPE	447	\N	https://cpicpgx.org/gene/cyp2c19/	\N	Legacy Name/Class	t	t
IFNL3	chr19	NG_042193.1	NP_000101.2	NC_000019.10	NM_001042351.2	HGNC:18365	282617	ENSG00000197110	PA134952671	\N	ALLELE_STATUS	234	\N	https://cpicpgx.org/gene/ifnl/	\N	Common Name	t	t
G6PD	chrX	NG_009015.2	NP_000101.2	NC_000023.11	NM_001042351.2	HGNC:4057	2539	ENSG00000160211	PA28469	Methods\n\nThe allele frequency table was made by searching the gnomAD database.\n\nBiogeographical groups. Biogeographical groups are derived from PMID 30506572. Further details can be found at https://www.pharmgkb.org/page/biogeographicalGroups. These tables group individuals from particular geographic locations into larger biogeographical groups. It is difficult to group populations with certainty, because some populations are often admixed, or at the least, a combination of different ethnicities. Therefore, the margin of error is increased when different subpopulations are grouped together.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n	PHENOTYPE	392	\N	https://cpicpgx.org/gene/g6pd/	\N	Legacy Name/Class	f	f
TPMT	chr6	NG_012137.3	NP_000358.1	NC_000006.12	NM_000540.2	HGNC:12014	7172	ENSG00000137364	PA356	The allele frequency table was made by searching the PubMed® database (no start date to 1/2018). Allele frequencies reported in the gnomAD browser (http://gnomad.broadinstitute.org/ - exomes and genomes) and ensembl (grch37.ensembl.org - exomes or genomes) were also included. URLs are included in the "PMID" column.\n\nDiplotype and Phenotype Calculations. Diplotype and phenotype frequencies were estimated using the equation describing Hardy Weinberg equilibrium based on reported allele frequencies.\n\nCaveats to estimated allele, diplotype and phenotype frequencies:\n\nSampling. Allele frequencies collected by CPIC for the supplemental tables are based on published literature reports which typically study small groups of people based on a geographic location (e.g. Malaysia, Berlin, Cairo). Almost no studies use genetic markers to estimate ancestry. Manuscripts are often focused on a specific phenotype (e.g. disease) or study only individuals taking a particular drug. Such samples would not be considered a random sample of the general population. Another consideration is that sample size is important, and PGx studies are typically not large. The frequencies collected from these studies are then used to estimate general estimates of entire ethnic population allele frequencies. Therefore, frequencies from larger groups of subjects and frequencies averaged from many sample populations probably result in better estimates.\n\nEstimation of *1 frequency. In general, there are no population studies that test for all known variant alleles. Because *1 is not genotyped directly in many studies, all alleles that are negative for a sequence variation are defaulted to a *1 assignment. The inferred frequency for *1 is estimated as: 100 - (sum of averaged variant allele frequencies). For genes where many alleles are not tested for in any population, and frequency of 'common' alleles is not well documented in many understudied populations (Oceania, South Asian, Latino), the *1 frequency will deviate even more from true values.\n\nDiplotype/Phenotype frequency estimates. Diplotype and phenotype frequencies were estimated using the equation describing Hardy Weinberg equilibrium based on reported allele frequencies. When calculating diplotype frequencies from these allele frequencies, the margin of error is compounded based on the margin of error on each allele in the diplotype. So, the margin of error will necessarily increase for diplotype frequency estimates compared to allele frequency estimates. For allele frequencies with already large margins of error due to small and non-random sampling, the diplotype margin of error could potentially be quite large. On the other hand, for well-studied alleles, the margin of error is likely low.\n\nBiogeographical groups. Biogeographical groups are derived from PMID 30506572. Further details can be found at https://www.pharmgkb.org/page/biogeographicalGroups. These tables group individuals from particular geographic locations into larger biogeographical groups. It is difficult to group populations with certainty, because some populations are often admixed, or at the least, a combination of different ethnicities. Therefore, the margin of error is increased when different subpopulations are grouped together.	PHENOTYPE	436	\N	https://cpicpgx.org/gene/tpmt/	\N	Nucleotide change on cDNA from https://liu.se/en/research/tpmt-nomenclature-committee	t	t
CYP2B6	chr19	NG_007929.1	NP_000758.1	NC_000019.10	NM_000069.2	HGNC:2615	1555	ENSG00000197408	PA123	Methods\n\nThe allele frequency table was made by searching the PubMed® database (no start date to May 2018). Studies were considered for inclusion in the CYP2B6 Frequency Table if (1) the ethnicity of the population was clearly indicated; (2) either allele frequencies or genotype frequencies were reported; and (3) the method by which genes were genotyped was indicated. Allele frequencies reported in the gnomAD browser (http://gnomad.broadinstitute.org/ - exomes and genomes) and 1000 Genomes Project phase 3 data on Ensemble browser (https://uswest.ensembl.org/index.html) were also included.\n\nDiplotype and Phenotype Calculations. Diplotype and phenotype frequencies were estimated using the equation describing Hardy Weinberg equilibrium based on reported allele frequencies.\n\nCaveats to estimated allele, diplotype and phenotype frequencies:\n\nSampling. Allele frequencies collected by CPIC for the supplemental tables are based on published literature reports which typically study small groups of people based on a geographic location (e.g. Malaysia, Berlin, Cairo). Almost no studies use genetic markers to estimate ancestry. Manuscripts are often focused on a specific phenotype (e.g. disease) or study only individuals taking a particular drug. Such samples would not be considered a random sample of the general population. Another consideration is that sample size is important, and PGx studies are typically not large. Studies were included in the frequency calculation regardless of number. The frequencies collected from these studies are then used to estimate general estimates of entire ethnic population allele frequencies. Therefore, frequencies from larger groups of subjects and frequencies averaged from many sample populations probably result in better estimates.\n\nEstimation of *1 frequency. In general, there are no population studies that test for all known variant alleles. Because *1 is not genotyped directly in many studies, all alleles that are negative for a sequence variation are defaulted to a *1 assignment. The inferred frequency for *1 is estimated as: 1 - (sum of averaged variant allele frequencies). For genes where many alleles are not tested for in any population, and frequency of 'common' alleles is not well documented in many understudied populations (Oceania, Middle eastern, South Asian, Latino), the *1 frequency will deviate even more from true values.\n\nDiplotype/Phenotype frequency estimates. Diplotype and phenotype frequencies were estimated using the equation describing Hardy Weinberg equilibrium based on reported allele frequencies. When calculating diplotype frequencies from these allele frequencies, the margin of error is compounded based on the margin of error on each allele in the diplotype. So, the margin of error will necessarily increase for diplotype frequency estimates compared to allele frequency estimates. For allele frequencies with already large margins of error due to small and non-random sampling, the diplotype margin of error could potentially be quite large. On the other hand, for well-studied alleles, the margin of error is likely low.\n\nBiogeographical groups. Biogeographical groups are derived from PMID 30506572. Further details, including the definitions of each group, can be found at https://www.pharmgkb.org/page/biogeographicalGroups. We strongly recommend that users use either the publication or the PharmGKB link provided to familiarize themselves with the grouping system before using these allele frequencies. These tables group individuals from particular geographic locations into larger biogeographical groups. It is difficult to group populations with certainty, because some populations are often admixed, or at the least, a combination of different ethnicities. Therefore, the margin of error is increased when different subpopulations are grouped together.	PHENOTYPE	448	\N	https://cpicpgx.org/gene/cyp2b6/	\N	Legacy Name/Class	t	t
VKORC1	chr16	NG_011564.1	NP_076869.1	NC_000016.10	NM_000540.2	HGNC:23663	79001	ENSG00000167397	PA133787052	Methods\n\nThe allele frequency table was made by searching the PubMed® database (1995 to 2016). Allele frequencies reported in phase 3 1000 Genomes were also included (http://browser.1000genomes.org/index.html).\n\nCaveats to estimated allele, diplotype and phenotype frequencies:\n\nSampling. Allele frequencies collected by CPIC for the supplemental tables are based on published literature reports which typically study small groups of people based on a geographic location (e.g. Malaysia, Berlin, Cairo). Almost no studies use genetic markers to estimate ancestry. Manuscripts are often focused on a specific phenotype (e.g. disease) or study only individuals taking a particular drug. Such samples would not be considered a random sample of the general population. Another consideration is that sample size is important, and PGx studies are typically not large. The frequencies collected from these studies are then used to estimate general estimates of entire ethnic population allele frequencies. Therefore, frequencies from larger groups of subjects and frequencies averaged from many sample populations probably result in better estimates.\n\nBiogeographical groups. Biogeographical groups are derived from PMID 30506572. Further details can be found at https://www.pharmgkb.org/page/biogeographicalGroups. These tables group individuals from particular geographic locations into larger biogeographical groups. It is difficult to group populations with certainty, because some populations are often admixed, or at the least, a combination of different ethnicities. Therefore, the margin of error is increased when different subpopulations are grouped together.	PHENOTYPE	343	VKORC1 diplotype to phenotype translation is not applicable to the warfarin guideline.	https://cpicpgx.org/gene/vkorc1/	\N	Common Name	f	f
CACNA1S	chr1	NG_009816.1	NP_000060.2	NC_000001.11	NM_000069.2	HGNC:1397	779	ENSG00000081248	PA85	Methods\n\nThe allele frequency table was made by searching the Genome Aggregation Database (gnomAD) by each rsID\n\nCaveats to estimated allele, frequencies:\n\nSampling. Allele frequencies collected by CPIC for the supplemental tables are based on published literature reports which typically study small groups of people based on a geographic location (e.g. Malaysia, Berlin, Cairo). Almost no studies use genetic markers to estimate ancestry. Manuscripts are often focused on a specific phenotype (e.g. disease) or study only individuals taking a particular drug. Such samples would not be considered a random sample of the general population. Another consideration is that sample size is important, and PGx studies are typically not large. The frequencies collected from these studies are then used to estimate general estimates of entire ethnic population allele frequencies. Therefore, frequencies from larger groups of subjects and frequencies averaged from many sample populations probably result in better estimates.\n\nBiogeographical groups. Biogeographical groups are derived from PMID 30506572. Further details, including the definitions of each group, can be found at https://www.pharmgkb.org/page/biogeographicalGroups. We strongly recommend that users use either the publication or the PharmGKB link provided to familiarize themselves with the grouping system before using these allele frequencies. These tables group individuals from particular geographic locations into larger biogeographical groups. It is difficult to group populations with certainty, because some populations are often admixed, or at the least, a combination of different ethnicities. Therefore, the margin of error is increased when different subpopulations are grouped together.	PHENOTYPE	449	\N	https://cpicpgx.org/gene/cacna1s/	\N	\N	f	f
\.


--
-- Data for Name: gene_result; Type: TABLE DATA; Schema: cpic; Owner: -
--

COPY cpic.gene_result (id, genesymbol, result, activityscore, ehrpriority, consultationtext, version, frequency) FROM stdin;
7983656	CFTR	ivacaftor non-responsive in CF patients	n/a	\N	\N	1	\N
8087846	TPMT	Intermediate Metabolizer	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has one copy of a normal function allele and one copy of a no function allele OR two copies of a decreased function allele. Based on the genotype result this patient is predicted to be a TPMT intermediate metabolizer. This patient may be at risk for an adverse reactions to medications that are metabolized by TPMT (eg. thiopurines). To avoid an untoward drug response, dose adjustments or alternative therapeutic agents may be necessary for medications metabolized by TPMT. However, thiopurines can be affected by a patient's TPMT and NUDT15 phenotype. Please consult a clinical pharmacist for more information about how TPMT and NUDT15 metabolic status influences drug selection and dosing.	3	{"Latino": 0.10138224, "European": 0.087302946, "East Asian": 0.039815668, "Near Eastern": 0.06641302, "Central/South Asian": 0.036385097, "Sub-Saharan African": 0.10365061, "African American/Afro-Caribbean": 0.069424435}
8087886	TPMT	Poor Metabolizer	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has two copies of a no function allele. Based on the genotype result this patient is predicted to be a TPMT poor metabolizer. This patient may be at a high risk for an adverse reactions to medications that are metabolized by TPMT (eg. thiopurines). To avoid an untoward drug response, dose adjustments or or alternative therapy may be necessary for medications metabolized by TPMT. However, thiopurines can be affected by a patient's TPMT and NUDT15 phenotype. Please consult a clinical pharmacist for more information about how TPMT and NUDT16 metabolic status influences drug selection and dosing.	3	{"Latino": 0.0028794738, "European": 0.0020956735, "East Asian": 0.00041297937, "Near Eastern": 0.0011826118, "Central/South Asian": 0.0003435882, "Sub-Saharan African": 0.002971174, "African American/Afro-Caribbean": 0.0013917874}
8088675	TPMT	Indeterminate	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has one copy of a normal function allele and one copy of an uncertain or unknown function allele OR one copy of a decreased function allele and one copy of an uncertain or unknown function allele OR two copies of an uncertain or unknown function allele. The expected phenotype for this patient cannot be determined currently based on the TPMT diplotype result. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity. Please consult a clinical pharmacist for more specific information about how TPMT function influences drug dosing.	3	{"Latino": 0.0032013063, "European": 0.0013079308, "East Asian": 0.000104039, "Near Eastern": 0.0, "Central/South Asian": 0.0, "Sub-Saharan African": 0.0, "African American/Afro-Caribbean": 0.06207684}
7988646	CYP2D6	Ultrarapid Metabolizer	2.75	Abnormal/Priority/High Risk	This result signifies that this patient has [X copies of a normal function allele (*_xN)] [X copies of a decreased function allele (*_)] [X copies of a no function allele (*_)]. Based on the genotype result this patient is predicted to be an ultrarapid metabolizer of CYP2D6 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2D6. To avoid an untoward drug response, dose adjustments may be necessary for medications metabolized by CYP2D6. Please consult a clinical pharmacist for more information about how CYP2D6 metabolic status influences drug selection and dosing.	3	{"Latino": 0.0, "American": 0.0, "European": 0.0, "Oceanian": 0.0, "East Asian": 0.0, "Near Eastern": 0.0, "Central/South Asian": 0.0, "Sub-Saharan African": 0.0, "African American/Afro-Caribbean": 0.0}
7988832	CYP2D6	Normal Metabolizer	2.25	Normal/Routine/ Low Risk	This result signifies that this patient has two copies of a normal function allele (*_x2) and one copy of decreased function allele with an activity value of 0.25 (*_). Based on the genotype result this patient is predicted to be a normal metabolizer of CYP2D6 substrates. There is no reason to selectively adjust the dose of most medications that are metabolized by CYP2D6. Please consult a clinical pharmacist for more information about how CYP2D6 metabolic status influences drug selection and dosing.	3	{"Latino": 0.005172111, "American": 0.0031386076, "European": 0.004804125, "Oceanian": 0.021296859, "East Asian": 0.0072455397, "Near Eastern": 0.029094387, "Central/South Asian": 0.005050826, "Sub-Saharan African": 0.0048336256, "African American/Afro-Caribbean": 0.004428509}
7988900	CYP2D6	Normal Metabolizer	2.0	Normal/Routine/ Low Risk	This result signifies that this patient has [X copies of a normal function allele (*_xN)] [X copies of a decreased function allele (*_)] [X copies of a no function allele (*_)]. Based on the genotype result this patient is predicted to be a normal metabolizer of CYP2D6 substrates. There is no reason to selectively adjust the dose of most medications that are metabolized by CYP2D6. Please consult a clinical pharmacist for more information about how CYP2D6 metabolic status influences drug selection and dosing.	3	{"Latino": 0.42007107, "American": 0.57988566, "European": 0.32166475, "Oceanian": 0.48931405, "East Asian": 0.1527359, "Near Eastern": 0.2670007, "Central/South Asian": 0.34187043, "Sub-Saharan African": 0.15406683, "African American/Afro-Caribbean": 0.22171879}
7989190	CYP2D6	Normal Metabolizer	1.5	Normal/Routine/ Low Risk	This result signifies that this patient has [1 copy of a normal function allele (*_)] [X copies of a decreased function allele (*_)] [X copies of a no function allele (*_)]. Based on the genotype result this patient is predicted to be a normal metabolizer of CYP2D6 substrates. There is no reason to selectively adjust the dose of most medications that are metabolized by CYP2D6. Please consult a clinical pharmacist for more information about how CYP2D6 metabolic status influences drug selection and dosing.	3	{"Latino": 0.051568672, "American": 0.012521543, "European": 0.010339902, "Oceanian": 0.00143701, "East Asian": 0.017062929, "Near Eastern": 0.045171212, "Central/South Asian": 0.0029989334, "Sub-Saharan African": 0.23161727, "African American/Afro-Caribbean": 0.23827769}
7983852	CYP2B6	Poor Metabolizer	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has two copies of a no function allele OR two copies of a decreased function allele OR one copy of a no function allele and one copy of a decreased function allele. Based on the genotype result this patient is predicted to be a poor metabolizer of CYP2B6 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2B6. To avoid an untoward drug response, dose adjustments or or alternative therapy may be necessary for medications metabolized by CYP2B6. Please consult a clinical pharmacist for more information about how CYP2B6 metabolic status influences drug selection and dosing.	3	{"Latino": 0.09452413, "European": 0.07428478, "Oceanian": 0.4096, "East Asian": 0.0436291, "Near Eastern": 0.127449, "Central/South Asian": 0.059536003, "Sub-Saharan African": 0.23673655, "African American/Afro-Caribbean": 0.15714757}
7984109	CYP2B6	Indeterminate	n/a	none	This result signifies that the patient has an allele combination with uncertain and/or unknown function alleles. The expected phenotype for this patient cannot be determined currently based on the CYP2B6 diplotype result. Please consult a clinical pharmacist for more specific information about how CYP2B6 function influences drug dosing.	3	{"Latino": 0.013596146, "European": 0.06145065, "Oceanian": 0.0, "East Asian": 0.020025712, "Near Eastern": 0.0, "Central/South Asian": 0.014973663, "Sub-Saharan African": 0.25210795, "African American/Afro-Caribbean": 0.031204166}
7983670	CYP2B6	Normal Metabolizer	n/a	Normal/Routine/Low Risk	This result signifies that the patient has two copies of normal function alleles. Based on the genotype result this patient is predicted to be an normal metabolizer of CYP2B6 substrates. There is no reason to selectively adjust the dose of most medications that are metabolized by CYP2B6. Please consult a clinical pharmacist for more information about how CYP2B6 metabolic status influences drug selection and dosing.	3	{"Latino": 0.33582056, "European": 0.42950228, "Oceanian": 0.12960002, "East Asian": 0.48562673, "Near Eastern": 0.29052103, "Central/South Asian": 0.42183065, "Sub-Saharan African": 0.14307445, "African American/Afro-Caribbean": 0.333572}
7983662	CYP2B6	Rapid Metabolizer	n/a	Normal/Routine/Low Risk	This result signifies that the patient has one copy of a normal function allele and one copy of an increased function allele. Based on the genotype result this patient is predicted to be a rapid metabolizer of CYP2B6 substrates. There is no reason to selectively adjust the dose of most medications that are metabolized by CYP2B6. Please consult a clinical pharmacist for more information about how CYP2B6 metabolic status influences drug selection and dosing.	3	{"Latino": 0.1231214, "European": 0.05357082, "Oceanian": 0.0, "East Asian": 0.11734093, "Near Eastern": 0.112112, "Central/South Asian": 0.12859802, "Sub-Saharan African": 0.0, "African American/Afro-Caribbean": 0.011896482}
8088791	UGT1A1	Indeterminate	n/a	none	This result signifies that the patient has an allele combination with uncertain and/or unknown function alleles. The expected phenotype for this patient cannot be determined currently based on the UGT1A1 diplotype result. UGT1A1*80 is in very high linkage disequilibrium with *28 and *37. In the rare event that *80 is detected but *28 and *37 are not, there are not enough clinical data to predict metabolizer status with certainty. However, if only *80 is interrogated and the patient is heterozygous or homozygous for *80, an intermediate or poor metabolizer phenotype may be inferred, respectively. Please consult a clinical pharmacist for more specific information about how UGT1A1 function influences drug dosing.	2	\N
8088753	UGT1A1	Intermediate Metabolizer	n/a	Normal/Routine/Low Risk	This result signifies that the patient has one copy of a normal function allele (*1) OR one copy of an increased function allele (*36), AND and one copy of a decreased function allele (*_). Based on the genotype result this patient is predicted to be an intermediate metabolizer of UGT1A1 substrates. There is no reason to selectively adjust the dose of most medications that inhibit or are inactivated by UGT1A1. Please consult a clinical pharmacist for more information about how UGT1A1 metabolic status influences drug selection and dosing.	2	\N
8088746	UGT1A1	Normal Metabolizer	n/a	Normal/Routine/Low Risk	This result signifies that the patient has two copies of a normal function allele (*1) OR one copy of a normal function allele (*1) and one copy of an increased function allele (*36) OR two copies of an increased function allele (*36). Based on the genotype result this patient is predicted to be an normal metabolizer of UGT1A1 substrates. There is no reason to selectively adjust the dose of most medications that inhibit or are inactivated by UGT1A1. Please consult a clinical pharmacist for more information about how UGT1A1 metabolic status influences drug selection and dosing.	2	\N
8088768	UGT1A1	Poor Metabolizer	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has two copies of decreased function alleles (*_ and *_). Based on the genotype result this patient is predicted to be a poor metabolizer of UGT1A1 substrates. This patient may be at risk for an adverse or poor response to medications that inhibit or are inactivated by UGT1A1. Based on the genotype result, this patient is predicted to have low UGT1A1 function, which is generally indicative of Gilbert syndrome. This patient may be at high risk for toxicity from select medications that inhibit or are inactivated by UGT1A1. Please consult a clinical pharmacist for more information about how UGT1A1 metabolic status influences drug selection and dosing.	2	\N
7983659	CYP2B6	Ultrarapid Metabolizer	n/a	Normal/Routine/Low Risk	This result signifies that the patient has two copies of increased function alleles. Based on the genotype result this patient is predicted to be an ultrarapid metabolizer of CYP2B6 substrates. There is no reason to selectively adjust the dose of most medications that are metabolized by CYP2B6. Please consult a clinical pharmacist for more information about how CYP2B6 metabolic status influences drug selection and dosing.	3	{"Latino": 0.011284955, "European": 0.0016704409, "Oceanian": 0.0, "East Asian": 0.007088209, "Near Eastern": 0.010816, "Central/South Asian": 0.009801, "Sub-Saharan African": 0.0, "African American/Afro-Caribbean": 0.000106068765}
7988752	CYP2D6	Ultrarapid Metabolizer	2.5	Abnormal/Priority/High Risk	This result signifies that this patient has [X copies of a normal function allele (*_xN)] [X copies of a decreased function allele (*_)]. Based on the genotype result this patient is predicted to be an ultrarapid metabolizer of CYP2D6 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2D6. To avoid an untoward drug response, dose adjustments may be necessary for medications metabolized by CYP2D6. Please consult a clinical pharmacist for more information about how CYP2D6 metabolic status influences drug selection and dosing.	3	{"Latino": 0.0022434974, "American": 0.0005345896, "European": 0.0003203256, "Oceanian": 0.00024761492, "East Asian": 0.00034846712, "Near Eastern": 0.005864233, "Central/South Asian": 0.00006554563, "Sub-Saharan African": 0.015329994, "African American/Afro-Caribbean": 0.01435911}
7985070	CYP2C19	Likely Poor Metabolizer	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has one copy of a decreased function allele and one copy of a no function allele. Based on the genotype result this patient MAY be a poor metabolizer of CYP2C19 substrates. This patient may be at a high risk for an adverse or poor response to medications that are metabolized by CYP2C19. To avoid an untoward drug response, dose adjustments or or alternative therapy may be necessary for medications metabolized by the CYP2C19. Please consult a clinical pharmacist for more information about how CYP2C19 metabolic status influences drug selection and dosing.	3	{"Latino": 0.0004440685, "American": 0.0, "European": 0.00020405183, "Oceanian": 0.0, "East Asian": 0.0004349198, "Near Eastern": 0.0, "Central/South Asian": 0.0, "Sub-Saharan African": 0.010332189, "African American/Afro-Caribbean": 0.007090685}
7984971	CYP2C19	Intermediate Metabolizer	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has one copy of a normal function allele and one copy of a no function allele OR one copy of an increased function and one copy of a no function allele. Based on the genotype result this patient is predicted to be an intermediate metabolizer of CYP2C19 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2C19. To avoid an untoward drug response, dose adjustments or alternative therapeutic agents may be necessary for medications metabolized by CYP2C19. Please consult a clinical pharmacist for more information about how CYP2C19 metabolic status influences drug selection and dosing.	3	{"Latino": 0.19035932, "American": 0.21383229, "European": 0.26108757, "Oceanian": 0.36902928, "East Asian": 0.45928204, "Near Eastern": 0.2354828, "Central/South Asian": 0.40806636, "Sub-Saharan African": 0.29945874, "African American/Afro-Caribbean": 0.31398684}
7985144	CYP2C19	Poor Metabolizer	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has two copies of a no function allele. Based on the genotype result this patient is predicted to be a poor metabolizer of CYP2C19 substrates. This patient may be at a high risk for an adverse or poor response to medications that are metabolized by CYP2C19. To avoid an untoward drug response, dose adjustments or or alternative therapy may be necessary for medications metabolized by the CYP2C19. Please consult a clinical pharmacist for more information about how CYP2C19 metabolic status influences drug selection and dosing.	3	{"Latino": 0.011408395, "American": 0.014819587, "European": 0.02387743, "Oceanian": 0.5713864, "East Asian": 0.12978691, "Near Eastern": 0.018584846, "Central/South Asian": 0.08156806, "Sub-Saharan African": 0.036714304, "African American/Afro-Caribbean": 0.040512204}
7985224	CYP2C19	Indeterminate	n/a	none	This result signifies that the patient has an allele combination with uncertain and/or unknown function alleles. The expected phenotype for this patient cannot be determined currently based on the CYP2C19 diplotype result. Please consult a clinical pharmacist for more specific information about how CYP2C19 function influences drug dosing.	3	{"Latino": 0.0, "American": 0.0, "European": 0.0, "Oceanian": 0.0, "East Asian": 0.0034064606, "Near Eastern": 0.0, "Central/South Asian": 0.0, "Sub-Saharan African": 0.0, "African American/Afro-Caribbean": 0.0022393465}
7984868	CYP2C19	Normal Metabolizer	n/a	Normal/Routine/Low Risk	This result signifies that the patient has two copies of a normal function allele. Based on the genotype result this patient is predicted to be an normal metabolizer of CYP2C19 substrates. There is no reason to selectively adjust the dose of most medications that are metabolized by CYP2C19. Please consult a clinical pharmacist for more information about how CYP2C19 metabolic status influences drug selection and dosing.	3	{"Latino": 0.5249766, "American": 0.62755567, "European": 0.39611652, "Oceanian": 0.035006005, "East Asian": 0.38055435, "Near Eastern": 0.45192146, "Central/South Asian": 0.29552925, "Sub-Saharan African": 0.36977687, "African American/Afro-Caribbean": 0.32805592}
7984859	CYP2C19	Rapid Metabolizer	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has one copy of a normal function allele and one copy of an increased function allele. Based on the genotype result this patient is predicted to be a rapid metabolizer of CYP2C19 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2C19. To avoid an untoward drug response, dose adjustments or alternative therapeutic agents may be necessary for medications metabolized by CYP2C19. Please consult a clinical pharmacist for more information about how CYP2C19 metabolic status influences drug selection and dosing.	3	{"Latino": 0.24136075, "American": 0.13638271, "European": 0.2711846, "Oceanian": 0.021329276, "East Asian": 0.025343522, "Near Eastern": 0.2573682, "Central/South Asian": 0.18567303, "Sub-Saharan African": 0.21080859, "African American/Afro-Caribbean": 0.2373838}
7989193	CYP2D6	Normal Metabolizer	1.75	Normal/Routine/ Low Risk	This result signifies that this patient has three copies of *41 (*41x3) and one copy of a normal function allele (*_) or [2 copies of a decreased function allele with an activity value of 0.5 (*_x2)]. Based on the genotype result this patient is predicted to be a normal metabolizer of CYP2D6 substrates. There is no reason to selectively adjust the dose of most medications that are metabolized by CYP2D6. Please consult a clinical pharmacist for more information about how CYP2D6 metabolic status influences drug selection and dosing.	3	{"Latino": 0.0, "American": 0.0, "European": 0.0, "Oceanian": 0.0, "East Asian": 0.0, "Near Eastern": 0.0, "Central/South Asian": 0.0, "Sub-Saharan African": 0.0, "African American/Afro-Caribbean": 0.0}
7989211	CYP2D6	Normal Metabolizer	1.25	Normal/Routine/ Low Risk	This result signifies that this patient has [1 copy of a normal function allele (*_)] or [2 copies of a decreased function allele with an activity value of 0.5 (*_x2)] and [1 copy of a decreased function allele with an activity value of 0.25 (*_)] OR *41x3 and [1 copy of a decreased function allele with an activity value of 0.5 (*_)] or [2 copies of a decreased function allele with an activity value of 0.25 (*_x2)]. Based on the genotype result this patient is predicted to be a normal metabolizer of CYP2D6 substrates. There is no reason to selectively adjust the dose of most medications that are metabolized by CYP2D6. Please consult a clinical pharmacist for more information about how CYP2D6 metabolic status influences drug selection and dosing.	3	{"Latino": 0.11888533, "American": 0.07351474, "European": 0.15507403, "Oceanian": 0.12359433, "East Asian": 0.3547828, "Near Eastern": 0.22410923, "Central/South Asian": 0.23109229, "Sub-Saharan African": 0.073030114, "African American/Afro-Caribbean": 0.07348749}
7989226	CYP2D6	Intermediate Metabolizer	1.0	Abnormal/Priority/High Risk	This result signifies that this patient has [1 copy of a normal function allele (*_)] [X copies of a decreased function allele (*_)] [X copies of a no function allele (*_)]. Based on the genotype result this patient is predicted to be an intermediate metabolizer of CYP2D6 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2D6. To avoid an untoward drug response, dose adjustments may be necessary for medications metabolized by CYP2D6. Please consult a clinical pharmacist for more information about how CYP2D6 metabolic status influences drug selection and dosing.	3	{"Latino": 0.2278144, "American": 0.21460281, "European": 0.28533316, "Oceanian": 0.077126324, "East Asian": 0.070599586, "Near Eastern": 0.14959782, "Central/South Asian": 0.17827679, "Sub-Saharan African": 0.20079781, "African American/Afro-Caribbean": 0.2080644}
7985550	CYP2C9	Intermediate Metabolizer	1.5	Abnormal/Priority/High Risk	This result signifies that the patient has one copy of a normal function allele and one copy of a decreased function allele. Based on the genotype result, this patient is predicted to be a CYP2C9 intermediate metabolizer (activity score of 1.5). This patient may be at risk for an adverse response to medications that are affected by CYP2C9. Please consult a clinical pharmacist for more specific information about how CYP2C9 intermediate metabolizer status influences drug dosing.	3	{"Latino": 0.1647683, "American": 0.10592343, "European": 0.20758142, "Oceanian": 0.05599055, "East Asian": 0.052658077, "Near Eastern": 0.2097067, "Central/South Asian": 0.17885593, "Sub-Saharan African": 0.21372117, "African American/Afro-Caribbean": 0.1863267}
7985854	CYP2C9	Poor Metabolizer	0.5	Abnormal/Priority/High Risk	This result signifies that the patient has one copy of a decreased function allele and one copy of a no function allele. Based on the genotype result, this patient is predicted to be a CYP2C9 poor metabolizer. This patient may be at high risk for an adverse response to medications that are affected by CYP2C9. Please consult a clinical pharmacist for more specific information about how CYP2C9 intermediate metabolizer status influences drug dosing.	3	{"Latino": 0.007974847, "American": 0.0034911723, "European": 0.019907156, "Oceanian": 0.0009130932, "East Asian": 0.0030826868, "Near Eastern": 0.022547128, "Central/South Asian": 0.025517693, "Sub-Saharan African": 0.0049882242, "African American/Afro-Caribbean": 0.004712071}
7986129	CYP2C9	Poor Metabolizer	0.0	Abnormal/Priority/High Risk	This result signifies that the patient has two copies of no function alleles. Based on the genotype result, this patient is predicted to be a CYP2C9 poor metabolizer. This patient may be at high risk for an adverse response to medications that are affected by CYP2C9. Please consult a clinical pharmacist for more specific information about how CYP2C9 intermediate metabolizer status influences drug dosing.	3	{"Latino": 0.0017415384, "American": 0.00090327376, "European": 0.0057798154, "Oceanian": 0.00024261088, "East Asian": 0.0028714235, "Near Eastern": 0.007066085, "Central/South Asian": 0.012135133, "Sub-Saharan African": 0.0003982905, "African American/Afro-Caribbean": 0.00048520204}
7986222	CYP2C9	Indeterminate	n/a	none	This result signifies that the patient has an allele combination with uncertain and/or unknown function alleles. The expected phenotype for this patient cannot be determined currently based on the CYP2C9 diplotype result. Please consult a clinical pharmacist for more specific information about how CYP2C9 function influences drug dosing.	3	{"Latino": 0.0009997501, "American": 0.0, "European": 0.00059991, "Oceanian": 0.0, "East Asian": 0.0046076896, "Near Eastern": 0.0, "Central/South Asian": 0.0037963898, "Sub-Saharan African": 0.0, "African American/Afro-Caribbean": 0.0}
7988439	CYP2D6	Ultrarapid Metabolizer	≥4.0	Abnormal/Priority/High Risk	This result signifies that this patient has [X copies of a normal function allele (*_xN)] [X copies of a decreased function allele (*_)] [X copies of a no function allele (*_)]. Based on the genotype result this patient is predicted to be an ultrarapid metabolizer of CYP2D6 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2D6. To avoid an untoward drug response, dose adjustments may be necessary for medications metabolized by CYP2D6. Please consult a clinical pharmacist for more information about how CYP2D6 metabolic status influences drug selection and dosing.	3	{"Latino": 0.0012809848, "American": 0.0015109289, "European": 0.0018874556, "Oceanian": 0.0, "East Asian": 0.0007779561, "Near Eastern": 0.0, "Central/South Asian": 0.0, "Sub-Saharan African": 0.0038317435, "African American/Afro-Caribbean": 0.0}
7988435	CYP2D6	Ultrarapid Metabolizer	≥3.75	Abnormal/Priority/High Risk	This result signifies that this patient has [X copies of a normal function allele (*_xN)] [X copies of a decreased function allele (*_)] [X copies of a no function allele (*_)]. Based on the genotype result this patient is predicted to be an ultrarapid metabolizer of CYP2D6 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2D6. To avoid an untoward drug response, dose adjustments may be necessary for medications metabolized by CYP2D6. Please consult a clinical pharmacist for more information about how CYP2D6 metabolic status influences drug selection and dosing.	3	{"Latino": 0.0, "American": 0.0, "European": 0.0, "Oceanian": 0.0, "East Asian": 0.0, "Near Eastern": 0.0, "Central/South Asian": 0.0, "Sub-Saharan African": 0.0, "African American/Afro-Caribbean": 0.0}
7988473	CYP2D6	Ultrarapid Metabolizer	≥3.5	Abnormal/Priority/High Risk	This result signifies that this patient has [X copies of a normal function allele (*_xN)] [X copies of a decreased function allele (*_)] [X copies of a no function allele (*_)]. Based on the genotype result this patient is predicted to be an ultrarapid metabolizer of CYP2D6 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2D6. To avoid an untoward drug response, dose adjustments may be necessary for medications metabolized by CYP2D6. Please consult a clinical pharmacist for more information about how CYP2D6 metabolic status influences drug selection and dosing.	3	{"Latino": 0.00008051411, "American": 0.00001657463, "European": 0.000031193038, "Oceanian": 0.0, "East Asian": 0.00004386605, "Near Eastern": 0.0, "Central/South Asian": 0.0, "Sub-Saharan African": 0.0030223487, "African American/Afro-Caribbean": 0.0}
7988525	CYP2D6	Ultrarapid Metabolizer	≥3.0	Abnormal/Priority/High Risk	This result signifies that this patient has [X copies of a normal function allele (*_xN)] [X copies of a decreased function allele (*_)] [X copies of a no function allele (*_)]. Based on the genotype result this patient is predicted to be an ultrarapid metabolizer of CYP2D6 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2D6. To avoid an untoward drug response, dose adjustments may be necessary for medications metabolized by CYP2D6. Please consult a clinical pharmacist for more information about how CYP2D6 metabolic status influences drug selection and dosing.	3	{"Latino": 0.00035315607, "American": 0.0002839765, "European": 0.0008605249, "Oceanian": 0.0, "East Asian": 0.00018026348, "Near Eastern": 0.0, "Central/South Asian": 0.0, "Sub-Saharan African": 0.001428226, "African American/Afro-Caribbean": 0.0}
7993218	CYP2D6	Indeterminate	n/a	none	This result signifies that the patient has an allele combination with uncertain and/or unknown function alleles. The expected phenotype for this patient cannot be determined currently based on the CYP2D6 diplotype result. Please consult a clinical pharmacist for more specific information about how CYP2D6 function influences drug dosing.	3	{"Latino": 0.041558996, "American": 0.02454997, "European": 0.03725156, "Oceanian": 0.087338224, "East Asian": 0.066782884, "Near Eastern": 0.03744279, "Central/South Asian": 0.09993659, "Sub-Saharan African": 0.09009597, "African American/Afro-Caribbean": 0.038868744}
7988654	CYP2D6	Ultrarapid Metabolizer	3.0	Abnormal/Priority/High Risk	This result signifies that this patient has [X copies of a normal function allele (*_xN)] [X copies of a decreased function allele (*_)] [X copies of a no function allele (*_)]. Based on the genotype result this patient is predicted to be an ultrarapid metabolizer of CYP2D6 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2D6. To avoid an untoward drug response, dose adjustments may be necessary for medications metabolized by CYP2D6. Please consult a clinical pharmacist for more information about how CYP2D6 metabolic status influences drug selection and dosing.	3	{"Latino": 0.035694193, "American": 0.048732717, "European": 0.019382542, "Oceanian": 0.16405001, "East Asian": 0.006179998, "Near Eastern": 0.06435209, "Central/South Asian": 0.014773737, "Sub-Saharan African": 0.019435417, "African American/Afro-Caribbean": 0.025694855}
7991510	CYP2D6	Intermediate Metabolizer	0.25	Abnormal/Priority/High Risk	This result signifies that this patient has one copy of a decreased function allele with an activity value of 0.25 (*_) and one copy of a no function allele (*_). Based on the genotype result this patient is predicted to be an intermediate metabolizer of CYP2D6 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2D6. To avoid an untoward drug response, dose adjustments may be necessary for medications metabolized by CYP2D6. Please consult a clinical pharmacist for more information about how CYP2D6 metabolic status influences drug selection and dosing.	3	{"Latino": 0.03277562, "American": 0.0138169695, "European": 0.07070104, "Oceanian": 0.010012345, "East Asian": 0.08220821, "Near Eastern": 0.06670452, "Central/South Asian": 0.060946763, "Sub-Saharan African": 0.027220901, "African American/Afro-Caribbean": 0.024385082}
8005322	CYP3A5	Intermediate Metabolizer	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has one copy of a normal function allele and one copy of a no function allele. Patients with this genotype are expected to require higher starting tacrolimus dosing (1.5 times to 2 times the standard dose-maximum starting dose not to exceed 0.3mg/kg/day). Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors (e.g., medication interactions, or hepatic function). Please consult a clinical pharmacist for more specific dosing information.	3	{"Latino": 0.28587034, "European": 0.13722531, "East Asian": 0.37852672, "Near Eastern": 0.21414419, "Central/South Asian": 0.43994826, "Sub-Saharan African": 0.499152, "African American/Afro-Caribbean": 0.4955547}
8005327	CYP3A5	Poor Metabolizer	n/a	Normal/Routine/Low Risk	This result signifies that the patient has two copies of a no function allele. Patients with this genotype are expected to require standard tacrolimus dosing. Please consult a clinical pharmacist for more specific dosing information.	3	{"Latino": 0.68427247, "European": 0.85728335, "East Asian": 0.5571847, "Near Eastern": 0.770986, "Central/South Asian": 0.45330563, "Sub-Saharan African": 0.2710154, "African American/Afro-Caribbean": 0.2993679}
8005335	CYP3A5	Possible Intermediate Metabolizer	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has one copy of a normal function allele and one copy of an uncertain or unknown function allele. Patients with this genotype are expected to require higher starting tacrolimus dosing (1.5 times to 2 times the standard dose-maximum starting dose not to exceed 0.3mg/kg/day). Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors (e.g., medication interactions, or hepatic function). Please consult a clinical pharmacist for more specific dosing information.	3	{"Latino": 0.0, "European": 0.0, "East Asian": 0.0, "Near Eastern": 0.0, "Central/South Asian": 0.0, "Sub-Saharan African": 0.0, "African American/Afro-Caribbean": 0.0}
7989239	CYP2D6	Intermediate Metabolizer	0.75	Abnormal/Priority/High Risk	This result signifies that this patient has has three copies of *41 (*41x3) and one copy of a no function allele (*_) OR [1 copy of a decreased function allele with an activity value of 0.25 (*_)] and [1 copy of a decreased function allele with an activity value of 0.5 (*_)] or [2 copies of a decreased function allele with an activity value of 0.25 (*_x2)] . Based on the genotype result this patient is predicted to be an intermediate metabolizer of CYP2D6 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2D6. To avoid an untoward drug response, dose adjustments may be necessary for medications metabolized by CYP2D6. Please consult a clinical pharmacist for more information about how CYP2D6 metabolic status influences drug selection and dosing.	3	{"Latino": 0.0074723335, "American": 0.00080644403, "European": 0.0025628314, "Oceanian": 0.00018655165, "East Asian": 0.020004882, "Near Eastern": 0.02042247, "Central/South Asian": 0.0010252715, "Sub-Saharan African": 0.05760366, "African American/Afro-Caribbean": 0.041067164}
7988416	CYP2D6	Ultrarapid Metabolizer	≥6.0	Abnormal/Priority/High Risk	This result signifies that this patient has [X copies of a normal function allele (*_xN)] [X copies of a decreased function allele (*_)] [X copies of a no function allele (*_)]. Based on the genotype result this patient is predicted to be an ultrarapid metabolizer of CYP2D6 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2D6. To avoid an untoward drug response, dose adjustments may be necessary for medications metabolized by CYP2D6. Please consult a clinical pharmacist for more information about how CYP2D6 metabolic status influences drug selection and dosing.	3	{"Latino": 0.0000010000001, "American": 0.0000010000001, "European": 0.0000028470035, "Oceanian": 0.0, "East Asian": 0.0000010000001, "Near Eastern": 0.0, "Central/South Asian": 0.0, "Sub-Saharan African": 0.000025000001, "African American/Afro-Caribbean": 0.0}
7988421	CYP2D6	Ultrarapid Metabolizer	≥5.0	Abnormal/Priority/High Risk	This result signifies that this patient has [X copies of a normal function allele (*_xN)] [X copies of a decreased function allele (*_)] [X copies of a no function allele (*_)]. Based on the genotype result this patient is predicted to be an ultrarapid metabolizer of CYP2D6 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2D6. To avoid an untoward drug response, dose adjustments may be necessary for medications metabolized by CYP2D6. Please consult a clinical pharmacist for more information about how CYP2D6 metabolic status influences drug selection and dosing.	3	{"Latino": 0.000055729302, "American": 0.00006450697, "European": 0.000058472542, "Oceanian": 0.0, "East Asian": 0.000015887783, "Near Eastern": 0.0, "Central/South Asian": 0.0, "Sub-Saharan African": 0.00025361063, "African American/Afro-Caribbean": 0.0}
7992040	CYP2D6	Poor Metabolizer	0.0	Abnormal/Priority/High Risk	This result signifies that the patient has two copies of a no function allele (*_/*_). Based on the genotype result this patient is predicted to be a poor metabolizer of CYP2D6 substrates. This patient may be at a high risk for an adverse or poor response to medications that are metabolized by CYP2D6. To avoid an untoward drug response, dose adjustments or alternative therapeutic agents may be necessary for medications metabolized by the CYP2D6. Please consult a clinical pharmacist for more information about how CYP2D6 metabolic status influences drug selection and dosing.	3	{"Latino": 0.0311798, "American": 0.020160662, "European": 0.065024786, "Oceanian": 0.0031239481, "East Asian": 0.008123729, "Near Eastern": 0.021957064, "Central/South Asian": 0.023507897, "Sub-Saharan African": 0.020398295, "African American/Afro-Caribbean": 0.023474354}
8005339	CYP3A5	Indeterminate	n/a	none	This result signifies that the patient has an allele combination with uncertain and/or unknown function alleles. The expected phenotype for this patient cannot be determined currently based on the CYP3A5 diplotype result. Please consult a clinical pharmacist for more specific information about how CYP3A5 function influences drug dosing.	3	{"Latino": 0.0, "European": 0.0, "East Asian": 0.0, "Near Eastern": 0.0, "Central/South Asian": 0.0, "Sub-Saharan African": 0.0, "African American/Afro-Caribbean": 0.0}
8005351	DPYD	Normal Metabolizer	2.0	Normal/Routine/Low Risk	This result signifies that the patient has two copies of normal function DPYD alleles. Based on the genotype result this patient is predicted to be DPYD Normal Metabolizer with a DPYD activity score of 2. For this genotype, no selective dose adjustment is indicated for medications that are metabolized by DPD. Please consult a clinical pharmacist for more information about how DPD metabolic status influences drug selection and dosing.	2	\N
8006949	DPYD	Intermediate Metabolizer	1.5	Abnormal/Priority/High Risk	This result signifies that the patient has one copy of a normal function allele and one copy of a decreased function allele of the DPYD gene. Based on the genotype result this patient is predicted to be a DPYD Intermediate Metabolizer with a DPYD activity score of 1.5. This patient may be at risk for adverse drug reactions to medications that are metabolized by DPD (i.e. 5-fluorouracil, capecitabine, and tegafur) and a dose adjustment may be indicated. Please consult a clinical pharmacist for more information about how DPD metabolic status influences drug selection and dosing.	2	\N
8007343	DPYD	Intermediate Metabolizer	1.0	Abnormal/Priority/High Risk	This result signifies that the patient has either one copy of a normal function allele and one copy of a no function allele of the DPYD gene OR two copies of decreased function alleles of the DPYD gene. Based on the genotype result this patient is predicted to be a DPYD Intermediate Metabolizer with a DPYD activity score of 1. This patient may be at risk for adverse drug reactions to medications that are metabolized by DPD (i.e. 5-fluorouracil, capecitabine, and tegafur) and a dose adjustment may be indicated. Please consult a clinical pharmacist for more information about how DPD metabolic status influences drug selection and dosing.	2	\N
8008550	DPYD	Poor Metabolizer	0.5	Abnormal/Priority/High Risk	This result signifies that the patient has one copy of a decreased function allele and one copy of a no function allele of the DPYD gene. Based on the genotype result this patient is predicted to be a DPYD Poor Metabolizer with a DPYD activity score of 0.5. This patient may be at risk for adverse drug reactions to medications that are metabolized by DPD (i.e. 5-fluorouracil, capecitabine, and tegafur) and a dose adjustment or alternative therapeutic agents may be indicated. Please consult a clinical pharmacist for more information about how DPD metabolic status influences drug selection and dosing.	2	\N
8008699	DPYD	Poor Metabolizer	0.0	Abnormal/Priority/High Risk	This result signifies that the patient has two copies of no function alleles of the DPYD gene. Based on the genotype result this patient is predicted to be a DPYD Poor Metabolizer with a DPYD activity score of 0. This patient may be at risk for adverse drug reactions to medications that are metabolized by DPD (i.e. 5-fluorouracil, capecitabine, and tegafur) and alternative therapeutic agents may be indicated. Please consult a clinical pharmacist for more information about how DPD metabolic status influences drug selection and dosing.	2	\N
8088805	HLA-A	*31:01 negative	n/a	Routine/Low-Risk	The HLA-A*31:01 allele, which is associated with severe cutaneous adverse reactions among patients taking certain aromatic anticonvulsants, was not detected in this patient. No change in therapy is warranted based on these results. It should be noted that a negative HLA-A*31:01 result does not absolutely rule out the possibility of an adverse drug reaction. Please consult a clinical pharmacist for more information.	1	\N
8088808	HLA-A	*31:01 positive	n/a	Priority/High-Risk	This result signifies that the patient has one or two copies of HLA-A*31:01. Patients with this genotype are at increased risk of severe cutaneous adverse reactions, including Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and maculopapular exanthema (MPE), with certain aromatic anticonvulsants (e.g., carbamazepine). Alternative therapy may be warranted. Please consult a clinical pharmacist for more information.	1	\N
7988501	CYP2D6	Ultrarapid Metabolizer	≥3.25	Abnormal/Priority/High Risk	This result signifies that this patient has [X copies of a normal function allele (*_xN)] [X copies of a decreased function allele (*_)] [X copies of a no function allele (*_)]. Based on the genotype result this patient is predicted to be an ultrarapid metabolizer of CYP2D6 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2D6. To avoid an untoward drug response, dose adjustments may be necessary for medications metabolized by CYP2D6. Please consult a clinical pharmacist for more information about how CYP2D6 metabolic status influences drug selection and dosing.	3	{"Latino": 0.00018561553, "American": 0.00009731066, "European": 0.00046782166, "Oceanian": 0.0, "East Asian": 0.0009120896, "Near Eastern": 0.0, "Central/South Asian": 0.0, "Sub-Saharan African": 0.000952962, "African American/Afro-Caribbean": 0.0}
7988623	CYP2D6	Ultrarapid Metabolizer	4.0	Abnormal/Priority/High Risk	This result signifies that this patient has [X copies of a normal function allele (*_xN)] [X copies of a decreased function allele (*_)] [X copies of a no function allele (*_)]. Based on the genotype result this patient is predicted to be an ultrarapid metabolizer of CYP2D6 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2D6. To avoid an untoward drug response, dose adjustments may be necessary for medications metabolized by CYP2D6. Please consult a clinical pharmacist for more information about how CYP2D6 metabolic status influences drug selection and dosing.	3	{"Latino": 0.0007764387, "American": 0.0010402872, "European": 0.0003002313, "Oceanian": 0.014133941, "East Asian": 0.000063105406, "Near Eastern": 0.0041771694, "Central/South Asian": 0.00016144973, "Sub-Saharan African": 0.0006431835, "African American/Afro-Caribbean": 0.0007742127}
7990817	CYP2D6	Intermediate Metabolizer	0.5	Abnormal/Priority/High Risk	This result signifies that this patient has [1 copy of a decreased function allele with an activity value of 0.5 (*_)] or [2 copies of a decreased function allele with an activity value of 0.25 (*_x2)] and one copy of a no function allele (*_) OR two copies for a decreased function allele with an activity value of 0.25 (*_/*_). Based on the genotype result this patient is predicted to be an intermediate metabolizer of CYP2D6 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2D6. To avoid an untoward drug response, dose adjustments may be necessary for medications metabolized by CYP2D6. Please consult a clinical pharmacist for more information about how CYP2D6 metabolic status influences drug selection and dosing.	3	{"Latino": 0.022830304, "American": 0.0047207433, "European": 0.023932345, "Oceanian": 0.008138877, "East Asian": 0.21193053, "Near Eastern": 0.06410619, "Central/South Asian": 0.040293686, "Sub-Saharan African": 0.0954133, "African American/Afro-Caribbean": 0.08539959}
8008939	G6PD	Deficient	n/a	Abnormal/Priority/High Risk	Based on the genotype result, this patient is predicted to be G6PD deficient and is at risk for developing hemolytic anemia when exposed to certain medications (such as dapsone, methylene blue, pegloticase, primaquine (at certain doses), rasburicase, tafenoquine, toluidine blue) or foods (such as fava beans). Please consult a clinical pharmacist for more information.	2	\N
8009032	G6PD	Deficient with CNSHA	n/a	Abnormal/Priority/High Risk	Based on the genotype result, this patient is predicted to be G6PD deficient with CNSHA and is at risk for developing or worsening hemolytic anemia when exposed to certain medications (such as dapsone, methylene blue, pegloticase, primaquine (at certain doses), rasburicase, tafenoquine, toluidine blue) or foods (such as fava beans). Please consult a clinical pharmacist for more information.	2	\N
8025602	G6PD	Indeterminate	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has an allele combination with uncertain and/or unknown function alleles. The expected phenotype for this patient cannot be determined currently based on genotype alone. A G6PD enzyme activity test is recommended to assess for G6PD deficiency. Please consult a clinical pharmacist for more specific information about how G6PD function influences drug dosing.	2	\N
8008932	G6PD	Normal	n/a	Normal Risk	Based on the genotype result, this patient is predicted to have normal G6PD enzyme activity. This means there is no reason to selectively avoid G6PD associated medications based on the G6PD status alone. Please consult a clinical pharmacist for more information.	2	\N
8009136	G6PD	Variable	n/a	Abnormal/Priority/High Risk	This patient carries one copy of a deficient G6PD allele and one copy of a normal G6PD allele. Due to X inactivation, patients who are heterozygous with one deficient allele and one normal allele may exhibit G6PD activity ranging from normal to deficient. A G6PD enzyme activity test is recommended to assess for G6PD deficiency. Please consult a clinical pharmacist for more information.	2	\N
8088811	HLA-B	*15:02 negative	n/a	Routine/Low-Risk	The HLA-B*15:02 allele, which is associated with severe cutaneous adverse reactions among patients taking certain aromatic anticonvulsants, was not detected in this patient. No change in therapy is warranted based on these results. It should be noted that a negative HLA-B*15:02 result does not absolutely rule out the possibility of an adverse drug reaction. Please consult a clinical pharmacist for more information.	1	\N
8088814	HLA-B	*15:02 positive	n/a	Priority/High-Risk	This result signifies that the patient has one or two copies of HLA-B*15:02. Patients with this genotype are at increased risk of severe cutaneous adverse reactions, including Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), with certain aromatic anticonvulsants (e.g., carbamazepine, oxcarbazepine, phenytoin/fosphenytoin). Alternative therapy may be warranted. Please consult a clinical pharmacist for more information.	1	\N
8088817	HLA-B	*57:01 negative	n/a	Normal/Routine/Low Risk	The HLA-B*57:01 allele, associated with abacavir hypersensitivity, was not detected in this patient. The patient may be prescribed abacavir. Please refer to the hospital formulary guidelines for specific dosing information. It should be noted that a negative HLA-B*57:01 result does not absolutely rule out the possibility of some form of abacavir hypersensitivity. Administration of abacavir therapy requires close observation including immediate discontinuation of therapy should any signs or symptoms of hypersensitivity develop.	1	\N
8088820	HLA-B	*57:01 positive	n/a	Abnormal/Priority/High Risk	The HLA-B*57:01 allele, associated with abacavir hypersensitivity, was detected in this patient. HLA-B*5701 positive patients should NOT be prescribed abacavir.	1	\N
8088823	HLA-B	*58:01 negative	n/a	Normal/Routine/Low Risk	The HLA-B*58:01 allele, associated with allopurinol hypersensitivity, was not detected in this patient. Allopurinol can be used per standard dosing guidelines. Patients should be monitored closely for any signs of sensitivity reactions, especially those patients receiving allopurinol (of >300 mg/day), concomitant medications (i.e. thiazide diuretics or penicillin/cephalosporin) or with medical conditions (i.e. chronic kidney disease) that increase the non-genetic risk for allopurinol-related hypersensitivity reactions.	1	\N
8088826	HLA-B	*58:01 positive	n/a	Abnormal/Priority/High Risk	The HLA-B*58:01 allele, associated with allopurinol hypersensitivity, was detected in this patient. Allopurinol is contraindicated.	1	\N
8005319	CYP3A5	Normal Metabolizer	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has two copies of a normal function allele. Patients with this genotype are expected to require higher starting tacrolimus dosing (1.5 times to 2 times the standard dose-maximum starting dose not to exceed 0.3mg/kg/day). Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors (e.g., medication interactions, or hepatic function). Please consult a clinical pharmacist for more specific dosing information.	3	{"Latino": 0.029857205, "European": 0.005491413, "East Asian": 0.064288594, "Near Eastern": 0.014869832, "Central/South Asian": 0.106746115, "Sub-Saharan African": 0.22983262, "African American/Afro-Caribbean": 0.20507748}
8026722	MT-RNR1	increased risk of aminoglycoside-induced hearing loss	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has a copy of the MT-RNR1 [variant]. Based on this genotype result, the patient is predicted to be at increased risk of aminoglycoside-induced hearing loss. This means that the patient is likely to develop irreversible hearing loss if aminoglycosides (e.g. amikacin, gentamicin, tobramycin) are prescribed. Please consult a clinical pharmacist or Infectious Diseases Service for help selecting alternative therapies.	2	\N
8026727	MT-RNR1	normal risk of aminoglycoside-induced hearing loss	n/a	Normal/Routine/Low Risk	This result signifies that MT-RNR1 variants associated with aminoglycoside-induced hearing loss were not detected in this patient. Based on this genotype result, no change in aminoglycoside therapy is warranted. It should be noted that this result does not absolutely rule out the possibility of the patient developing ototoxicity with aminoglycoside use.	2	\N
8026730	MT-RNR1	uncertain risk of aminoglycoside-induced hearing loss	n/a	Normal/Routine/Low Risk	This result signifies that the patient has a copy of MT-RNR1 [variant]. At this time, the association of this allele with aminoglycoside-induced hearing loss is unknown/uncertain. Based on this genotype result, no change in aminoglycoside therapy is warranted. It should be noted that this result does not absolutely rule out the possibility of the patient developing ototoxicity with aminoglycoside use.	2	\N
7983693	CYP2B6	Intermediate Metabolizer	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has one copy of a normal function allele and one copy of a no function allele OR one copy of a normal function allele and one copy of a decreased function allele OR one copy of an increased function allele and one copy of a no function allele OR one copy of an increased function allele and one copy of a decreased function allele. Based on the genotype result this patient is predicted to be an intermediate metabolizer of CYP2B6 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2B6. To avoid an untoward drug response, dose adjustments or alternative therapeutic agents may be necessary for medications metabolized by CYP2B6. Please consult a clinical pharmacist for more information about how CYP2B6 metabolic status influences drug selection and dosing.	3	{"Latino": 0.42165288, "European": 0.37952113, "Oceanian": 0.46080005, "East Asian": 0.32628936, "Near Eastern": 0.459102, "Central/South Asian": 0.36526063, "Sub-Saharan African": 0.36808127, "African American/Afro-Caribbean": 0.4660738}
8028559	NUDT15	Possible Intermediate Metabolizer	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has one copy of an uncertain function allele and one copy of a no function allele. Based on the genotype result this patient is predicted to be a NUDT15 possible intermediate metabolizer. This patient may be at risk for an adverse reactions to medications that are metabolized by NUDT15 (eg thiopurines). To avoid an untoward drug response, dose adjustments or alternative therapeutic agents may be necessary for medications metabolized by NUDT15. Please consult a clinical pharmacist for more information about how NUDT15 metabolic status influences drug selection and dosing.	3	{"Latino": 0.0, "European": 0.0, "East Asian": 0.0, "Central/South Asian": 0.0}
8026752	NAT2	Rapid Metabolizer	n/a	Priority/High Risk	This result signifies that the patient has inherited two increased function alleles. Based on the genotype result this patient is predicted to be a rapid metabolizer of NAT2 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by NAT2. To avoid an untoward drug response, dose adjustments or alternative therapeutic agents may be necessary for medications metabolized by NAT2. Please consult a clinical pharmacist for more information about how NAT2 metabolic status influences drug selection and dosing.	2	\N
8026757	NAT2	Intermediate Metabolizer	n/a	Priority/High Risk	This result signifies that the patient has inherited one increased function allele and one decreased function allele. Based on the genotype result this patient is predicted to be an intermediate metabolizer of NAT2 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by NAT2. To avoid an untoward drug response, dose adjustments or alternative therapeutic agents may be necessary for medications metabolized by NAT2. Please consult a clinical pharmacist for more information about how NAT2 metabolic status influences drug selection and dosing.	2	\N
8026839	NAT2	Poor Metabolizer	n/a	Priority/High Risk	This result signifies that the patient has inherited two decreased function alleles. Based on the genotype result this patient is predicted to be a poor metabolizer of NAT2 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by NAT2. To avoid an untoward drug response, dose adjustments or alternative therapeutic agents may be necessary for medications metabolized by NAT2. Please consult a clinical pharmacist for more information about how NAT2 metabolic status influences drug selection and dosing.	2	\N
8027661	NAT2	Indeterminate	n/a	none	This result signifies that the patient has inhertied an allele combination with uncertain and/or unknown function alleles. The expected phenotype for this patient cannot be determined currently based on the NAT2 diplotype result. Please consult a clinical pharmacist for more specific information about how NAT2 function influences drug dosing.	2	\N
7984856	CYP2C19	Ultrarapid Metabolizer	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has two copies of an increased function allele. Based on the genotype result this patient is predicted to be an ultrarapid metabolizer of CYP2C19 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2C19. To avoid an untoward drug response, dose adjustments or alternative therapeutic agents may be necessary for medications metabolized by CYP2C19. Please consult a clinical pharmacist for more information about how CYP2C19 metabolic status influences drug selection and dosing.	3	{"Latino": 0.02774172, "American": 0.0074097984, "European": 0.04641379, "Oceanian": 0.003249, "East Asian": 0.00042194634, "Near Eastern": 0.036642652, "Central/South Asian": 0.029163336, "Sub-Saharan African": 0.030045323, "African American/Afro-Caribbean": 0.042943195}
7984898	CYP2C19	Likely Intermediate Metabolizer	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has one copy of a normal function allele and one copy of a decreased function allele OR one copy of an increased function allele and one copy of a decreased function allele OR two copies of a decreased function allele. Based on the genotype result this patient MAY be an intermediate metabolizer of CYP2C19 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by CYP2C19. To avoid an untoward drug response, dose adjustments or alternative therapeutic agents may be necessary for medications metabolized by CYP2C19. Please consult a clinical pharmacist for more information about how CYP2C19 metabolic status influences drug selection and dosing.	3	{"Latino": 0.003709162, "American": 0.0, "European": 0.0011160374, "Oceanian": 0.0, "East Asian": 0.00076989824, "Near Eastern": 0.0, "Central/South Asian": 0.0, "Sub-Saharan African": 0.042863965, "African American/Afro-Caribbean": 0.027788177}
8088629	TPMT	Normal Metabolizer	n/a	Normal/Routine/Low Risk	This result signifies that the patient has two copies of a normal function allele OR one copy of a normal function allele and one copy of a decreased function allele. Based on the genotype result this patient is predicted to be a TPMT normal metabolizer. There is no reason to selectively adjust the dose of most medications that are metabolized by TPMT. However, thiopurines can be affected by a patient's TPMT and NUDT15 phenotype. Please consult a clinical pharmacist for more information about how TPMT and NUDT15 metabolic status influences drug selection and dosing.	3	{"Latino": 0.8923553, "European": 0.90923065, "East Asian": 0.9596651, "Near Eastern": 0.93240434, "Central/South Asian": 0.96327126, "Sub-Saharan African": 0.8933782, "African American/Afro-Caribbean": 0.8646596}
8087501	TPMT	Possible Intermediate Metabolizer	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has one copy of an uncertain or unknown function allele and one copy of a no function allele OR one copy of a no function allele and one copy of a decreased function allele. Based on the genotype result this patient has a priority result (TPMT possible intermediate metabolizer) because their activity is not likely to be any higher than that of an intermediate metabolizer; if the uncertain/unknown function allele is also low, activity may be even lower than that of an intermediate metabolizer. This patient may be at risk for an adverse reactions to medications that are metabolized by TPMT (eg. thiopurines). To avoid an untoward drug response, dose adjustments or alternative therapeutic agents may be necessary for medications metabolized by TPMT. However, thiopurines can be affected by a patient's TPMT and NUDT15 phenotype. Please consult a clinical pharmacist for more information about how TPMT and NUDT15metabolic status influences drug selection and dosing.	3	{"Latino": 0.00018168772, "European": 0.000062770196, "East Asian": 0.0000021581852, "Near Eastern": 0.0, "Central/South Asian": 0.0, "Sub-Saharan African": 0.0, "African American/Afro-Caribbean": 0.0024473174}
7978180	ABCG2	Normal Function	n/a	Normal/Routine/Low Risk	This result signifies that the patient has two copies of a normal function allele. Based on the genotype result, this patient is predicted to have normal ABCG2 function. This means that there is no reason to adjust the dose of most medications that are affected by ABCG2 on the basis of ABCG2 genetic status. Please consult a clinical pharmacist for more specific information about how ABCG2 function influences drug dosing.	3	{"Latino": 0.6015554, "American": 0.64000005, "European": 0.8035329, "Oceanian": 0.63246274, "East Asian": 0.4801104, "Near Eastern": 0.87366414, "Central/South Asian": 0.8222862, "Sub-Saharan African": 0.9883421, "African American/Afro-Caribbean": 0.9314832}
8028536	NUDT15	Normal Metabolizer	n/a	Normal/Routine/Low Risk	This result signifies that the patient has two copies of a normal function allele OR one copy of a normal function allele and one copy of a decreased function allele. Based on the genotype result this patient is predicted to be a NUDT15 normal metabolizer. There is no reason to selectively adjust the dose of most medications that are metabolized by NUDT15. Please consult a clinical pharmacist for more information about how NUDT15 metabolic status influences drug selection and dosing.	3	{"Latino": 0.94649667, "European": 0.98632336, "East Asian": 0.8551724, "Central/South Asian": 0.8657786}
7985545	CYP2C9	Normal Metabolizer	2.0	Normal/Routine/Low Risk	This result signifies that the patient has two copies of a normal function allele. Based on the genotype result, this patient is predicted to be a CYP2C9 Normal metabolizer. Based only on the CYP2C9 genotype, there is no reason to adjust the dose of most medications that are affected by CYP2C9. Please consult a clinical pharmacist for more specific information about how CYP2C9 function influences drug dosing.	3	{"Latino": 0.74342215, "American": 0.83149743, "European": 0.62845254, "Oceanian": 0.9122409, "East Asian": 0.8378542, "Near Eastern": 0.61125296, "Central/South Asian": 0.5961676, "Sub-Saharan African": 0.73114437, "African American/Afro-Caribbean": 0.75866354}
8028542	NUDT15	Intermediate Metabolizer	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has one copy of a normal function allele and one copy of a no function allele OR two copies of a decreased function allele. Based on the genotype result this patient is predicted to be a NUDT15 intermediate metabolizer. This patient may be at risk for an adverse reactions to medications that are metabolized by NUDT15 (eg thiopurines). To avoid an untoward drug response, dose adjustments or alternative therapeutic agents may be necessary for medications metabolized by NUDT15. Please consult a clinical pharmacist for more information about how NUDT15 metabolic status influences drug selection and dosing.	3	{"Latino": 0.0527679, "European": 0.013629507, "East Asian": 0.13750981, "Central/South Asian": 0.12932494}
8028627	NUDT15	Poor Metabolizer	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has two copies of a no function allele OR one copy of a no function allele and one copy of a decreased function allele. Based on the genotype result this patient is predicted to be a NUDT15 poor metabolizer. This patient may be at a high risk for an adverse reactions to medications that are metabolized by NUDT15 (eg. thiopurines). To avoid an untoward drug response, dose adjustments or or alternative therapy may be necessary for medications metabolized by NUDT15. Please consult a clinical pharmacist for more information about how NUDT15 metabolic status influences drug selection and dosing.	3	{"Latino": 0.00073546247, "European": 0.000047192545, "East Asian": 0.0073177223, "Central/South Asian": 0.004896416}
8028718	NUDT15	Indeterminate	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has one copy of a normal function allele and one copy of an uncertain function allele OR one copy of a decreased function allele and one copy of an uncertain function allele OR two copies of an uncertain function allele. The expected phenotype for this patient cannot be determined currently based on the NUDT15 diplotype result. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity. Please consult a clinical pharmacist for more specific information about how NUDT15 function influences drug dosing.	3	{"Latino": 0.0, "European": 0.0, "East Asian": 0.0, "Central/South Asian": 0.0}
7978174	ABCG2	Poor Function	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has two copies of a decreased function allele. Based on the genotype result, this patient is predicted to have poor ABCG2 function. This patient may be at a high risk for an adverse response to medications that are affected by ABCG2 (i.e. statins). To avoid an untoward drug response, dose adjustments or alternative therapeutic agents may be necessary for medications affected by ABCG2. Please consult a clinical pharmacist for more specific information about how ABCG2 function influences drug dosing.	3	{"Latino": 0.05035536, "American": 0.040000003, "European": 0.010732961, "Oceanian": 0.0419122, "East Asian": 0.09431041, "Near Eastern": 0.00426409, "Central/South Asian": 0.00868624, "Sub-Saharan African": 0.000034175762, "African American/Afro-Caribbean": 0.0012156549}
7978177	ABCG2	Decreased Function	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has one copy of a normal function allele and one copy of a no decreased allele . Based on the genotype result, this patient is predicted to have decreased ABCG2 function. This patient may be at risk for an adverse response to medications that are affected by ABCG2. To avoid an untoward drug response, dose adjustments may be necessary for medications affected by ABCG2 (i.e. statins). Please consult a clinical pharmacist for more specific information about how ABCG2 function influences drug dosing.	3	{"Latino": 0.34808928, "American": 0.32000002, "European": 0.18573408, "Oceanian": 0.32562497, "East Asian": 0.4255792, "Near Eastern": 0.122071825, "Central/South Asian": 0.1690275, "Sub-Saharan African": 0.011623656, "African American/Afro-Caribbean": 0.06730118}
7978183	CACNA1S	Malignant Hyperthermia Susceptibility	n/a	Abnormal/Priority/High Risk	This result signifies that this patient has one copy of a variant [variant] associated with malignant hyperthermia susceptibility. Halogenated volatile anesthetics or depolarizing muscle relaxants are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. Please consult a MHS specialist or contact MHAUS (https://www.mhaus.org/healthcare-professionals/) for further information.	2	\N
7978191	CACNA1S	Uncertain Susceptibility	n/a	Normal Risk	Variation in RYR1 and/or CACNA1S genes is associated with increased risk of Malignant hyperthermia after administration of depolarizing muscle relaxants and potent volatile anesthetics. Although listed causative CACNA1S variants were NOT detected in this patient, it should be noted that this finding does not absolutely rule out the possibility of malignant hyperthermia. These results should be interpreted in the context of other genetic and clinical findings, family history and other laboratory data.	2	\N
8060391	RYR1	Malignant Hyperthermia Susceptibility	n/a	Abnormal/Priority/High Risk	This result signifies that this patient has one copy of a variant [variant] associated with malignant hyperthermia susceptibility. Halogenated volatile anesthetics or depolarizing muscle relaxants are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. Please consult a MHS specialist or contact MHAUS (https://www.mhaus.org/healthcare-professionals/) for further information.	2	\N
8028761	RYR1	Uncertain Susceptibility	n/a	Normal Risk	Variation in RYR1 and/or CACNA1S genes is associated with increased risk of Malignant hyperthermia after administration of depolarizing muscle relaxants and potent volatile anesthetics. Although listed causative RYR1 variants were NOT detected in this patient, it should be noted that this finding does not absolutely rule out the possibility of malignant hyperthermia. These results should be interpreted in the context of other genetic and clinical findings, family history and other laboratory data.	2	\N
7985594	CYP2C9	Intermediate Metabolizer	1.0	Abnormal/Priority/High Risk	This result signifies that the patient has one copy of a normal function allele and one copy of a no function allele OR two copies of decreased function alleles. Based on the genotype result, this patient is predicted to be a CYP2C9 intermediate metabolizer (activity score of 1). This patient may be at risk for an adverse response to medications that are affected by CYP2C9. Please consult a clinical pharmacist for more specific information about how CYP2C9 intermediate metabolizer status influences drug dosing.	3	{"Latino": 0.08109343, "American": 0.05818467, "European": 0.13767911, "Oceanian": 0.03061276, "East Asian": 0.098925985, "Near Eastern": 0.1494271, "Central/South Asian": 0.18352722, "Sub-Saharan African": 0.049747862, "African American/Afro-Caribbean": 0.049812526}
7978194	CFTR	ivacaftor responsive in CF patients	n/a	\N	\N	1	\N
8086918	SLCO1B1	Possible Decreased Function	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has one copy of a uncertain or unknown function allele (*_) and one copy of a no function allele (*_). Based on the genotype result, this patient is predicted to have possible decreased SLCO1B1 function. This patient may be at risk for an adverse response to medications that are affected by SLCO1B1. To avoid an untoward drug response, dose adjustments may be necessary for medications affected by SLCO1B1 (i.e. statins). Please consult a clinical pharmacist for more specific information about how SLCO1B1 function influences drug dosing.	3	{"American": 0.0, "European": 0.00026362084, "Oceanian": 0.0, "East Asian": 0.0011306308, "Near Eastern": 0.0, "Central/South Asian": 0.0000418451, "Sub-Saharan African": 0.0, "African American/Afro-Caribbean": 0.0}
8086744	SLCO1B1	Decreased Function	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has one copy of a normal function allele (*_) and one copy of a no function allele (*_). Based on the genotype result, this patient is predicted to have decreased SLCO1B1 function. This patient may be at risk for an adverse response to medications that are affected by SLCO1B1. To avoid an untoward drug response, dose adjustments may be necessary for medications affected by SLCO1B1 (i.e. statins). Please consult a clinical pharmacist for more specific information about how SLCO1B1 function influences drug dosing.	3	{"American": 0.3648, "European": 0.28296122, "Oceanian": 0.0, "East Asian": 0.21842287, "Near Eastern": 0.32000002, "Central/South Asian": 0.12971397, "Sub-Saharan African": 0.054308295, "African American/Afro-Caribbean": 0.0198}
8086739	SLCO1B1	Increased Function	n/a	Normal/Routine/Low Risk	This result signifies that the patient has two copies of an increased function allele. Based on the genotype result, this patient is predicted to have increased SLCO1B1 function. This means that there is no reason to adjust the dose of most medications that are affected by SLCO1B1 on the basis of SLCO1B1 genetic status at this time. Please consult a clinical pharmacist for more specific information about how SLCO1B1 function influences drug dosing.	3	{"American": 0.0, "European": 0.029916462, "Oceanian": 0.0, "East Asian": 0.0, "Near Eastern": 0.0, "Central/South Asian": 0.0, "Sub-Saharan African": 0.0, "African American/Afro-Caribbean": 0.0}
8086774	SLCO1B1	Indeterminate	n/a	none	This result signifies that the patient has an allele combination with unknown or uncertain function alleles. The expected phenotype for this patient cannot be determined currently based on the SLCO1B1 diplotype result. Please consult a clinical pharmacist for more specific information about how SLCO1B1 function influences drug dosing.	3	{"American": 0.0, "European": 0.001279436, "Oceanian": 0.0, "East Asian": 0.007855513, "Near Eastern": 0.0, "Central/South Asian": 0.0005580649, "Sub-Saharan African": 0.0, "African American/Afro-Caribbean": 0.0}
8086768	SLCO1B1	Normal Function	n/a	Normal/Routine/Low Risk	This result signifies that the patient has two copies of a normal function allele. Based on the genotype result, this patient is predicted to have normal SLCO1B1 function. This means that there is no reason to adjust the dose of most medications that are affected by SLCO1B1 on the basis of SLCO1B1 genetic status. Please consult a clinical pharmacist for more specific information about how SLCO1B1 function influences drug dosing.	3	{"American": 0.5776, "European": 0.6564144, "Oceanian": 1.0, "East Asian": 0.75683165, "Near Eastern": 0.64000005, "Central/South Asian": 0.8648222, "Sub-Saharan African": 0.94491136, "African American/Afro-Caribbean": 0.98010004}
8086823	SLCO1B1	Poor Function	n/a	Abnormal/Priority/High Risk	This result signifies that the patient has two copies of a no function allele. Based on the genotype result, this patient is predicted to have low SLCO1B1 function. This patient may be at a high risk for an adverse response to medications that are affected by SLCO1B1 (i.e. statins). To avoid an untoward drug response, dose adjustments or alternative therapeutic agents may be necessary for medications affected by SLCO1B1. Please consult a clinical pharmacist for more specific information about how SLCO1B1 function influences drug dosing.	3	{"American": 0.0576, "European": 0.02916489, "Oceanian": 0.0, "East Asian": 0.015759302, "Near Eastern": 0.040000003, "Central/South Asian": 0.004863923, "Sub-Saharan African": 0.0007803353, "African American/Afro-Caribbean": 0.00010}
\.


--
